PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7:

C12N 15/82, 15/11, A01H 5/00

A3

(11) International Publication Number:

WO 00/15816

(43) International Publication Date:

23 March 2000 (23.03.00)

(21) International Application Number:

PCT/US99/21277

(22) International Filing Date:

15 September 1999 (15.09.99)

(30) Priority Data:

60/100.690 60/123.896 17 September 1998 (17.09.98) US US

11 March 1999 (11.03.99)

(71) Applicant (for all designated States except US): PIONEER HI-BRED INTERNATIONAL, INC. [US/US]; 800 Capital Square, 400 Locust Street, Des Moines, IA 50319 (US).

(72) Inventor; and

- (75) Inventor/Applicant (for US only): MAHAJAN, Pramod [IN/US]; 8029 Brookview Drive, Urbandale, IA 50322 (US).
- (74) Agents: SPRUILL, W., Murray et al.; Alston & Bird LLP, P.O. Drawer 34009, Charlotte, NC 28234-4009 (US).

(81) Designated States: AE, AL, AM, AT, AT (Utility model), AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, CZ (Utility model), DE, DE (Utility model), DK, DK (Utility model), DM, EE, EE (Utility model), ES, FI, FI (Utility model), GB, GD, GE, GH, GM, HR. HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO. NZ, PL, PT, RO, RU. SD. SE, SG, SI, SK, SK (Utility model), SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).


Published

With international search report.

(88) Date of publication of the international search report:

25 May 2000 (25.05.00)

(54) Title: MAIZE REPLICATION PROTEIN A



(57) Abstract

Methods and compositions for modulating DNA metabolism are provided. Nucleotide and amino acid sequences encoding a maize replication protein A subunit are provided. The sequences can be used in expression cassettes for modulating DNA replication, DNA repair, and recombination.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	F1	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav	TM	Turkmenistan
BF	Burkina Faso	GR	Greece		Republic of Macedonia	TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Солдо	KE	Kenya	NL	Netherlands	YU	Yugoslavia
СН	Switzerland	KG	Kyrgyzstan	NO	Norway	zw	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's	NZ	New Zealand		
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

MAIZE REPLICATION PROTEIN A

FIELD OF THE INVENTION

The invention relates to the genetic manipulation of plants, particularly to modulating DNA metabolism in transformed plants and plant cells.

BACKGROUND OF THE INVENTION

5

10

15

20

25

30

Replication protein A (RPA) is a single-stranded DNA-binding protein that is required for multiple processes in eukaryotic cells. RPA from human cells is a stable complex of 70-, 32-, and 14-kDa subunits. Homologues of RPA have been identified in all eukaryotes examined. However, only human RPA and closely related homologues can support SV40 DNA replication.

The RPA complex appears to be highly conserved in all eukaryotes. The three RPA genes in budding yeast cells are essential for cell viability.

Nevertheless, yeast RPA only partially substitutes for human RPA in the *in vitro* replication of simian virus 40 indicating that species-specific interactions between RPA and other replication proteins may be important for its biological activity.

RPA binds tightly to single stranded DNA as a heterotrimeric complex. The binding activity has been localized to the 70 kDa subunit. The affinity of RPA for both double-stranded DNA and RNA is at least three orders of magnitude lower than it is for single-stranded DNA. It has been reported that RPA binds preferentially to the pyrimidine-rich strand of both *S. cerevisiae* sequences and the SV40 origin of replication. However, studies examining the determinants of replication origins in *S. cerevisiae* indicate that this preferential binding is not critical for the initiation of DNA replication.

Subunits of RPA in the 70-, 32- and 14 kDa ranges have been identified from various sources. The 32kDa subunit has also been referred to as "RPA2", "B", "small", "32kDa", "P32", "P34", and "middle" subunit. For the purposes of this invention, the "middle" subunit is intended as the subunit having a molecular weight of about 32 kDa.

The middle subunit of RPA has a role in cell cycle regulation; single stranded DNA binding; affinity of DNA binding; species-specificity of DNA

binding; DNA recombination, repair, replication and metabolism; and response to DNA damages. (Anderson (1966) Calif. Inst. Technol.; Seroussi et al. (1993) J. Biol. Chem. 268:7147-54; Kenny et al. (1989) Proc. Natl. Acad. Sci. USA 86:9757-61; Brush et al. (1995) Methods Enzymol. 262:522-48; Stigger et al. (1994) Proc. Natl. Acad. Sci. USA 91:579-83; Philipova et al. (1996) Genes Dev. 10:2222-33).

Much research has centered on the exploration of the biochemical and genetic mechanisms by which cell cycle regulation of DNA synthesis is achieved. While there have been advances in delineating the existence of cell cycle proteins, more information is needed on the mechanism of action of DNA replication, recombination, and repair. Furthermore, methods for regulating or altering the cell cycle is needed.

Related Literature

5

10

15

20

25

30

Braun *et al.* (1997) *Biochemistry 36*:8443-8454; report on the role of protein-protein interactions and the function of replication protein A. It is reported that RPA modulates the activity of DNA polymerase α by multiple mechanisms.

Loor et al. (1997) Nucleic Acids Research 25:5041-5046 report on the identification of DNA replication in cell cycle proteins that interact with proliferating cell nuclear antigen.

Longhese et al. (1994) Molecular and Cellular Biology 14:7884-7890 report that replication factor A is required for in vivo DNA replication, repair, and recombination.

Stigger et al. (1998) J. Biol. Chem. 273:9337-9343 provide a functional analysis of human replication protein A in nucleotide excision repair.

Abremova et al. (1997) Proc. Natl. Acad. Sci. USA 94:7186-7191 report that the interaction between replication protein A and p53 is disrupted after ultraviolet damage in a DNA repair-dependent manner.

New et al. (1998) Nature 391:407-410 reports that RAD52 protein stimulates DNA strand exchange by RAD51 and replication protein A. Stimulation was dependent on the concerted action of both RAD51 protein and RPA implying that specific protein-protein interactions between RAD52 protein, RAD51 protein and RPA are required.

Dutta et al. (1992) EMBO J 11(6):2189-2199 and Niu et al. (1997) J. Biol. Chem. 272(19):12634-41 report cell cycle-dependent phosphorylation of the middle subunit of RPA, implying a role for the subunit in cell cycle regulation.

Bochkareva *et al.* (1998) *J. Biol. Chem.* 273(7):3932-3936 report the formation of a single stranded DNA binding site on the human RPA middle subunit.

Mass et al. (1998) Mol. Cell. Biol. 18(11):6399-6407 report that the RPA middle subunit contacts nascent simian virus 40 DNA, particularly the early DNA chain intermediates synthesized by DNA polymerase alpha-primase (RNA-DNA primers), but not more advanced products.

Lavrik et al. (1998) Nucleic Acids Res 26(2):602-607 report on location of binding of individual subunits of human RPA to DNA primer-template complexes in various elongation reactions.

Sibenaller et al. (1998) 37(36):12496-12506 report that differences in the activity of the middle (32kDa) and the small (14 Kda) subunits of RPA are responsible for variations in the single stranded DNA-binding properties of sacchromyces cerevisiae and human RPA, thus implying a role for the subunits in species-specificity of DNA binding of RPA.

SUMMARY OF THE INVENTION

Compositions and methods for modulating DNA metabolism in a host cell is provided. Particularly, the complete cDNA and amino acid sequence for homologues of maize replication protein A (RPA) large- and middle subunits are provided. The sequences of the invention find use in modulating DNA replication, DNA repair, and recombination.

Transformed plants can be obtained having altered metabolic states. The invention has implications in genetic transformation and gene targeting in plants. Additionally, the methods can be used to promote cell death particularly in an inducible or tissue-preferred manner.

30

25

5

10

15

20

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 provides a comparison of eukaryotic RPA large subunit amino acid sequences. Amino acid sequences for the RPA large subunits from

Sacchromyces Cerevisiae (Rfal Yeast, SEQ ID NO:10), Schizosacchromyces pombe (Rfal_Schpo, SEQ ID NO: 9), Drosophila melanogaster (Rfal_Drome, SEQ ID NO:8), Homo sapiens (Rfal_Human, SEQ ID NO: 7), Xenopus laevis (Rfa_Xenla, SEQ ID NO: 6), and Oryza sativa (O24183, SEQ ID NO:5) were compared with the maize RPA LS homologue 1 (ZMRPALSH1, SEQ ID NO:2) and homologue 2 (ZMRPALSH2, SEQ ID NO:4) using the GCG PileUp program utilizing default parameters. The putative zinc finger region is shown in italics.

Figure 2 provides an expression construct for inducible expression of the maize RPA large or middle subunit antisense construct.

10

15

20

25

30

DETAILED DESCRIPTION OF THE INVENTION

Nucleotide sequences and proteins useful for modulating DNA metabolism are provided. The nucleotide and amino acid sequences correspond to the maize replication protein A (RPA) subunits. RPA is a single-stranded DNA-binding protein that is required for multiple processes in DNA metabolism, including DNA replication, DNA repair, and recombination. The RPA complex generally comprises subunits of approximately 70, 32, and 14 kDa. By "large subunit", "middle subunit", and "small subunit" is herein intended a RPA subunit having the approximate molecular weight of 70-, 32-, and 14 kDa respectively. The sequences of the invention comprise the large- and middle subunits of the RPA complex. The sequences of the invention additionally find use in modulating gene expression.

Compositions of the invention include RPA nucleotide and amino acid sequences that are involved in modulating DNA metabolism. In particular, the present invention provides for isolated nucleic acid molecules comprising nucleotide sequences encoding the amino acid sequences shown in SEQ ID NOs:2 and 4 for the large subunit, and SEQ ID NOs: 12, 14, 16, 18, 20, and 22 for the middle subunit. SEQ ID NO:2 and SEQ ID NO:4 correspond to the amino acid sequences for the maize RPA large subunit homologue 1 (ZmRPALSH1) and homologue 2 (ZmRPALSH2). SEQ ID NOs: 12, 14, 16, 18, 20, and 22 correspond to the amino acid sequences for the maize middle subunit homologue 1 (ZmRPAMSH1); homologues 2 and 3 (ZmRPAMSH2 and ZmRPAMSH3);

homologue 4 (ZmRPAMSH4); homologue 5 (ZmRPAMSH5); homologue 6 (ZmRPAMSH6); and homologue 7 (ZmRPAMSH7) respectively.

5

10

15

20

25

30

For the large subunit, the present invention alternatively provides the nucleotide sequences encoding the DNA sequences deposited in a bacterial host as Patent Deposit Nos: 98754 and 98843. For the large subunits, further are polypeptides having an amino acid sequence encoded by a nucleic acid molecule described herein, for example those set forth in SEQ ID NOs: 1 and 3, those deposited in a bacterial host as Patent Deposit Nos: 98754 and 98843, and fragments and variants thereof.

Plasmids containing the RPA large subunit nucleotide sequences of the invention were deposited with the Patent Depository of the American Type Culture Collection (ATCC), Manassas, Virginia, and assigned Patent Deposit NOs: 98754 and 98843. These deposits will be maintained under the terms of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure. These deposits were made merely as a convenience for those of skill in the art and are not an admission that a deposit is required under 35 U.S.C. §112.

Nucleotide sequences encoding the amino acid sequences for the maize RPA large subunit homologue 1 (ZmRPALSH1) and homologue 2 (ZmRPALSH2) are set forth in SEQ ID NOs 1 and 3. Nucleotide sequences encoding the amino acid sequences for the maize RPA middle subunit homologue 1 (ZmRPAMSH1); homologues 2 and 3 (ZmRPAMSH2 and ZmRPAMSH3); homologue 4 (ZmRPAMSH4); homologue 5 (ZmRPAMSH5); homologue 6 (ZmRPAMSH6); and homologue 7 (ZmRPAMSH7) are set forth in SEQ ID NOs: 11, 13, 15, 17, 19, and 21 respectively.

The invention encompasses isolated or substantially purified nucleic acid or protein compositions. An "isolated" or "purified" nucleic acid molecule or protein, or biologically active portion thereof, is substantially free of other cellular material, or culture medium when produced by recombinant techniques, or substantially free of chemical precursors or other chemicals when chemically synthesized.

Preferably, an "isolated" nucleic acid is free of sequences (preferably protein encoding sequences) that naturally flank the nucleic acid (i.e., sequences located at the 5' and 3' ends of the nucleic acid) in the genomic DNA of the organism from

which the nucleic acid is derived. For example, in various embodiments, the isolated nucleic acid molecule can contain less than about 5 kb, 4 kb, 3 kb, 2 kb, 1 kb, 0.5 kb, or 0.1 kb of nucleotide sequences that naturally flank the nucleic acid molecule in genomic DNA of the cell from which the nucleic acid is derived. A protein that is substantially free of cellular material includes preparations of protein having less than about 30%, 20%, 10%, 5%, (by dry weight) of contaminating protein. When the protein of the invention or biologically active portion thereof is recombinantly produced, preferably culture medium represents less than about 30%, 20%, 10%, or 5% (by dry weight) of chemical precursors or non-protein-of-interest chemicals.

5

10

15

20

25

30

RPA binds tightly to single-stranded DNA (ssDNA). The affinity of binding to double-stranded DNA (dsDNA) is three to four orders of magnitude lower than the binding affinity for ssDNA. Because RPA has been found to bind specifically to certain dsDNA sequences that seem to be involved in the regulation of transcription, modulation of gene expression may be affected by an increase or decrease in RPA expression in the host cell.

RPA has a wide range of activity and therefore uses relating to DNA metabolism and cell cycle. RPA interacts specifically with several proteins required for nucleotide excision repair. Interactions with repair proteins indicate that RPA may be important for efficient damage recognition and cleavage. RPA additionally interacts with RAD52 protein, a protein that is essential for dsDNA-break repair. This interaction appears to be essential for homologous recombination. In this manner, expression of the nucleotides of the invention may promote homologous recombination by recruiting factors which are essential for recombination to occur. Thus, the methods and compositions of the invention find use in promoting homologous recombination.

In one embodiment, genetic manipulation by homologous recombination can be improved by either expression of the RPA coding sequences of the invention during transformation, or by providing RPA protein. RPA protein, for example, may be provided as a coating to particles during particle bombardment. Alternatively, DNA constructs providing for the expression of RPA may be included with the DNA to be transformed. The increase in RPA during transformation, particularly integration of polynucleotides by homologous

recombination, promotes integration and insertion of the DNA sequences of interest into the plant genome.

In the same manner, it may be beneficial to inhibit the expression or presence of the RPA protein to encourage non-specific recombination events. In this manner, antibodies, peptides, antisense oligonucleotides and the like may be utilized to inhibit the activity of RPA. Alternatively, antisense constructs may be provided to inhibit the expression of RPA and encourage non-specific recombination.

5

10

15

20

25

30

Catalytic RNA molecules or ribozymes can also be used to inhibit expression of plant genes. It is possible to design ribozymes that specifically pair with virtually any target RNA and cleave the phosphodiester backbone at a specific location, thereby functionally inactivating the target RNA. In carrying out this cleavage, the ribozyme is not itself altered, and is thus capable of recycling and cleaving other molecules, making it a true enzyme. The inclusion of ribozyme sequences within antisense RNAs confers RNA-cleaving activity upon them, thereby increasing the activity of the constructs. The design and use of target RNA-specific ribozymes is described in Haseloff *et al.* (1988) *Nature* 334:585-591.

A variety of cross-linking agents, alkylating agents and radical generating species as pendant groups on polynucleotides of the present invention can be used to bind, label, detect, and/or cleave nucleic acids. For example, Vlassov, V. V. et al. (1986) Nucleic Acids Res. 14:4065-4076, describe covalent bonding of a single-stranded DNA fragment with alkylating derivatives of nucleotides complementary to target sequences. A report of similar work by the same group is that by Knorre et al. (1985) Biochimie 67:785-789. Iverson and Dervan also showed sequence-specific cleavage of single-stranded DNA mediated by incorporation of a modified nucleotide which was capable of activating cleavage (1987) J. Am. Chem. Soc. 109:1241-1243). Meyer et al. (1989) J. Am. Chem. Soc. 111:8517-8519, effect covalent crosslinking to a target nucleotide using an alkylating agent complementary to the single-stranded target nucleotide sequence. A photoactivated crosslinking to single-stranded oligonucleotides mediated by psoralen was disclosed by Lee et al. (1988) Biochem. 27:3197-3203. Use of crosslinking in triple-helix forming probes was also disclosed by Home et al.

(1990) J. Am. Chem. Soc. 112:2435-2437. Use of N4, N4-ethanocytosine as an alkylating agent to crosslink to single-stranded oligonucleotides has also been described by Webb et al. (1986) J. Am. Chem. Soc. 108:2764-2765; Webb et al. (1986) Nucleic Acids Res. 14:7661-7674; Feteritz et al. (1991) J. Am. Chem. Soc. 113:4000. Various compounds to bind, detect, label, and/or cleave nucleic acids are known in the art. See, for example, U.S. Patent Nos. 5,543,507; 5,672,593; 5,484,908; 5,256,648; and 5,681,941.

RPA is required for the replication of chromosomal DNA. Inhibition of endogenous RPA expression is deleterious to the cell, organism, or plant. Thus, the constructs of the invention can be used to selectively kill target cells or tissues. This can be accomplished through the use of inducible or tissue-preferred promoters. In this manner, the sequences of the invention may find use in enhancing pathogen resistance. An antisense construct for the RPA coding sequence is operably linked to a pathogen-inducible promoter. Upon contact with the pathogen, the RPA antisense construct is expressed resulting in cell death and effectively preventing the invasion of the pathogen.

10

15

20

25

30

The invention is drawn to compositions and methods for inducing resistance in a plant to plant pests. Accordingly, the compositions and methods are also useful in protecting plants against fungal pathogens, viruses, nematodes, insects and the like.

By "disease resistance" is intended that the plants avoid the disease symptoms that are the outcome of plant-pathogen interactions. That is, pathogens are prevented from causing plant diseases and the associated disease symptoms, or alternatively, the disease symptoms caused by the pathogen is minimized or lessened. The methods of the invention can be utilized to protect plants from disease, particularly those diseases that are caused by plant pathogens.

Pathogens of the invention include, but are not limited to, viruses or viroids, bacteria, insects, nematodes, fungi, and the like. Viruses include any plant virus, for example, tobacco or cucumber mosaic virus, ringspot virus, necrosis virus, maize dwarf mosaic virus, etc. Specific fungal and viral pathogens for the major crops include: Soybeans: Phytophthora megasperma fsp. glycinea, Macrophomina phaseolina, Rhizoctonia solani, Sclerotinia sclerotiorum, Fusarium oxysporum, Diaporthe phaseolorum var. sojae (Phomopsis sojae), Diaporthe

phaseolorum var. caulivora, Sclerotium rolfsii, Cercospora kikuchii, Cercospora sojina, Peronospora manshurica, Colletotrichum dematium (Colletotichum truncatum), Corynespora cassiicola, Septoria glycines, Phyllosticta sojicola, Alternaria alternata, Pseudomonas syringae p.v. glycinea, Xanthomonas campestris p.v. phaseoli, Microsphaera diffusa, Fusarium semitectum, Phialophora gregata, Soybean mosaic virus, Glomerella glycines, Tobacco Ring spot virus, Tobacco Streak virus, Phakopsora pachyrhizi, Pythium aphanidermatum, Pythium ultimum, Pythium debaryanum, Tomato spotted wilt virus, Heterodera glycines Fusarium solani, Canola: Albugo candida, Alternaria 10 brassicae, Leptosphaeria maculans, Rhizoctonia solani, Sclerotinia sclerotiorum, Mycosphaerella brassiccola, Pythium ultimum, Peronospora parasitica, Fusarium roseum, Alternaria alternata; Alfalfa: Clavibater michiganese subsp. insidiosum, Pythium ultimum, Pythium irregulare, Pythium splendens, Pythium debarvanum, Pythium aphanidermatum, Phytophthora megasperma, Peronospora trifoliorum, 15 Phoma medicaginis var medicaginis, Cercospora medicaginis, Pseudopeziza medicaginis, Leptotrochila medicaginis, Fusarium, Xanthomonas campestris p.v. alfalfae, Aphanomyces euteiches, Stemphylium herbarum, Stemphylium alfalfae; Wheat: Pseudomonas syringae p.v. atrofaciens, Urocystis agropyri, Xanthomonas campestris p.v. translucens, Pseudomonas syringae p.v. syringae, Alternaria 20 alternata, Cladosporium herbarum, Fusarium graminearum, Fusarium avenaceum, Fusarium culmorum, Ustilago tritici, Ascochyta tritici, Cephalosporium gramineum, Collotetrichum graminicola, Erysiphe graminis f.sp. tritici, Puccinia graminis f.sp. tritici, Puccinia recondita f.sp. tritici, Puccinia striiformis, Pyrenophora tritici-repentis, Septoria nodorum, Septoria tritici, Septoria avenae, Pseudocercosporella herpotrichoides, Rhizoctonia solani, 25 Rhizoctonia cerealis, Gaeumannomyces graminis var. tritici, Pythium aphanidermatum, Pythium arrhenomanes, Pythium ultimum, Bipolaris sorokiniana, Barley Yellow Dwarf Virus, Brome Mosaic Virus, Soil Borne Wheat Mosaic Virus, Wheat Streak Mosaic Virus, Wheat Spindle Streak Virus, American 30 Wheat Striate Virus, Claviceps purpurea, Tilletia tritici, Tilletia laevis, Ustilago tritici, Tilletia indica, Rhizoctonia solani, Pythium arrhenomannes, Pythium gramicola, Pythium aphanidermatum, High Plains Virus, European wheat striate virus; Sunflower: Plasmophora halstedii, Sclerotinia sclerotiorum, Aster Yellows,

- Septoria helianthi, Phomopsis helianthi, Alternaria helianthi, Alternaria zinniae,
Botrytis cinerea, Phoma macdonaldii, Macrophomina phaseolina, Erysiphe
cichoracearum, Rhizopus oryzae, Rhizopus arrhizus, Rhizopus stolonifer, Puccinia
helianthi, Verticillium dahliae, Erwinia carotovorum pv. carotovora,

- Cephalosporium acremonium, Phytophthora cryptogea, Albugo tragopogonis, Corn: Fusarium moniliforme var. subglutinans, Erwinia stewartii, Fusarium moniliforme, Gibberella zeae (Fusarium graminearum), Stenocarpella maydi (Diplodia maydis), Pythium irregulare, Pythium debaryanum, Pythium graminicola, Pythium splendens, Pythium ultimum, Pythium aphanidermatum,
- Aspergillus flavus, Bipolaris maydis O, T (Cochliobolus heterostrophus),
 Helminthosporium carbonum I, II & III (Cochliobolus carbonum), Exserohilum
 turcicum I, II & III, Helminthosporium pedicellatum, Physoderma maydis,
 Phyllosticta maydis, Kabatiella maydis, Cercospora sorghi, Ustilago maydis,
 Puccinia sorghi, Puccinia polysora, Macrophomina phaseolina, Penicillium
- oxalicum, Nigrospora oryzae, Cladosporium herbarum, Curvularia lunata, Curvularia inaequalis, Curvularia pallescens, Clavibacter michiganense subsp. nebraskense, Trichoderma viride, Maize Dwarf Mosaic Virus A & B, Wheat Streak Mosaic Virus, Maize Chlorotic Dwarf Virus, Claviceps sorghi, Pseudonomas avenae, Erwinia chrysanthemi pv. zea, Erwinia carotovora, Corn
- 20 stunt spiroplasma, Diplodia macrospora, Sclerophthora macrospora, Peronosclerospora sorghi, Peronosclerospora philippinensis, Peronosclerospora maydis, Peronosclerospora sacchari, Sphacelotheca reiliana, Physopella zeae, Cephalosporium maydis, Cephalosporium acremonium, Maize Chlorotic Mottle Virus, High Plains Virus, Maize Mosaic Virus, Maize Rayado Fino Virus, Maize
- 25 Streak Virus, Maize Stripe Virus, Maize Rough Dwarf Virus; Sorghum:

 Exserohilum turcicum, Colletotrichum graminicola (Glomerella graminicola),

 Cercospora sorghi, Gloeocercospora sorghi, Ascochyta sorghina, Pseudomonas

 syringae p.v. syringae, Xanthomonas campestris p.v. holcicola, Pseudomonas

 andropogonis, Puccinia purpurea, Macrophomina phaseolina, Perconia circinata,
- Fusarium moniliforme, Alternaria alternata, Bipolaris sorghicola,
 Helminthosporium sorghicola, Curvularia lunata, Phoma insidiosa, Pseudomonas
 avenae (Pseudomonas alboprecipitans), Ramulispora sorghi, Ramulispora
 sorghicola, Phyllachara sacchari, Sporisorium reilianum (Sphacelotheca reiliana),

Sphacelotheca cruenta, Sporisorium sorghi, Sugarcane mosaic H, Maize Dwarf Mosaic Virus A & B, Claviceps sorghi, Rhizoctonia solani, Acremonium strictum, Sclerophthona macrospora, Peronosclerospora sorghi, Peronosclerospora philippinensis, Sclerospora graminicola, Fusarium graminearum, Fusarium oxysporum, Pythium arrhenomanes, Pythium graminicola, etc.

5

10

Nematodes include parasitic nematodes such as root-knot, cyst, and lesion nematodes, including *Heterodera* and *Globodera spp*; particularly *Globodera rostochiensis* and *globodera pailida* (potato cyst nematodes); *Heterodera glycines* (soybean cyst nematode); *Heterodera schachtii* (beet cyst nematode); and *Heterodera avenae* (cereal cyst nematode).

Insect pests include insects selected from the orders Coleoptera, Diptera, Hymenoptera, Lepidoptera, Mallophaga, Homoptera, Hemiptera, Orthoptera, Thysanoptera, Dermaptera, Isoptera, Anoplura, Siphonaptera, Trichoptera, etc., particularly Coleoptera and Lepidoptera. Insect pests of the invention for the major crops include: Maize: Ostrinia nubilalis, European corn borer; Agrotis 15 ipsilon, black cutworm; Helicoverpa zea, com earworm; Spodopiera frugiperda, fall armyworm; Diatraea grandiosella, southwestern corn borer; Elasmopalpus lignosellus, lesser cornstalk borer; Diatraea saccharalis, surgarcane borer; Diabrotica virgifera, western corn rootworm; Diabrotica longicornis barberi, northern corn rootworm; Diabrotica undecimpunctata howardi, southern corn 20 rootworm; Melanotus spp., wireworms; Cyclocephala borealis, northern masked chafer (white grub); Cvclocephala immaculata, southern masked chafer (white grub); Popillia japonica, Japanese beetle; Chaetocnema pulicaria, corn flea beetle; Sphenophorus maidis, maize billbug; Rhopalosiphum maidis, corn leaf aphid; Anuraphis maidiradicis, com root aphid, Blissus leucopterus leucopterus, chinch 25 bug, Melanoplus femurrubrum, redlegged grasshopper; Melanoplus sanguinipes, migratory grasshopper; Hylemya platura, seedcorn maggot; Agromyza parvicornis, corn blot leafminer; Anaphothrips obscrurus, grass thrips; Solenopsis milesta, thief ant; Tetranychus urticae, twosported spider mite; Sorghum: Chilo partellus, 30 sorghum borer, Spodoptera frugiperda, fall armyworm, Helicoverpa zea, corn earworm; Elasmopalpus lignosellus, lesser cornstalk borer; Feltia subterranea, granulate cutworm; Phyllophaga crinita, white grub; Eleodes, Conoderus, and Aeolus spp., wireworms; Oulema melanopus, cereal leaf beetle; Chaetocnema

pulicaria, corn flea beetle; Sphenophorus maidis, maize billbug; Rhopalosiphum maidis; corn leaf aphid; Sipha flava, yellow sugarcane aphid; Blissus leucopterus leucopterus, chinch bug; Contarinia sorghicola, sorghum midge; Tetranychus cinnabarinus, carmine spider mite; Tetranychus urticae, twospotted spider mite;

- Wheat: Pseudaletia unipunctata, army worm; Spodoptera frugiperda, fall armyworm; Elasmopalpus lignosellus, lesser cornstalk borer; Agrotis orthogonia, western cutworm; Elasmopalpus lignosellus, lesser cornstalk borer; Oulema melanopus, cereal leaf beetle; Hypera punctata, clover leaf weevil; Diabrotica undecimpunctata howardi, southern corn rootworm; Russian wheat aphid;
- Schizaphis graminum, greenbug; Macrosiphum avenae, English grain aphid;
 Melanoplus femurrubrum, redlegged grasshopper; Melanoplus differentialis,
 differential grasshopper; Melanoplus sanguinipes, migratory grasshopper;
 Mayetiola destructor, Hessian fly; Sitodiplosis mosellana, wheat midge; Meromyza
 americana, wheat stem maggot; Hylemya coarctata, wheat bulb fly; Frankliniella
- 15 fusca, tobacco thrips; Cephus cinctus, wheat stem sawfly; Aceria tulipae, wheat curl mite; Sunflower: Suleima helianthana, sunflower bud moth; Homoeosoma electellum, sunflower moth; zygogramma exclamationis, sunflower beetle; Bothyrus gibbosus, carrot beetle; Neolasioptera murtfeldtiana, sunflower seed midge; Cotton: Heliothis virescens, cotton budworm; Helicoverpa zea, cotton
- bollworm; Spodoptera exigua, beet armyworm; Pectinophora gossypiella, pink bollworm; Anthonomus grandis grandis, boll weevil; Aphis gossypii, cotton aphid; Pseudatomoscelis seriaius, cotton fleahopper; Trialeurodes abutilonea, bandedwinged whitefly; Lygus lineolaris, tarnished plant bug; Melanoplus femurrubrum, redlegged grasshopper; Melanoplus differentialis, differential
- grasshopper; Thrips tabaci, onion thrips; Franklinkiella fusca, tobacco thrips;

 Tetranychus cinnabarinus, carmine spider mite; Tetranychus urticae, twospotted spider mite; Rice: Diatraea saccharalis, sugarcane borer; Spodoptera frugiperda, fall armyworm; Helicoverpa zea, corn earworm; Colaspis brunnea, grape colaspis; Lissorhoptrus oryzophilus, rice water weevil; Sitophilus oryzae, rice weevil;
- Nephotettix nigropictus, rice leafhopper; Blissus leucopterus leucopterus, chinch bug; Acrosternum hilare, green stink bug; Soybean: Pseudoplusia includens, soybean looper; Anticarsia gemmatalis, velvetbean caterpillar; Plathypena scabra, green cloverworm; Ostrinia nubilalis, European corn borer; Agrotis ipsilon, black

5

10

15

cutworm; Spodoptera exigua, beet armyworm; Heliothis virescens, cotton budworm; Helicoverpa zea, cotton bollworm; Epilachna varivestis, Mexican bean beetle; Myzus persicae, green peach aphid; Empoasca fabae, potato leafhopper; Acrosternum hilare, green stink bug; Melanoplus femurrubrum, redlegged grasshopper; Melanoplus differentialis, differential grasshopper; Hylemya platura, seedcorn maggot; Sericothrips variabilis, soybean thrips; Thrips tabaci, onion thrips; Tetranychus turkestani, strawberry spider mite; Tetranychus urticae, twospotted spider mite; Barley: Ostrinia nubilalis, European corn borer; Agrotis ipsilon, black cutworm; Schizaphis graminum, greenbug; Blissus leucopterus leucopterus, chinch bug; Acrosternum hilare, green stink bug; Euschistus servus, brown stink bug; Delia platura, seedcorn maggot; Mayetiola destructor, Hessian fly; Petrobia latens, brown wheat mite; Oil Seed Rape: Brevicoryne brassicae, cabbage aphid; Phyllotreta cruciferae, Flea beetle; Mamestra configurata, Bertha armyworm; Plutella xylostella, Diamond-back moth; Delia ssp., Root maggots.

A number of promoters can be used in the practice of the invention. The promoters can be selected based on the desired outcome. The nucleic acids can be combined with constitutive, tissue-preferred, or other promoters for expression in plants.

A plant promoter can be employed which will direct expression of a polynucleotide of the present invention in all tissues of a regenerated plant. Such 20 promoters are referred to herein as "constitutive" promoters and are active under most environmental conditions and states of development or cell differentiation. Such constitutive promoters include, for example, the core promoter of the Rsyn7 (WO 99/43838); the core CaMV 35S promoter (Odell et al. (1985) Nature 313:810-812); rice actin (McElroy et al. (1990) Plant Cell 2:163-171); ubiquitin 25 (Christensen et al. (1989) Plant Mol. Biol. 12:619-632 and Christensen et al. (1992) Plant Mol. Biol. 18:675-689); pEMU (Last et al. (1991) Theor. Appl. Genet. 81:581-588); MAS (Velten et al. (1984) EMBO J. 3:2723-2730); ALS promoter (U.S. Patent No. 5,659,026), and the like. Other constitutive promoters include, for example, U.S. Patent Nos. 5,608,149; 5,608,144; 5,604,121; 30 5,569,597, 5,466,785, 5,399,680, 5,268,463, and 5,608,142.

Alternatively, the plant promoter can direct expression of a polynucleotide of present invention in a specific tissue or may be otherwise under more precise

environmental or developmental control. Such promoters are referred to here as "inducible" promoters. Environmental conditions that may effect transcription by inducible promoters include pathogen attack, anaerobic conditions, or the presence of light. Examples of inducible promoters are the Adhl promoter which is inducible by hypoxia or cold stress, the Hsp70 promoter which is inducible by heat stress, and the PPDK promoter which is inducible by light.

Examples of promoters under developmental control include promoters that initiate transcription only, or preferentially, in certain tissues, such as leaves, roots, fruit, seeds, or flowers. An exemplary promoter is the anther specific promoter 5126 (U.S. Patent Nos. 5,689,049 and 5,689,051). The operation of a promoter may also vary depending on its location in the genome. Thus, an inducible promoter may become fully or partially constitutive in certain locations.

10

15

20

25

30

The promoters can be selected based on the desired outcome. When the genes are expressed at levels to cause cell death, an inducible promoter or tissue specific promoters can be used to drive the expression of the genes of the invention. The inducible promoter must be tightly regulated to prevent unnecessary cell death, yet be expressed in the presence of a pathogen to prevent infection and disease symptoms.

Generally, it will be beneficial to express the gene from an inducible promoter, particularly from a pathogen-inducible promoter. Such promoters include those from pathogenesis-related proteins (PR proteins), which are induced following infection by a pathogen; e.g., PR proteins, SAR proteins, beta-1,3-glucanase, chitinase, etc. See, for example, Redolfi et al. (1983) Neth. J. Plant Pathol. 89:245-254; Uknes et al. (1992) Plant Cell 4:645-656; and Van Loon (1985) Plant Mol. Virol. 4:111-116. See also the copending application entitled "Inducible Maize Promoters", U.S. Application Serial No. 09/257,583, filed February 25, 1999, herein incorporated by reference.

Of interest are promoters that are expressed locally at or near the site of pathogen infection. See, for example, Marineau et al. (1987) Plant Mol. Biol. 9:335-342; Matton et al. (1989) Molecular Plant-Microbe Interactions 2:325-331; Somsisch et al. (1986) Proc. Natl. Acad. Sci. USA 83:2427-2430; Somsisch et al. (1988) Mol. Gen. Genet. 2:93-98; and Yang (1996) Proc. Natl. Acad. Sci. USA 93:14972-14977. See also, Chen et al. (1996) Plant J. 10:955-966; Zhang et al.

(1994) Proc. Natl. Acad. Sci. USA 91:2507-2511; Warner et al. (1993) Plant J. 3:191-201; Siebertz et al. (1989) Plant Cell 1:961-968; U.S. Patent No. 5,750,386 (nematode-inducible); and the references cited therein. Of particular interest is the inducible promoter for the maize PRms gene, whose expression is induced by the pathogen Fusarium moniliforme (see, for example, Cordero et al. (1992) Physiol. Mol. Plant Path. 41:189-200).

Additionally, as pathogens find entry into plants through wounds or insect damage, a wound-inducible promoter may be used in the constructions of the invention. Such wound-inducible promoters include potato proteinase inhibitor (pin II) gene (Ryan (1990) *Ann. Rev. Phytopath. 28*:425-449; Duan *et al.* (1996) *Nature Biotechnology 14*:494-498); wun1 and wun2, US Patent No. 5,428,148; win1 and win2 (Stanford *et al.* (1989) *Mol. Gen. Genet. 215*:200-208); systemin (McGurl *et al.* (1992) *Science 225*:1570-1573); WIP1 (Rohmeier *et al.* (1993) *Plant Mol. Biol. 22*:783-792; Eckelkamp *et al.* (1993) *FEBS Letters 323*:73-76); MPI gene (Corderok *et al.* (1994) *Plant J. 6(2)*:141-150); and the like, herein incorporated by reference.

10

15

Chemical-regulated promoters can be used to modulate the expression of a gene in a plant through the application of an exogenous chemical regulator. Depending upon the objective, the promoter may be a chemical-inducible 20 promoter, where application of the chemical induces gene expression, or a chemical-repressible promoter, where application of the chemical represses gene expression. Chemical-inducible promoters are known in the art and include, but are not limited to, the maize In2-2 promoter, which is activated by benzenesulfonamide herbicide safeners, the maize GST promoter, which is 25 activated by hydrophobic electrophilic compounds that are used as pre-emergent herbicides, and the tobacco PR-la promoter, which is activated by salicylic acid. Other chemical-regulated promoters of interest include steroid-responsive promoters (see, for example, the glucocorticoid-inducible promoter in Schena et al. (1991) Proc. Natl. Acad. Sci. USA 88:10421-10425 and McNellis et al. (1998) 30 Plant J. 14(2):247-257) and tetracycline-inducible and tetracycline-repressible promoters (see, for example, Gatz et al. (1991) Mol. Gen. Genet. 227:229-237, and U.S. Patent Nos. 5,814,618 and 5,789,156), herein incorporated by reference.

Where low level expression is desired, weak promoters will be used. Generally, by "weak promoter" is intended a promoter that drives expression of a coding sequence at a low level. By low level is intended at levels of about 1/1000 transcripts to about 1/100,000 transcripts to about 1/500,000 transcripts.

Alternatively, it is recognized that weak promoters also encompasses promoters that are expressed in only a few cells and not in others to give a total low level of expression. Where a promoter is expressed at unacceptably high levels, portions of the promoter sequence can be deleted or modified to decrease expression levels.

10

15

20

25

30

Such weak constitutive promoters include, for example, the core promoter of the Rsyn7 (WO 99/43838), the core 35S CaMV promoter, and the like. Other constitutive promoters include, for example, U.S. Patent Nos. 5,608,149; 5,608,144; 5,604,121; 5,569,597; 5,466,785; 5,399,680; 5,268,463; and 5,608,142. See also, the copending application entitled "Constitutive Maize Promoters", U.S. Application Serial No. 09/257,584, filed February 25, 1999, and herein incorporated by reference.

Tissue-preferred promoters can be utilized to target enhanced RPA expression within a particular plant tissue. In this aspect of the invention, the antisense constructs are useful for tissue-preferred expression. Male or female sterility may be affected by use of the antisense constructs with tissue-preferred promoters. Although not a limitation, of particular interest are promoters for male sterility. For example, the anther-preferred promoter 5126 can be used. See, for example, U.S. Patent Nos. 5,689,049 and 5,689,051, herein incorporated by reference.

Tissue-preferred promoters include Yamamoto et al. (1997) Plant J. 12(2)255-265; Kawamata et al. (1997) Plant Cell Physiol. 38(7):792-803; Hansen et al. (1997) Mol. Gen Genet. 254(3):337-343; Russell et al. (1997) Transgenic Res. 6(2):157-168; Rinehart et al. (1996) Plant Physiol. 112(3):1331-1341; Van Camp et al. (1996) Plant Physiol. 112(2):525-535; Canevascini et al. (1996) Plant Physiol. 112(2):513-524; Yamamoto et al. (1994) Plant Cell Physiol. 35(5):773-778; Lam (1994) Results Probl. Cell Differ. 20:181-196; Orozco et al. (1993) Plant Mol Biol. 23(6):1129-1138; Matsuoka et al. (1993) Proc Natl. Acad. Sci. USA 90(20):9586-9590; and Guevara-Garcia et al. (1993) Plant J. 4(3):495-505. Such promoters can be modified, if necessary, for weak expression.

Leaf-specific promoters are known in the art. See, for example, Yamamoto et al. (1997) Plant J. 12(2):255-265; Kwon et al. (1994) Plant Physiol. 105:357-67; Yamamoto et al. (1994) Plant Cell Physiol. 35(5):773-778; Gotor et al. (1993) Plant J. 3:509-18; Orozco et al. (1993) Plant Mol. Biol. 23(6):1129-1138; and Matsuoka et al. (1993) Proc. Natl. Acad. Sci. USA 90(20):9586-9590.

Root-specific promoters are known and can be selected from the many available from the literature or isolated de novo from various compatible species. See, for example, Hire et al. (1992) Plant Mol. Biol. 20(2): 207-218 (soybean rootspecific glutamine synthetase gene); Keller and Baumgartner (1991) Plant Cell 3(10):1051-1061 (root-specific control element in the GRP 1.8 gene of French 10 bean); Sanger et al. (1990) Plant Mol. Biol. 14(3):433-443 (root-specific promoter of the mannopine synthase (MAS) gene of Agrobacterium tumefaciens); and Miao et al. (1991) Plant Cell 3(1):11-22 (full-length cDNA clone encoding cytosolic glutamine synthetase (GS), which is expressed in roots and root nodules of 15 soybean). See also Bogusz et al. (1990) Plant Cell 2(7):633-641, where two rootspecific promoters isolated from hemoglobin genes from the nitrogen-fixing nonlegume Parasponia andersonii and the related non-nitrogen-fixing nonlegume Trema tomentosa are described. The promoters of these genes were linked to a β glucuronidase reporter gene and introduced into both the nonlegume Nicotiana 20 tabacum and the legume Lotus corniculatus, and in both instances root-specific promoter activity was preserved. Leach and Aoyagi (1991) describe their analysis of the promoters of the highly expressed rolC and rolD root-inducing genes of Agrobacterium rhizogenes (see Plant Science (Limerick) 79(1):69-76). They concluded that enhancer and tissue-preferred DNA determinants are dissociated in 25 those promoters. Teeri et al. (1989) used gene fusion to lacZ to show that the Agrobacterium T-DNA gene encoding octopine synthase is especially active in the epidermis of the root tip and that the TR2' gene is root specific in the intact plant and stimulated by wounding in leaf tissue, an especially desirable combination of characteristics for use with an insecticidal or larvicidal gene (see EMBO J. 30 8(2):343-350). The TR1' gene, fused to *nptll* (neomycin phosphotransferase II) showed similar characteristics. Additional root-preferred promoters include the VfENOD-GRP3 gene promoter (Kuster et al. (1995) Plant Mol. Biol. 29(4):759-

also U.S. Patent Nos. 5,837,876; 5,750,386; 5,633,363; 5,459,252; 5,401,836; 5,110,732; and 5,023,179.

5

10

15

30

"Seed-preferred" promoters include both "seed-specific" promoters (those promoters active during seed development such as promoters of seed storage proteins) as well as "seed-germinating" promoters (those promoters active during seed germination). See Thompson *et al.* (1989) *BioEssays 10*:108, herein incorporated by reference. Such seed-preferred promoters include, but are not limited to, Cim1 (cytokinin-induced message); cZ19B1 (maize 19 kDa zein); milps (myo-inositol-1-phosphate synthase); and celA (cellulose synthase) (see the copending application entitled "Seed-Preferred Promoters," U.S. Application Serial No. 60/097,233, filed August 20, 1998, herein incorporated by reference. Gama-zein is a preferred endosperm-specific promoter. Glob-1 is a preferred embryo-specific promoter. For dicots, seed-specific promoters include, but are not limited to, bean β-phaseolin, napin, β-conglycinin, soybean lectin, cruciferin, and the like. For monocots, seed-specific promoters include, but are not limited to, maize 15 kDa zein, 22 kDa zein, 27 kDa zein, g-zein, waxy, shrunken 1, shrunken 2, globulin 1, etc.

Both heterologous and non-heterologous (i.e., endogenous) promoters can be employed to direct expression of the nucleic acids of the present invention.

These promoters can also be used, for example, in recombinant expression cassettes to drive expression of antisense nucleic acids to reduce, increase, or alter RPA content and/or composition in a desired tissue, or to generate sterile plants. Optionally, RPA nucleic acids from a variety of sources, as discussed above can be employed to create male sterile plants. In optional embodiments, the RPA gene or cDNA is operably linked to an anther-specific promoter such as 5126, as discussed above. Preferably, the male sterile plant is maize.

Thus, in some embodiments, the nucleic acid construct will comprise a promoter functional in a plant cell, such as in *Zea mays*, operably linked to a polynucleotide of the present invention. Promoters useful in these embodiments include the endogenous promoters driving expression of a polypeptide of the present invention.

In some embodiments, isolated nucleic acids which serve as promoter or enhancer elements can be introduced in the appropriate position (generally

upstream) of a non-heterologous form of a polynucleotide of the present invention so as to up or down regulate expression of a polynucleotide of the present invention. For example, endogenous promoters can be altered *in vivo* by mutation, deletion, and/or substitution (see, Kmiec, U.S. Patent No. 5,565,350; Zarling *et al.*, PCT/US93/03868), or isolated promoters can be introduced into a plant cell in the proper orientation and distance from a RPA gene so as to control the expression of the gene. Gene expression can be modulated under conditions suitable for plant growth so as to alter RPA content and/or composition. Thus, the present invention provides compositions, and methods for making, heterologous promoters and/or enhancers operably linked to a native, endogenous (i.e., non-heterologous) form of a polynucleotide of the present invention.

Methods for identifying promoters with a particular expression pattern, in terms of e.g., tissue type, cell type, stage of development, and/or environmental conditions, are well known in the art. See, e.g., *The Maize Handbook*, Chapters 114-115, Freeling and Walbot, eds., Springer, New York (1994); *Corn and Corn Improvement*, 3rd edition, Chapter 6, Sprague and Dudley, eds., American Society of Agronomy, Madison, Wisconsin (1988). A typical step in promoter isolation methods is identification of gene products that are expressed with some degree of specificity in the target tissue. Amongst the range of methodologies are: differential hybridization to cDNA libraries; subtractive hybridization; differential display; differential 2-D protein gel electrophoresis; DNA probe arrays; and isolation of proteins known to be expressed with some specificity in the target tissue. Such methods are well known to those of skill in the art. Commercially available products for identifying promoters are known in the art such as Clontech's (Palo Alto, CA) Universal GenomeWalker Kit.

For the protein-based methods, it is helpful to obtain the amino acid sequence for at least a portion of the identified protein, and then to use the protein sequence as the basis for preparing a nucleic acid that can be used as a probe to identify either genomic DNA directly, or preferably, to identify a cDNA clone from a library prepared from the target tissue. Once such a cDNA clone has been identified, that sequence can be used to identify the sequence at the 5' end of the transcript of the indicated gene. For differential hybridization, subtractive hybridization and differential display, the nucleic acid sequence identified as

enriched in the target tissue is used to identify the sequence at the 5' end of the transcript of the indicated gene. Once such sequences are identified, starting either from protein sequences or nucleic acid sequences, any of these sequences identified as being from the gene transcript can be used to screen a genomic library prepared from the target organism. Methods for identifying and confirming the transcriptional start site are well known in the art.

5

10

30

In the process of isolating promoters expressed under particular environmental conditions or stresses, or in specific tissues, or at particular developmental stages, a number of genes are identified that are expressed under the desired circumstances, in the desired tissue, or at the desired stage. Further analysis will reveal expression of each particular gene in one or more other tissues of the plant. One can identify a promoter with activity in the desired tissue or condition but that do not have activity in any other common tissue.

To identify the promoter sequence, the 5' portions of the clones described 15 here are analyzed for sequences characteristic of promoter sequences. For instance, promoter sequence elements include the TATA box consensus sequence (TATAAT), which is usually an AT-rich stretch of 5-10 bp located approximately 20 to 40 base pairs upstream of the transcription start site. Identification of the TATA box is well known in the art. For example, one way to predict the location of this element is to identify the transcription start site using standard 20 RNA-mapping techniques such as primer extension, S1 analysis, and/or RNase protection. To confirm the presence of the AT-rich sequence, a structure-function analysis can be performed involving mutagenesis of the putative region and quantification of the mutation's effect on expression of a linked downstream reporter gene. See, e.g., The Maize Handbook, Chapter 114, Freeling and Walbot, 25 eds., Springer, New York (1994).

In plants, further upstream from the TATA box, at positions -80 to -100, there is typically a promoter element (i.e., the CAAT box) with a series of adenines surrounding the trinucleotide G (or T) N G. J. Messing et al., in Genetic Engineering in Plants, Kosage, Meredith and Hollaender, eds., pp. 221-227 (1983). In maize, there no well-conserved CAAT box but there are several short, conserved protein-binding motifs upstream of the TATA box. These include motifs for the transacting transcription factors involved in light regulation,

anaerobic induction, hormonal regulation, or anthocyanin biosynthesis, as appropriate for each gene.

5

10

15

20

25

30

Once promoter and/or gene sequences are known, a region of suitable size is selected from the genomic DNA that is 5' to the transcriptional start, or the translational start site, and such sequences are then linked to a coding sequence. If the transcriptional start site is used as the point of fusion, any of a number of possible 5' untranslated regions can be used in between the transcriptional start site and the partial coding sequence. If the translational start site at the 3' end of the specific promoter is used, then it is linked directly to the methionine start codon of a coding sequence.

If polypeptide expression is desired, it is generally desirable to include apolyadenylation region at the 3'-end of a polynucleotide coding region. The polyadenylation region can be derived from the natural gene, from a variety of other plant genes, or from T-DNA. The 3' end sequence to be added can be derived from, example, the nopaline synthase or octopine synthase genes, or alternatively from another plant gene, or less preferably from any other eukaryotic gene.

An intron sequence can be added to the 5' untranslated region or the coding sequence of the partial coding sequence to increase the amount of the mature message that accumulates in the cytosol. Inclusion of a spliceable intron in the transcription unit in both plant and animal expression constructs has been shown to increase gene expression at both the mRNA and protein levels up to 1000-fold. Buchman et al. (1988) Mol. Cell Biol. 8:4395-4405; Callis et al. (1987) Genes Dev. 1:1183-1200. Such intron enhancement of gene expression is typically greatest when placed near the 5' end of the transcription unit. Use of maize introns Adhl-S intron 1, 2, and 6, the Bronze-l intron are known in the art. See generally, The Maize Handbook, Chapter 116, Freeling and Walbot, eds., Springer, New York (1994).

The vector comprising the sequences from a polynucleotide of the present invention could comprise a selectable marker gene for the selection of transformed cells or tissues. Selectable marker genes include genes encoding antibiotic resistance, such as those encoding neomycin phosphotransferase II (NEO) and hygromycin phosphotransferase (HPT), as well as genes conferring resistance to herbicidal

compounds, such as glufosinate ammonium, bromoxynil, imidazolinones, and 2,4-dichlorophenoxyacetate (2,4-D). See generally, Yarranton (1992) Curr. Opin.

Biotech. 3:506-511; Christopherson et al. (1992) Proc. Natl. Acad. Sci. USA 89:6314-6318; Yao et al. (1992) Cell 71:63-72; Reznikoff (1992) Mol. Microbiol. 6:2419-2422; Barkley et al. (1980) in The Operon, pp. 177-220; Hu et al. (1987) Cell 48:555-

2422; Barkley et al. (1980) in The Operon, pp. 177-220; Hu et al. (1987) Cell 48:555-566; Brown et al. (1987) Cell 49:603-612; Figge et al. (1988) Cell 52:713-722;
 Deuschle et al. (1989) Proc. Natl. Acad. Aci. USA 86:5400-5404; Fuerst et al. (1989) Proc. Natl. Acad. Sci. USA 86:2549-2553; Deuschle et al. (1990) Science 248:480-483; Gossen (1993) Ph.D. Thesis, University of Heidelberg; Reines et al. (1993)

Proc. Natl. Acad. Sci. USA 90:1917-1921; Labow et al. (1990) Mol. Cell. Biol.
 10:3343-3356; Zambretti et al. (1992) Proc. Natl. Acad. Sci. USA 89:3952-3956;
 Baim et al. (1991) Proc. Natl. Acad. Sci. USA 88:5072-5076; Wyborski et al. (1991)
 Nucleic Acids Res. 19:4647-4653; Hillenand-Wissman (1989) Topics Mol. Struc.
 Biol. 10:143-162; Degenkolb et al. (1991) Antimicrob. Agents Chemother. 35:1591-

1595; Kleinschnidt et al. (1988) Biochemistry 27:1094-1104; Bonin (1993) Ph.D.
Thesis, University of Heidelberg; Gossen et al. (1992) Proc. Natl. Acad. Sci. USA 89:5547-5551; Oliva et al. (1992) Antimicrob. Agents Chemother. 36:913-919;
Hlavka et al. (1985) Handbook of Experimental Pharmacology, Vol. 78 (Springer-Verlag, Berlin); Gill et al. (1988) Nature 334:721-724. Such disclosures are herein incorporated by reference.

The above list of selectable marker genes is not meant to be limiting. Any selectable marker gene can be used in the present invention.

Typical vectors useful for expression of genes in higher plants are well known in the art and include vectors derived from the tumor-inducing (Ti) plasmid of Agrobacterium tumefaciens described by Rogers et al. (1987) Meth. in Enzymol. 153:253-277. These vectors are plant integrating vectors in that on transformation, the vectors integrate a portion of vector DNA into the genome of the host plant. Exemplary A. tumefaciens vectors useful herein are plasmids pKYLX6 and pKYLX7 of Schardl et al. (1987) Gene 61:1-11 and Berger et al. (1989) Proc. Natl. Acad. Sci. (USA) 86:8402-8406. Another useful vector herein is plasmid pBI101.2 that is available from Clontech Laboratories, Inc. (Palo Alto, CA).

25

30

As discussed above, a polynucleotide of the present invention can be expressed in either sense or antisense orientation as desired. It will be appreciated

that control of gene expression in either sense or antisense orientation can have a direct impact on the observable plant characteristics. Antisense technology can be conveniently used for gene expression in plants. To accomplish this, a nucleic acid segment from the desired gene is cloned and operably linked to a promoter such that the antisense strand of RNA will be transcribed. The construct is then transformed into plants and the antisense strand of RNA is produced. In plant cells, it has been shown that antisense RNA inhibits gene expression by preventing the accumulation of mRNA which encodes the enzyme of interest, see, e.g., Sheehy et al. (1988) Proc. Natl. Acad. Sci. (USA) 85:8805-8809; and Hiatt et al., U.S. Patent No. 4,801,340.

5

10

15

20

25

30

In the methods of the invention, it is recognized that the entire coding sequence for the RPA construct may be utilized. Alternatively, portions or fragments of the sequence may be used in DNA constructs.

Fragments and variants of the disclosed nucleotide sequences and proteins encoded thereby are encompassed by the present invention. By "fragment" is intended a portion of the nucleotide sequence or a portion of the amino acid sequence and hence protein encoded thereby. Fragments of a nucleotide sequence may encode protein fragments that retain the biological activity of the native protein and hence modulate DNA metabolism. Alternatively, fragments of a nucleotide sequence that are useful as hybridization probes generally do not encode fragment proteins retaining biological activity. Thus, fragments of a nucleotide sequence may range from at least about 20 nucleotides, about 50 nucleotides, about 100 nucleotides, and up to the full-length nucleotide sequence encoding the proteins of the invention.

A fragment of a RPA nucleotide sequence that encodes a biologically active portion of a RPA protein of the invention will encode at least 15, 25, 30, 50, 100, 150, 200, or 250 contiguous amino acids, or up to the total number of amino acids present in a full-length RPA protein of the invention (for example, 623, 617, 273, 273, 273, 318, 273, 273 amino acids for SEQ ID NOs: 2, 4, 12, 14, 16, 18, 20, and 22 respectively. Fragments of a RPA nucleotide sequence that are useful as hybridization probes for PCR primers generally need not encode a biologically active portion of a RPA protein.

Thus, a fragment of a RPA nucleotide sequence may encode a biologically active portion of a RPA protein, or it may be a fragment that can be used as a hybridization probe or PCR primer using methods disclosed below. A biologically active portion of a RPA protein can be prepared by isolating a portion of one of the RPA nucleotide sequences of the invention, expressing the encoded portion of the RPA protein (e.g., by recombinant expression *in vitro*), and assessing the activity of the encoded portion of the RPA protein. Nucleic acid molecules that are fragments of a RPA nucleotide sequence comprise at least 16, 20, 50, 75, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 800, 900, 1,000 nucleotides, or up to the number of nucleotides present in a full-length RPA nucleotide sequence disclosed herein (for example, 2497, 2202, 1124, 979, 1051, 1087, 1074, and 1231 nucleotides for SEQ ID NOs: 1, 3, 11, 13, 15, 17, 19, and 21 respectively).

By "variants" is intended substantially similar sequences. For nucleotide sequences, conservative variants include those sequences that, because of the degeneracy of the genetic code, encode the amino acid sequence of one of the RPA polypeptides of the invention. Such naturally occurring variants including naturally occurring allelic variants, can be identified with the use of well-known molecular biology techniques, as, for example, with polymerase chain reaction (PCR) and hybridization techniques as outlined below. Variant nucleotide sequences also include synthetically derived nucleotide sequences, such as those generated, for example, by using site-directed mutagenesis but which still encode a RPA protein of the invention. Generally, variants of a particular nucleotide sequence of the invention will have at least 40%, 50%, 60%, 70%, generally at least 75%, 80%, 85%, preferably about 90% to 95% or more, and more preferably about 98% or more sequence identity to that particular nucleotide sequence as determined by sequence alignment programs described elsewhere herein using default parameters.

By "variant" protein is intended a protein derived from the native protein by deletion (so-called truncation) or addition of one or more amino acids to the N-terminal and/or C-terminal end of the native protein; deletion or addition of one or more amino acids at one or more sites in the native protein; or substitution of one or more amino acids at one or more sites in the native protein. Variant proteins

encompassed by the present invention are biologically active, that is they continue to possess the desired biological activity of the native protein, that is, modulating DNA metabolism as described herein. Such variants may result from, for example, genetic polymorphism or from human manipulation. Biologically active variants of a native RPA protein of the invention will have at least 40%, 50%, 60%, 70%, generally at least 75%, 80%, 85%, preferably about 90% to 95% or more, and more preferably about 98% or more sequence identity to the amino acid sequence for the native protein as determined by sequence alignment programs described elsewhere herein using default parameters. A biologically active variant of a protein of the invention may differ from that protein by as few as 1-15 amino acid residues, as few as 1-10, such as 6-10, as few as 5, as few as 4, 3, 2, or even 1 amino acid residue.

The proteins of the invention may be altered in various ways including amino acid substitutions, deletions, truncations, and insertions. Methods for such manipulations are generally known in the art. For example, amino acid sequence variants of the RPA proteins can be prepared by mutations in the DNA. Methods for mutagenesis and nucleotide sequence alterations are well known in the art. See, for example, Kunkel (1985) *Proc. Natl. Acad. Sci. USA 82*:488-492; Kunkel et al. (1987) *Methods in Enzymol. 154*:367-382; US Patent No. 4,873,192; Walker and Gaastra, eds. (1983) *Techniques in Molecular Biology* (MacMillan Publishing Company, New York) and the references cited therein Guidance as to appropriate amino acid substitutions that do not affect biological activity of the protein of interest may be found in the model of Dayhoff et al. (1978) *Atlas of Protein Sequence and Structure* (Natl. Biomed. Res. Found., Washington, D.C.), herein incorporated by reference. Conservative substitutions, such as exchanging one amino acid with another having similar properties, may be preferred.

Thus, the genes and nucleotide sequences of the invention include both the naturally occurring sequences as well as mutant forms. Likewise, the proteins of the invention encompass both naturally occurring proteins as well as variations and modified forms thereof. Such variants will continue to possess the desired activity in influencing DNA metabolism. Obviously, the mutations that will be made in the DNA encoding the variant must not place the sequence out of reading frame and

preferably will not create complementary regions that could produce secondary mRNA structure. See, EP Patent Application Publication No. 75,444.

The deletions, insertions, and substitutions of the protein sequence encompassed herein are not expected to produce radical changes in the characteristics of the protein. However, when it is difficult to predict the exact 5 effect of the substitution, deletion, or insertion in advance of doing so, one skilled in the art will appreciate that the effect will be evaluated by routine screening assays. That is, the activity can be evaluated by assessing DNA binding. recombination, repair and replication. See, for example, Braun et al. (1997) 10 Biochemistry 36:8443-8454, Longhese et al. (1994) Molecular and Cellular Biology 14:7884-7890; Stigger et al. (1998) J. Biol. Chem. 273:9337-9343; Abremova et al. (1997) Proc. Natl. Acad. Sci. USA 94:7186-7191; New et al. (1998) Nature 391:407-410; Bochkareva et al. (1998) J. Biol. Chem. 273(7):3932-6Mass et al. (1998) Mol. Cell. Biol. 18(11):6399-407; Lavrik et al. (1998) Nucleic 15 Acids Res 26(2):602-7; Sibenaller et al. (1998) 37(36):12496-506; Matsunaga et al. (1996) J. Biol. Chem. 271 (19): 11047-50; and Sung (1997) Genes & Development 11: 1111-21, herein incorporated by reference.

Variant nucleotide sequences and proteins also encompass nucleotide sequences and proteins derived from a mutagenic and recombinogenic procedure 20 such as DNA shuffling. With such a procedure, one or more different RPA coding sequences can be manipulated to create a new RPA possessing the desired properties. In this manner, libraries of recombinant polynucleotides are generated from a population of related sequence polynucleotides comprising sequence regions that have substantial sequence identity and can be homologously 25 recombined in vitro or in vivo. For example, using this approach, sequence motifs encoding a domain of interest may be shuffled between the RPA gene of the invention and other known RPA genes to obtain a new gene coding for a protein with an improved property of interest, such as an increased K_m in the case of an enzyme. Strategies for such DNA shuffling are known in the art. See, for 30 example, Stemmer (1994) Proc. Natl. Acad. Sci. USA 91:10747-10751; Stemmer (1994) Nature 370:389-391; Crameri et al. (1997) Nature Biotech. 15:436-438; Moore et al. (1997) J. Mol. Biol. 272:336-347; Zhang et al. (1997) Proc. Natl.

5

10

15

20

25

30

Acad. Sci. USA 94:4504-4509; Crameri et al. (1998) Nature 391:288-291; and U.S. Patent Nos. 5,605,793 and 5,837,458.

It is recognized that with these nucleotide sequences, antisense constructions, complementary to at least a portion of the messenger RNA (mRNA) for the RPA sequences can be constructed. Antisense nucleotides are constructed to hybridize with the corresponding mRNA. Modifications of the antisense sequences may be made as long as the sequences hybridize to and interfere with expression of the corresponding mRNA. In this manner, antisense constructions having 70%, preferably 80%, more preferably 85% sequence similarity to the corresponding antisense sequences may be used. Furthermore, portions of the antisense nucleotides may be used to disrupt the expression of the target gene. Generally, sequences of at least 50 nucleotides, 100 nucleotides, 200 nucleotides, or greater may be used.

The nucleotide sequences of the present invention may also be used in the sense orientation to suppress the expression of endogenous genes in plants. Methods for suppressing gene expression in plants using nucleotide sequences in the sense orientation are known in the art. The methods generally involve transforming plants with a DNA construct comprising a promoter that drives expression in a plant operably linked to at least a portion of a nucleotide sequence that corresponds to the transcript of the endogenous gene. Typically, such a nucleotide sequence has substantial sequence identity to the sequence of the transcript of the endogenous gene, preferably greater than about 65% sequence identity, more preferably greater than about 85% sequence identity, most preferably greater than about 95% sequence identity. See, U.S. Patent Nos. 5,283,184 and 5,034,323; herein incorporated by reference.

Use of the polypeptides and proteins, and fragments and variants thereof, for producing antibodies are also encompassed by the invention. The invention also encompasses using such antibodies to determine RPA protein levels, and to modulate one or more biological activities or interactions of RPA. Methods for the production of antibodies are known in the art. See, for example, Harlow and Lane, antibodies, A Laboratory Manual, Cold Spring Harbor Publications, New York (1988); and the reference is cited therein.

The RPA sequences of the invention may be optimized for enhanced expression in plants of interest. See, for example, EPA0359472; WO91/16432; Perlak et al. (1991) Proc. Natl. Acad. Sci. USA 88:3324-3328; and Murray et al. (1989) Nucleic Acids Res. 17:477-498. In this manner, the genes can be synthesized utilizing plant-preferred condons. See, for example, Murray et al. (1989) Nucleic Acids Res. 17:477-498, the disclosure of which is incorporated herein by reference. In this manner, synthetic genes can also be made based on the distribution of codons a particular host uses for a particular amino acid. Thus, the nucleotide sequences can be optimized for expression in any plant. It is recognized that all or any part of the gene sequence may be optimized or synthetic. That is, synthetic or partially optimized sequences may also be used.

5

10

15

20

25

30

Thus nucleotide sequences of the invention and the proteins encoded thereby include the native forms as well as variants thereof. The variant proteins will be substantially homologous and functionally equivalent to the native proteins. A variant of a native protein is "substantially homologous" to the native protein when at least about 80%, more preferably at least about 90%, and most preferably at least about 95% of its amino acid sequence is identical to the amino acid sequence of the native protein. By "functionally equivalent" is intended that the sequence of the variant defines a chain that produces a protein having substantially the same biological effect as the native protein of interest. Such functionally equivalent variants that comprise substantial sequence variations are also encompassed by the invention.

The nucleotide sequences of the invention can be used to isolate corresponding sequences from other organisms, particularly other plants, more particularly other monocots. In this manner, methods such as PCR, hybridization, and the like can be used to identify such sequences based on their sequence homology to the sequence set forth herein. Sequences isolated based on their sequence identity to the entire RPA sequences set forth herein or to fragments thereof are encompassed by the present invention.

In a PCR approach, oligonucleotide primers can be designed for use in PCR reactions to amplify corresponding DNA sequences from cDNA or genomic DNA extracted from any plant of interest. Methods for designing PCR primers and PCR cloning are generally known in the art and are disclosed in Sambrook et al. (1989)

Molecular Cloning: A Laboratory Manual (2d ed., Cold Spring Harbor Laboratory Press, Plainview, New York). See also Innis et al., eds. (1990) PCR Protocols: A Guide to Methods and Applications (Academic Press, New York); Innis and Gelfand, eds. (1995) PCR Strategies (Academic Press, New York); and Innis and Gelfand, eds. (1999) PCR Methods Manual (Academic Press, New York). Known methods of PCR include, but are not limited to, methods using paired primers, nested primers, single specific primers, degenerate primers, gene-specific primers, vector-specific primers, partially-mismatched primers, and the like.

10

15

20

25

30

In hybridization techniques, all or part of a known nucleotide sequence is used as a probe that selectively hybridizes to other corresponding nucleotide sequences present in a population of cloned genomic DNA fragments or cDNA fragments (i.e., genomic or cDNA libraries) from a chosen organism. The hybridization probes may be genomic DNA fragments, cDNA fragments. RNA fragments, or other oligonucleotides, and may be labeled with a detectable group such as ³²P, or any other detectable marker. Thus, for example, probes for hybridization can be made by labeling synthetic oligonucleotides based on the RPA sequences of the invention. Methods for preparation of probes for hybridization and for construction of cDNA and genomic libraries are generally known in the art and are disclosed in Sambrook *et al.* (1989) *Molecular Cloning: A Laboratory Manual* (2d ed., Cold Spring Harbor Laboratory Press, Plainview, New York).

For example, the entire RPA sequence disclosed herein, or one or more portions thereof, may be used as a probe capable of specifically hybridizing to corresponding RPA sequences and messenger RNAs. To achieve specific hybridization under a variety of conditions, such probes include sequences that are unique among RPA sequences and are preferably at least about 10 nucleotides in length, and most preferably at least about 20 nucleotides in length. Such probes may be used to amplify corresponding RPA sequences from a chosen plant by PCR. This technique may be used to isolate additional coding sequences from a desired plant or as a diagnostic assay to determine the presence of coding sequences in a plant Hybridization techniques include hybridization screening of plated DNA libraries (either plaques or colonies; see, for example, Sambrook et al.

(1989) Molecular Cloning: A Laboratory Manual (2d ed., Cold Spring Harbor Laboratory Press, Plainview, New York).

5

10

15

20

25

30

Hybridization of such sequences may be carried out under stringent conditions. By "stringent conditions" or "stringent hybridization conditions" is intended conditions under which a probe will hybridize to its target sequence to a detectably greater degree than to other sequences (e.g., at least 2-fold over background). Stringent conditions are sequence-dependent and will be different in different circumstances. By controlling the stringency of the hybridization and/or washing conditions, target sequences that are 100% complementary to the probe can be identified (homologous probing). Alternatively, stringency conditions can be adjusted to allow some mismatching in sequences so that lower degrees of similarity are detected (heterologous probing). Generally, a probe is less than about 1000 nucleotides in length, preferably less than 500 nucleotides in length.

Typically, stringent conditions will be those in which the salt concentration is less than about 1.5 M Na ion, typically about 0.01 to 1.0 M Na ion concentration (or other salts) at pH 7.0 to 8.3 and the temperature is at least about 30°C for short probes (e.g., 10 to 50 nucleotides) and at least about 60°C for long probes (e.g., greater than 50 nucleotides). Stringent conditions may also be achieved with the addition of destabilizing agents such as formamide. Exemplary low stringency conditions include hybridization with a buffer solution of 30 to 35% formamide, 1 M NaCl, 1% SDS (sodium dodecyl sulphate) at 37°C, and a wash in 1X to 2X SSC (20X SSC = 3.0 M NaCl/0.3 M trisodium citrate) at 50 to 55°C. Exemplary moderate stringency conditions include hybridization in 40 to 45% formamide, 1.0 M NaCl, 1% SDS at 37°C, and a wash in 0.5X to 1X SSC at 55 to 60°C.

Exemplary high stringency conditions include hybridization in 50% formamide, 1 M NaCl, 1% SDS at 37°C, and a wash in 0.1X SSC at 60 to 65°C.

Specificity is typically the function of post-hybridization washes, the critical factors being the ionic strength and temperature of the final wash solution. For DNA-DNA hybrids, the T_m can be approximated from the equation of Meinkoth and Wahl (1984) *Anal. Biochem.* 138:267-284: T_m = 81.5°C + 16.6 (log M) + 0.41 (%GC) - 0.61 (% form) - 500/L, where M is the molarity of monovalent cations, %GC is the percentage of guanosine and cytosine nucleotides in the DNA, % form is the percentage of formamide in the hybridization solution, and L is the

length of the hybrid in base pairs. The T_m is the temperature (under defined ionic strength and pH) at which 50% of a complementary target sequence hybridizes to a perfectly matched probe. T_m is reduced by about 1°C for each 1% of mismatching; thus, T_m, hybridization, and/or wash conditions can be adjusted to hybridize to sequences of the desired identity. For example, if sequences with $\geq 90\%$ identity are sought, the T_m can be decreased 10°C. Generally, stringent conditions are selected to be about 5°C lower than the thermal melting point (T_m) for the specific sequence and its complement at a defined ionic strength and pH. However, severely stringent conditions can utilize a hybridization and/or wash at 1, 2, 3, or 4°C lower than the thermal melting point (T_m); moderately stringent conditions can utilize a hybridization and/or wash at 6, 7, 8, 9, or 10°C lower than the thermal melting point (T_m), low stringency conditions can utilize a hybridization and/or wash at 11, 12, 13, 14, 15, or 20°C lower than the thermal melting point (T_m). Using the equation, hybridization and wash compositions, and desired T_m, those of ordinary skill will understand that variations in the stringency of hybridization and/or wash solutions are inherently described. If the desired degree of mismatching results in a T_m of less than 45°C (aqueous solution) or 32°C (formamide solution), it is preferred to increase the SSC concentration so that a higher temperature can be used. An extensive guide to the hybridization of nucleic acids is found in Tijssen (1993) Laboratory Techniques in Biochemistry and Molecular Biology-Hybridization with Nucleic Acid Probes, Part I, Chapter 2 (Elsevier, New York); and Ausubel et al., eds. (1995) Current Protocols in Molecular Biology, Chapter 2 (Greene Publishing and Wiley-Interscience, New York). See Sambrook et al. (1989) Molecular Cloning: A Laboratory Manual (2d ed., Cold Spring Harbor Laboratory Press, Plainview, New York).

10

15

20

25

30

Thus, isolated sequences that have promoter activity or encode for a RPA protein and which hybridize under stringent conditions to the RPA sequences disclosed herein, or to fragments thereof, are encompassed by the present invention. Such sequences will be at least 40% to 50% homologous, about 60% to 70% homologous, and even about 75%, 80%, 85%, 90%, 95% to 98% homologous or more with the disclosed sequences. That is, the sequence identity of sequences may range, sharing at least 40% to 50%, about 60% to 70%, and even about 75%, 80%, 85%, 90%, 95% to 98% or more sequence identity.

The following terms are used to describe the sequence relationships between two or more nucleic acids or polynucleotides: (a) "reference sequence", (b) "comparison window", (c) "sequence identity", (d) "percentage of sequence identity", and (e) "substantial identity".

(a) As used herein, "reference sequence" is a defined sequence used as a basis for sequence comparison. A reference sequence may be a subset or the entirety of a specified sequence; for example, as a segment of a full-length cDNA or gene sequence, or the complete cDNA or gene sequence.

5

10

15

20

25

30

(b) As used herein, "comparison window" makes reference to a contiguous and specified segment of a polynucleotide sequence, wherein the polynucleotide sequence in the comparison window may comprise additions or deletions (i.e., gaps) compared to the reference sequence (which does not comprise additions or deletions) for optimal alignment of the two sequences. Generally, the comparison window is at least 20 contiguous nucleotides in length, and optionally can be 30, 40, 50, 100, or longer. Those of skill in the art understand that to avoid a high similarity to a reference sequence due to inclusion of gaps in the polynucleotide sequence a gap penalty is typically introduced and is subtracted from the number of matches.

Methods of alignment of sequences for comparison are well known in the art. Thus, the determination of percent identity between any two sequences can be accomplished using a mathematical algorithm. Preferred, non-limiting examples of such mathematical algorithms are the algorithm of Myers and Miller (1988) CABIOS 4:11-17; the local homology algorithm of Smith et al. (1981) Adv. Appl. Math. 2:482; the homology alignment algorithm of Needleman and Wunsch (1970) J. Mol. Biol. 48:443-453; the search-for-similarity-method of Pearson and Lipman (1988) Proc. Natl. Acad. Sci. 85:2444-2448; the algorithm of Karlin and Altschul (1990) Proc. Natl. Acad. Sci. USA 872264, modified as in Karlin and Altschul (1993) Proc. Natl. Acad. Sci. USA 90:5873-5877.

Computer implementations of these mathematical algorithms can be utilized for comparison of sequences to determine sequence identity. Such implementations include, but are not limited to: CLUSTAL in the PC/Gene program (available from Intelligenetics, Mountain View, California); the ALIGN program (Version 2.0) and GAP, BESTFIT, BLAST, FASTA, and TFASTA in the

Wisconsin Genetics Software Package, Version 8 (available from Genetics Computer Group (GCG), 575 Science Drive, Madison, Wisconsin, USA). Alignments using these programs can be performed using the default parameters. The CLUSTAL program is well described by Higgins et al. (1988) Gene 73:237-244 (1988); Higgins et al. (1989) CABIOS 5:151-153; Corpet et al. (1988) Nucleic Acids Res. 16:10881-90; Huang et al. (1992) CABIOS 8:155-65; and Pearson et al. (1994) Meth. Mol. Biol. 24:307-331. The ALIGN program is based on the algorithm of Myers and Miller (1988) supra. A PAM120 weight residue table, a gap length penalty of 12, and a gap penalty of 4 can be used with the ALIGN 10 program when comparing amino acid sequences. The BLAST programs of Altschul et al (1990) J. Mol. Biol. 215:403 are based on the algorithm of Karlin and Altschul (1990) supra. BLAST nucleotide searches can be performed with the BLASTN program, score = 100, wordlength = 12, to obtain nucleotide sequences homologous to a nucleotide sequence encoding a protein of the invention. BLAST 15 protein searches can be performed with the BLASTX program, score = 50, wordlength = 3, to obtain amino acid sequences homologous to a protein or polypeptide of the invention. To obtain gapped alignments for comparison purposes, Gapped BLAST (in BLAST 2.0) can be utilized as described in Altschul et al. (1997) Nucleic Acids Res. 25:3389. Alternatively, PSI-BLAST (in BLAST 20 2.0) can be used to perform an iterated search that detects distant relationships between molecules. See Altschul et al. (1997) supra. When utilizing BLAST, Gapped BLAST, PSI-BLAST, the default parameters of the respective programs (e.g., BLASTN for nucleotide sequences, BLASTX for proteins) can be used. See http://www.ncbi.nlm.nih.gov. Alignment may also be performed manually by inspection. Alignment may also be performed manually by inspection. 25

For purposes of the present invention, comparison of nucleotide or protein sequences for determination of percent sequence identity to the RPA sequences disclosed herein is preferably made using the GCG PileUp program, version 10.00, with its default parameters or any equivalent program. By "equivalent program" is intended any sequence comparison program that, for any two sequences in question, generates an alignment having identical nucleotide or amino acid residue matches and an identical percent sequence identity when compared to the corresponding alignment generated by the preferred program.

30

5

10

15

20

25

30

As used herein, "sequence identity" or "identity" in the context of (c) two nucleic acid or polypeptide sequences makes reference to the residues in the two sequences that are the same when aligned for maximum correspondence over a specified comparison window. When percentage of sequence identity is used in reference to proteins it is recognized that residue positions which are not identical often differ by conservative amino acid substitutions, where amino acid residues are substituted for other amino acid residues with similar chemical properties (e.g., charge or hydrophobicity) and therefore do not change the functional properties of the molecule. When sequences differ in conservative substitutions, the percent sequence identity may be adjusted upwards to correct for the conservative nature of the substitution. Sequences that differ by such conservative substitutions are said to have "sequence similarity" or "similarity". Means for making this adjustment are well known to those of skill in the art. Typically this involves scoring a conservative substitution as a partial rather than a full mismatch, thereby increasing the percentage sequence identity. Thus, for example, where an identical amino acid is given a score of 1 and a non-conservative substitution is given a score of zero, a conservative substitution is given a score between zero and 1. The scoring of conservative substitutions is calculated, e.g., as implemented in the program PC/GENE (Intelligenetics, Mountain View, California).

determined by comparing two optimally aligned sequences over a comparison window, wherein the portion of the polynucleotide sequence in the comparison window may comprise additions or deletions (i.e., gaps) as compared to the reference sequence (which does not comprise additions or deletions) for optimal alignment of the two sequences. The percentage is calculated by determining the number of positions at which the identical nucleic acid base or amino acid residue occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the window of comparison, and multiplying the result by 100 to yield the percentage of sequence identity.

(e)(i) The term "substantial identity" of polynucleotide sequences means that a polynucleotide comprises a sequence that has at least 70% sequence identity, preferably at least 80%, more preferably at least 90%, and most preferably at least

95%, compared to a reference sequence using one of the alignment programs described using standard parameters. One of skill in the art will recognize that these values can be appropriately adjusted to determine corresponding identity of proteins encoded by two nucleotide sequences by taking into account codon degeneracy, amino acid similarity, reading frame positioning, and the like. Substantial identity of amino acid sequences for these purposes normally means sequence identity of at least 60%, more preferably at least 70%, 80%, 90%, and most preferably at least 95%.

Another indication that nucleotide sequences are substantially identical is if two molecules hybridize to each other under stringent conditions. Generally, stringent conditions are selected to be about 5°C lower than the thermal melting point (T_m) for the specific sequence at a defined ionic strength and pH. However, stringent conditions encompass temperatures in the range of about 1°C to about 20°C, depending upon the desired degree of stringency as otherwise qualified herein. Nucleic acids that do not hybridize to each other under stringent conditions are still substantially identical if the polypeptides they encode are substantially identical. This may occur, e.g., when a copy of a nucleic acid is created using the maximum codon degeneracy permitted by the genetic code. One indication that two nucleic acid sequences are substantially identical is when the polypeptide encoded by the first nucleic acid is immunologically cross reactive with the polypeptide encoded by the second nucleic acid.

(e)(ii) The term "substantial identity" in the context of a peptide indicates that a peptide comprises a sequence with at least 70% sequence identity to a reference sequence, preferably 80%, more preferably 85%, most preferably at least 90% or 95% sequence identity to the reference sequence over a specified comparison window. Preferably, optimal alignment is conducted using the homology alignment algorithm of Needleman *et al.* (1970) *J. Mol. Biol. 48*:443. An indication that two peptide sequences are substantially identical is that one peptide is immunologically reactive with antibodies raised against the second peptide. Thus, a peptide is substantially identical to a second peptide, for example, where the two peptides differ only by a conservative substitution. Peptides that are "substantially similar" share sequences as noted above except that residue positions that are not identical may differ by conservative amino acid changes.

Using the nucleic acids of the present invention, one may express a protein of the present invention in a recombinantly engineered cell such as bacteria, yeast, insect, mammalian, or preferably plant cells. The cells produce the protein in a non-natural condition (e.g., in quantity, composition, location, and/or time), because they have been genetically altered through human intervention to do so.

It is expected that those of skill in the art are knowledgeable in the numerous expression systems available for expression of a nucleic acid encoding a protein of the present invention. No attempt to describe in detail the various methods known for the expression of proteins in prokaryotes or eukaryotes will be made.

10

15

20

25

30

In brief summary, the expression of isolated nucleic acids encoding a protein of the present invention will typically be achieved by operably linking, for example, the DNA or cDNA to a promoter (which is either constitutive or inducible), followed by incorporation into an expression vector. The vectors can be suitable for replication and integration in either prokaryotes or eukaryotes. Typical expression vectors contain transcription and translation terminators, initiation sequences, and promoters useful for regulation of the expression of the DNA encoding a protein of the present invention. To obtain high level expression of a cloned gene, it is desirable to construct expression vectors which contain, at the minimum, a strong promoter to direct transcription, a ribosome binding site for translational initiation, and a transcription/translation terminator. One of skill would recognize that modifications can be made to a protein of the present invention without diminishing its biological activity. Some modifications may be made to facilitate the cloning, expression, or incorporation of the targeting molecule into a fusion protein. Such modifications are well known to those of skill in the art and include, for example, a methionine added at the amino terminus to provide an initiation site, or additional amino acids (e.g., poly His) placed on either terminus to create conveniently located restriction sites or termination codons or purification sequences.

Prokaryotic cells may be used as hosts for expression. Prokaryotes most frequently are represented by various strains of *E. coli*; however, other microbial strains may also be used. Commonly used prokaryotic control sequences which are defined herein to include promoters for transcription initiation, optionally with

an operator, along with ribosome binding site sequences, include such commonly used promoters as the beta lactamase (penicillinase) and lactose (lac) promoter systems (Chang et al. (1977) Nature 198:1056), the tryptophan (trp) promoter system (Goeddel et al. (1980) Nucleic Acids Res. 8:4057) and the lambda-derived P L promoter and N-gene ribosome binding site (Shimatake et al. (1981) Nature 292:128). The inclusion of selection markers in DNA vectors transfected in E. coli is also useful. Examples of such markers include genes specifying resistance to ampicillin, tetracycline, or chloramphenicol.

The vector is selected to allow introduction into the appropriate host cell. Bacterial vectors are typically of plasmid or phage origin. Appropriate bacterial cells are infected with phage vector particles or transfected with naked phage vector DNA. If a plasmid vector is used, the bacterial cells are transfected with the plasmid vector DNA. Expression systems for expressing a protein of the present invention are available using *Bacillus sp.* and *Salmonella* (Palva et al. (1983) *Gene* 22:229-235; Mosbach et al. (1983) *Nature* 302:543-545).

10

15

20

25

30

A variety of eukaryotic expression systems such as yeast, insect cell lines, plant and mammalian cells, are known to those of skill in the art. The sequences of the present invention can be expressed in these eukaryotic systems. In some embodiments, transformed/transfected plant cells are employed as expression systems for production of the proteins of the instant invention.

Synthesis of heterologous proteins in yeast is well known. Sherman, F. et al. (1982) Methods in Yeast Genetics, Cold Spring Harbor Laboratory is a well recognized work describing the various methods available to produce the protein in yeast. Two widely utilized yeast for production of eukaryotic proteins are Saccharomyces cerevisia and Pichia pastoris. Vectors, strains, and protocols for expression in Saccharomyces and Pichia are known in the art and available from commercial suppliers (e.g., Invitrogen). Suitable vectors usually have expression control sequences, such as promoters, including 3-phosphoglycerate kinase or alcohol oxidase, and an origin of replication, termination sequences and the like as desired.

A protein of the present invention, once expressed, can be isolated from yeast by lysing the cells and applying standard protein isolation techniques to the lysates. The monitoring of the purification process can be accomplished by using

Western blot techniques or radioimmunoassay of other standard immunoassay techniques.

The sequences encoding proteins of the present invention can also be ligated to various expression vectors for use in transfecting cell cultures of, for 5 instance, mammalian, insect, or plant origin. Illustrative of cell cultures useful for the production of the peptides are mammalian cells. Mammalian cell systems often will be in the form of monolayers of cells although mammalian cell suspensions may also be used. A number of suitable host cell lines capable of expressing intact proteins have been developed in the art, and include the HEK293, 10 BHK21, and CHO cell lines. Expression vectors for these cells can include expression control sequences, such as an origin of replication, a promoter (e.g., the CMV promoter, a HSV tk promoter or pgk (phosphoglycerate kinase promoter)), an enhancer (Queen et al. (1986) Immunol. Rev. 89:49), and necessary processing information sites, such as ribosome binding sites, RNA splice sites, 15 polyadenylation sites (e.g., an SV40 large T Ag poly A addition site), and transcriptional terminator sequences. Other animal cells useful for production of proteins of the present invention are available, for instance, from the American Type Culture Collection Catalogue of Cell Lines and Hybridomas (7th edition, 1992).

Appropriate vectors for expressing proteins of the present invention in insect cells are usually derived from the SF9 baculovirus. Suitable insect cell lines include mosquito larvae, silkworm, armyworm, moth and *Drosophila* cell lines such as a Schneider cell line (See Schneider et al. (1987) J. Embryol. Exp. Morphol. 27: 353-365).

25

30

As with yeast, when higher animal or plant host cells are employed, polyadenylation or transcription terminator sequences are typically incorporated into the vector. An example of a terminator sequence is the polyadenylation sequence from the bovine growth hormone gene. Sequences for accurate splicing of the transcript may also be included. An example of a splicing sequence is the VP1 intron from SV40 (Sprague *et al.* (1983) *J. Virol.* 45:773-781). Additionally, gene sequences to control replication in the host cell may be incorporated into the vector such as those found in bovine papilloma virus-type vectors. Saveria-Campo, M., Bovine Papilloma Virus DNA a Eukaryotic Cloning Vector in *DNA*

Cloning Vol. II a Practical Approach, D.M. Glover, ed., IRL Press, Arlington, Virginia pp. 213-238 (1985).

The sequences of the invention can be introduced into any plant of interest, and used for transformation of any plant species. The sequences to be introduced may be used in expression cassettes for expression in the particular plant of interest.

5

25

30

Plants of interest include, but are not limited to corn (Zea mays), Brassica sp. (e.g., B. napus, B. rapa, B. juncea), particularly those Brassica species useful as sources of seed oil, alfalfa (Medicago sativa), rice (Orvza sativa), rye (Secale cereale), sorghum (Sorghum bicolor, Sorghum vulgare), millet (e.g., pearl millet 10 (Pennisetum glaucum), proso millet (Panicum miliaceum), foxtail millet (Setaria italica), finger millet (Eleusine coracana)), sunflower (Helianthus annuus), safflower (Carthamus tinctorius), wheat (Triticum aestivum), soybean (Glycine max), tobacco (Nicotiana tabacum), potato (Solanum tuberosum), peanuts (Arachis hypogaea), 15 cotton (Gossypium barbadense, Gossypium hirsutum), sweet potato (Ipomoea batatus), cassava (Manihot esculenta), coffee (Cofea spp.), coconut (Cocos nucifera), pineapple (Ananas comosus), citrus trees (Citrus spp.), cocoa (Theobroma cacao), tea (Camellia sinensis), banana (Musa spp.), avocado (Persea americana), fig (Ficus casica), guava (Psidium guajava), mango (Mangifera indica), olive (Olea europaea), 20 papaya (Carica papaya), cashew (Anacardium occidentale), macadamia (Macadamia integrifolia), almond (Prunus amygdalus), sugar beets (Beta vulgaris), sugarcane (Saccharum spp.), oats, barley, vegetables, ornamentals, and conifers.

Vegetables include tomatoes (*Lycopersicon esculentum*), lettuce (e.g., *Lactuca sativa*), green beans (*Phaseolus vulgaris*), lima beans (*Phaseolus limensis*), peas (*Lathyrus* spp.), and members of the genus *Cucumis* such as cucumber (*C. sativus*), cantaloupe (*C. cantalupensis*), and musk melon (*C. melo*). Ornamentals include azalea (*Rhododendron* spp.), hydrangea (*Macrophylla hydrangea*), hibiscus (*Hibiscus rosasanensis*), roses (*Rosa* spp.), tulips (*Tulipa* spp.), daffodils (*Narcissus* spp.), petunias (*Petunia hybrida*), carnation (*Dianthus caryophyllus*), poinsettia (*Euphorbia pulcherrima*), and chrysanthemum. Conifers that may be employed in practicing the present invention include, for example, pines such as loblolly pine (*Pinus taeda*), slash pine (*Pinus elliotii*), ponderosa pine (*Pinus ponderosa*), lodgepole pine (*Pinus contorta*), and Monterey pine (*Pinus radiata*); Douglas-fir

(Pseudoisuga menziesii); Western hemlock (Tsuga canadensis); Sitka spruce (Picea glauca); redwood (Sequoia sempervirens); true firs such as silver fir (Abies amabilis) and balsam fir (Abies balsamea); and cedars such as Western red cedar (Thuja plicata) and Alaska yellow-cedar (Chamaecyparis nootkatensis). Preferably, plants of the present invention are crop plants (for example, corn, alfalfa, sunflower, Brassica, soybean, cotton, safflower, peanut, sorghum, wheat, millet, tobacco, etc.), more preferably corn and soybean plants, yet more preferably corn plants.

5

10

15

20

25

30

Plants of particular interest include grain plants that provide seeds of interest, oil-seed plants, and leguminous plants. Seeds of interest include grain seeds, such as corn, wheat, barley, rice, sorghum, rye, etc. Oil-seed plants include cotton, soybean, safflower, sunflower, *Brassica*, maize, alfalfa, palm, coconut, etc. Leguminous plants include beans and peas. Beans include guar, locust bean, fenugreek, soybean, garden beans, cowpea, mungbean, lima bean, fava bean, lentils, chickpea, etc.

The RPA coding and antisense sequences of the invention are provided in expression cassettes for expression in the plant of interest. The cassette will include 5' and 3' regulatory sequences operably linked to a RPA sequence of the invention. The cassette may additionally contain at least one additional gene to be cotransformed into the organism. Alternatively, the additional gene(s) can be provided on another expression cassette. By "operably linked" is intended a functional linkage between a promoter and a second sequence, wherein the promoter sequence initiates and mediates transcription of the DNA sequence corresponding to the second sequence. Generally, operably linked means that the nucleic acid sequences being linked are contiguous and, where necessary to join two protein coding regions, contiguous and in the same reading frame.

Such an expression cassette is provided with a plurality of restriction sites for insertion of the RPA sequence to be under the transcriptional regulation of the regulatory regions. The expression cassette may additionally contain selectable marker genes.

The expression cassette will include in the 5'-3' direction of transcription, a transcriptional and translational initiation region, a RPA DNA sequence of the invention, and a transcriptional and translational termination region functional in plants. The transcriptional initiation region, the promoter, may be native or

5

10

15

20

25

30

analogous or foreign or heterologous to the plant host. Additionally, the promoter may be the natural sequence or alternatively a synthetic sequence. By "foreign" is intended that the transcriptional initiation region is not found in the native plant into which the transcriptional initiation region is introduced. As used herein, a chimeric gene comprises a coding sequence operably linked to a transcription initiation region that is heterologous to the coding sequence.

While it may be preferable to express the sequences using heterologous promoters, the native promoter sequences may be used. Such constructs would change expression levels of RPA in the plant or plant cell. Thus, the phenotype of the plant or plant cell is altered.

The termination region may be native with the transcriptional initiation region, may be native with the operably linked DNA sequence of interest, or may be derived from another source. Convenient termination regions are available from the Ti-plasmid of A. tumefaciens, such as the octopine synthase and nopaline synthase termination regions. See also Guerineau et al. (1991) Mol. Gen. Genet. 262:141-144; Proudfoot (1991) Cell 64:671-674; Sanfacon et al. (1991) Genes Dev. 5:141-149; Mogen et al. (1990) Plant Cell 2:1261-1272; Munroe et al. (1990) Gene 91:151-158; Ballas et al. (1989) Nucleic Acids Res. 17:7891-7903; and Joshi et al. (1987) Nucleic Acid Res. 15:9627-9639.

Where appropriate, the gene(s) may be optimized for increased expression in the transformed plant. That is, the genes can be synthesized using plant-preferred codons for improved expression. See, for example, Campbell and Gown (1990) *Plant Physiol.* 92:1-11 for a discussion of host-preferred codon usage. Methods are available in the art for synthesizing plant-preferred genes. See, for example, U.S. Patent Nos. 5,380,831, and 5,436,391, and Murray *et al.* (1989) *Nucleic Acids Res.* 17:477-498, herein incorporated by reference.

Additional sequence modifications are known to enhance gene expression in a cellular host. These include elimination of sequences encoding spurious polyadenylation signals, exon-intron splice site signals, transposon-like repeats. and other such well-characterized sequences that may be deleterious to gene expression. The G-C content of the sequence may be adjusted to levels average for a given cellular host, as calculated by reference to known genes expressed in the

host cell. When possible, the sequence is modified to avoid predicted hairpin secondary mRNA structures.

5

10

15

20

25

30

The expression cassettes may additionally contain 5' leader sequences in the expression cassette construct. Such leader sequences can act to enhance translation. Translation leaders are known in the art and include: picornavirus leaders, for example, EMCV leader (Encephalomyocarditis 5' noncoding region) (Elroy-Stein et al. (1989) PNAS USA 86.6126-6130); potyvirus leaders, for example, TEV leader (Tobacco Etch Virus) (Allison et al. (1986); MDMV leader (Maize Dwarf Mosaic Virus); Virology 154:9-20), and human immunoglobulin heavy-chain binding protein (BiP), (Macejak et al. (1991) Nature 353:90-94); untranslated leader from the coat protein mRNA of alfalfa mosaic virus (AMV RNA 4) (Jobling et al. (1987) Nature 325:622-625); tobacco mosaic virus leader (TMV) (Gallie et al. (1989) in Molecular Biology of RNA, ed. Cech (Liss, New York), pp. 237-256); and maize chlorotic mottle virus leader (MCMV) (Lommel et al. (1991) Virology 81:382-385). See also, Della-Cioppa et al. (1987) Plant Physiol. 84:965-968. Other methods known to enhance translation can also be utilized, for example, introns, and the like.

In preparing the expression cassette, the various DNA fragments may be manipulated, so as to provide for the DNA sequences in the proper orientation and, as appropriate, in the proper reading frame. Toward this end, adapters or linkers may be employed to join the DNA fragments or other manipulations may be involved to provide for convenient restriction sites, removal of superfluous DNA, removal of restriction sites, or the like. For this purpose, *in vitro* mutagenesis, primer repair, restriction, annealing, resubstitutions, e.g., transitions and transversions, may be involved.

The sequences of the present invention can be used to transform or transfect any plant. In this manner, genetically modified plants, plant cells, plant tissue, seed, and the like can be obtained. Transformation protocols as well as protocols for introducing nucleotide sequences into plants may vary depending on the type of plant or plant cell, i.e., monocot or dicot, targeted for transformation. Suitable methods of introducing nucleotide sequences into plant cells and subsequent insertion into the plant genome include microinjection (Crossway et al. (1986) Biotechniques 4:320-334), electroporation (Riggs et al. (1986) Proc. Natl.

Acad. Sci. USA 83:5602-5606, Agrobacterium-mediated transformation (Townsend et al., U.S. Pat No. 5,563,055), direct gene transfer (Paszkowski et al. (1984) EMBO J. 3:2717-2722), and ballistic particle acceleration (see, for example, Sanford et al., U.S. Patent No. 4,945,050; Tomes et al., U.S. Patent No. 5,879,918;

- Tomes et al., U.S. Patent No. 5,886,244; Bidney et al., U.S. Patent No. 5,932,782; Tomes et al. (1995) "Direct DNA Transfer into Intact Plant Cells via Microprojectile Bombardment," in Plant Cell, Tissue, and Organ Culture: Fundamental Methods, ed. Gamborg and Phillips (Springer-Verlag, Berlin); and McCabe et al. (1988) Biotechnology 6:923-926). Also see Weissinger et al. (1988)
- Ann. Rev. Genet. 22:421-477; Sanford et al. (1987) Particulate Science and Technology 5:27-37 (onion); Christou et al. (1988) Plant Physiol. 87:671-674 (soybean); McCabe et al. (1988) Bio/Technology 6:923-926 (soybean); Finer and McMullen (1991) In Vitro Cell Dev. Biol. 27P:175-182 (soybean); Singh et al. (1998) Theor. Appl. Genet. 96:319-324 (soybean); Datta et al. (1990)
- Biotechnology 8:736-740 (rice); Klein et al. (1988) Proc. Natl. Acad. Sci. USA 85:4305-4309 (maize); Klein et al. (1988) Biotechnology 6:559-563 (maize); Tomes, U.S. Patent No. 5,240,855; Buising et al., U.S. Patent Nos. 5,322,783 and 5,324,646; Tomes et al. (1995) "Direct DNA Transfer into Intact Plant Cells via Microprojectile Bombardment," in Plant Cell, Tissue, and Organ Culture:
- Fundamental Methods, ed. Gamborg (Springer-Verlag, Berlin) (maize); Klein et al. (1988) Plant Physiol. 91:440-444 (maize); Fromm et al. (1990) Biotechnology 8:833-839 (maize); Hooykaas-Van Slogteren et al. (1984) Nature (London) 311:763-764, Bowen et al., U.S. Patent No. 5,736,369 (cereals); Bytebier et al. (1987) Proc. Natl. Acad. Sci. USA 84:5345-5349 (Liliaceae); De Wet et al. (1985)
- in The Experimental Manipulation of Ovule Tissues, ed. Chapman et al. (Longman, New York), pp. 197-209 (pollen); Kaeppler et al. (1990) Plant Cell Reports 9:415-418 and Kaeppler et al. (1992) Theor. Appl. Genet. 84:560-566 (whisker-mediated transformation); D'Halluin et al. (1992) Plant Cell 4:1495-1505 (electroporation); Li et al. (1993) Plant Cell Reports 12:250-255 and Christou and Ford (1995)
- Annals of Botany 75:407-413 (rice); Osjoda et al. (1996) Nature Biotechnology 14:745-750 (maize via Agrobacterium tumefaciens); all of which are herein incorporated by reference.

The cells that have been transformed may be grown into plants in accordance with conventional ways. See, for example, McCormick et al. (1986) Plant Cell Reports 5:81-84. These plants may then be grown, and either pollinated with the same transformed strain or different strains, and the resulting hybrid having constitutive expression of the desired phenotypic characteristic identified. Two or more generations may be grown to ensure that expression of the desired phenotypic characteristic is stably maintained and inherited and then seeds harvested to ensure expression of the desired phenotypic characteristic has been achieved.

5

10

15

20

25

30

Transgenic plants expressing the selectable marker can be screened for transmission of the nucleic acid of the present invention by, for example, standard immunoblot and DNA detection techniques. Transgenic lines are also typically evaluated on levels of expression of the heterologous nucleic acid. Expression at the RNA level can be determined initially to identify and quantitate expressionpositive plants. Standard techniques for RNA analysis can be employed and include PCR amplification assays using oligonucleotide primers designed to amplify only the heterologous RNA templates and solution hybridization assays using heterologous nucleic acid-specific probes. The RNA-positive plants can then be analyzed for protein expression by Western immunoblot analysis using the specifically reactive antibodies of the present invention. In addition, in situ hybridization and immunocytochemistry according to standard protocols can be done using heterologous nucleic acid specific polynucleotide probes and antibodies, respectively, to localize sites of expression within transgenic tissue. Generally, a number of transgenic lines are usually screened for the incorporated nucleic acid to identify and select plants with the most appropriate expression profiles.

A preferred embodiment is a transgenic plant that is homozygous for the added heterologous nucleic acid; i.e., a transgenic plant that contains two added nucleic acid sequences, one gene at the same locus on each chromosome of a chromosome pair. A homozygous transgenic plant can be obtained by sexually mating (selfing) a heterozygous transgenic plant that contains a single added heterologous nucleic acid, germinating some of the seed produced and analyzing the resulting plants produced for altered RPA expression relative to a control plant

(i.e., native, non-transgenic). Backcrossing to a parental plant and out-crossing with a non-transgenic plant are also contemplated.

5

10

30

The present invention further provides a method for modulating (i.e., increasing or decreasing) RPA levels in a plant or part thereof. Modulation can be effected by increasing or decreasing the total amount of RPA (i.e., its content) and/or the ratio of various RPA subunit proteins (i.e., its composition) in the plant. The method comprises transforming a plant cell with a recombinant expression cassette comprising a polynucleotide of the present invention as described above to obtain a transformed plant cell, growing the transformed plant cell under plant forming conditions, and inducing expression of a polynucleotide of the present invention in the plant for a time sufficient to modulate RPA content and/or composition in the plant or plant part.

In some embodiments, RPA in a plant may be modulated by altering, in vivo or in vitro, the promoter of a non-isolated RPA gene to up- or down-regulate 15 gene expression. In some embodiments, the coding regions of native RPA genes an be altered via substitution, addition, insertion, or deletion to decrease activity of the encoded enzyme. See, e.g., Kmiec, U.S. Patent 5,565,350; Zarling et al., PCT/US93/03868. And in some embodiments, an isolated nucleic acid (e.g., a vector) comprising a promoter sequence is transfected into a plant cell. Subsequently, a plant cell comprising the promoter operably linked to a 20 polynucleotide of the present invention is selected by means known to those of skill in the art such as, but not limited to, Southern blot, DNA sequencing, or PCR analysis using primers specific to the promoter and to the gene and detecting amplicons produced therefrom. A plant or plant part altered or modified by the 25 foregoing embodiments is grown under plant forming conditions for a time sufficient to modulate RPA content and/or composition in the plant. Plant forming conditions are well known in the art and discussed briefly, supra.

In general, content or composition is increased or decreased by at least 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, or 90% relative to a native control plant, plant part, or cell lacking the aforementioned recombinant expression cassette. Modulation in the present invention may occur during and/or subsequent to growth of the plant to the desired stage of development. Modulating nucleic acid expression temporally and/or in particular tissues can be controlled by

5

10

15

20

25

employing the appropriate promoter operably linked to a polynucleotide of the present invention in, for example, sense or antisense orientation as discussed in greater detail, *supra*. Induction of expression of a polynucleotide of the present invention can also be controlled by exogenous administration of an effective amount of inducing compound. Inducible promoters and inducing compounds that activate expression from these promoters are well known in the art. In preferred embodiments, RPA is modulated in monocots, particularly maize.

The ability of RPA to interact with multiple proteins or protein complexes allows it to participate and regulate these multiple pathways of DNA metabolism. For example, it has been shown in mammalian systems that are RPA interacts with DNA polymerase alpha (Barun et al. (1997) Biochemistry 36:8443-8454), p53 (Dutta et al. (1993) Nature 365:79-82), RAD 62 (Park et al. (1996) J. Biol. Chem. 271:18996-19000).

Participation of the middle subunit of RPA in protein-protein interactions has also been shown. Examples of such interactions include, but are not limited to interactions with XPA protein and RAD 52 (He et al. (1995) Nature 374:566-69; Matsuda et al. (1995) J. Biol. Chem. 270:4152-57; Li et al. (1995) Mol. Cell. Biol. 15:5396-402, Park et al. (1996) J. Biol. Chem. 271:18996-19000); and PCNA (Shivji et al. (1995) Biochemistry 34:5011-5017).

Similarly, yeast RPA has been shown to be involved in multiple functions in DNA metabolism (Umezu et al. (1998) Genetics 148:989-1005). Therefore, the proteins of the invention may be useful as a ligand to purify and clone other proteins involved in DNA recombination, repair, and replication. Particularly, the maize proteins may be useful to purify other maize proteins involved in DNA metabolism. For example, the RPA proteins of the invention may be insolubilized on a solid matrix (e.g. agrose or nylon beads) for affinity purification, or the RPA cDNA may be used as a bait in a yeast to-hybrid system. In this manner, other proteins may be used identified and isolated.

The following examples are offered by way of illustration and not by way of limitation.

PCT/US99/21277 WO 00/15816

EXPERIMENTAL

Example 1: cDNA Cloning

5

10

15

20

30

Total RNA was isolated from corn tissues with TRIzol Reagent (Life Technology, Inc. Gaithersburg, MD) using a modification of the guanidine isothiocyanate/acid-phenol procedure described by Chomozynski and Sacchi (Chomczynski et al. (1987) Anal. Biochem. 162:156). In brief, plant tissue samples were pulverized in liquid nitrogen before the addition of the TRIzol Reagent, and then were further homogenized with a mortar and pestle. Addition of chloroform by centrifugation was conducted for separation of an aqueous phase and an organic phase. The total RNA was recovered by precipitation with isopropyl alcohol from the aqueous phase.

The selection of poly(A)+RNA from total RNA was performed using PolyATract system (Promega Corporation, Madison, WI). In brief, biotinylated oligo (dT) primers were used to hybridize to the 3' poly(A) tails on mRNA. The hybrids were captured using streptavidin coupled to paramagnetic particles and a magnetic separation stand. The mRNA was washed at high stringent condition and cluted by Rnase-free deionized water.

Synthesis of the cDNA was performed and unidirectional cDNA libraries were constructed using the SuperScript Plasmid System (Life Technology, Inc., Gaithersburg, MD). First strand of CDNA was synthesized by priming an oligo(dT) primer containing a Not I site. The reaction was catalyzed by SuperScript Reverse Transcriptase II at 45°C. The second strand of cDNA was labeled with α^{-32} P-dCTP and portions of the molecules smaller than 500 base pairs and unligated adapters were removed by Sephacryl-S400 chromatography. The 25 selected cDNA molecules were ligated into pSPORT1 reference vector between the Not I and Sal I sites.

Individual colonies were picked and DNA was prepared either by PCR with M13 forward primers and M13 reverse primers, or by plasmid miniprep isolation. All the cDNA clones were sequenced using M13 reverse primers.

Two maize homologues for RPA large subunit (ZmRPALSH) have been isolated. The genes map to two different chromosomes as shown below in Table 1.

The amino acid and nucleotide sequences for the two homologues are set forth in SEQ ID NOs: 1-4.

5

Table 1

Maize RPA Large Subunit Genes Map to Two Different Chromosomes

Clone ID	Chromosome No.	Homologue
CBPBS68	c 9	ZmRPALSH1
CCRBJ83	с9	ZmRPALSH1
CDPGS47	c 9	ZmRPALSH1
CHCLE65	с9	ZmRPALSH1
CJLPL35	с9	ZmRPALSH1
COMGE67	с9	ZmRPALSH1
CBAAK06	c9	ZmRPALSH2
CDPGS46	c9	ZmRPALSH2
CERAG93	c9	ZmRPALSH2
COMFY67	c9	ZmRPALSH2

Ten ESTs, which form two different contigs for maize RPA large subunit, were used as probes for mapping experiments. Each contig represents one maize homologue for RPALS.

Seven maize homologues for RPA middle subunit (ZmRPAMSH) have been isolated. The genes map to chromosomes 5 as shown below in Table 2. The nucleotide and amino acid sequences of the seven homologues are set forth in SEQ ID NOs: 11-22.

Table 2

Maize Homologues of Eukaryotic Replication Protein A Middle Subunit

Clone ID	Homologue	Library	Map
			Position
CCRBK63	ZmRPAMSH-1	P0026	C5
CGEUZ26	ZmRPAMSH-2	P0002	TBD
CGEVJ74	ZmRPAMSH-3	P0002	TBD
CHSBX01	ZmRPABMS-4	P0118	C5
CIMME04	ZmRPAMSH-5	P0114	C5
CRTBB78	ZmRPAMSH-6	P0041	C5
CVRAP89	ZmRPAMSH-7	P0057	C5

5 TBD = To be determined.

10

20

Example 2: Transformation and Regeneration of Trnsgenic Plants:

Immature maize embryos from greenhouse donor plants are bombarded with a plasmid containing the RPA antisense sequence of the invention operably linked to a pathogen-inducible promoter (Figure 2) plus a plasmid containing the selectable marker gene PAT (Wohlleben et al. (1988) Gene 70:25-37) that confers resistance to the herbicide Bialaphos. Transformation is performed as follows. All media recipes are in the Appendix.

15 Preparation of Target Tissue

The ears are surface sterilized in 30% Chlorox bleach plus 0.5% Micro detergent for 20 minutes, and rinsed two times with sterile water. The immature embryos are excised and placed embryo axis side down (scutellum side up), 25 embryos per plate, on 560Y medium for 4 hours and then aligned within the 2.5-cm target zone in preparation for bombardment.

Preparation of DNA

5

10

30

A plasmid vector comprising the RPA sequence of the invention operably linked to a ubiquitin promoter is made. This plasmid DNA plus plasmid DNA containing a PAT selectable marker is precipitated onto 1.1 µm (average diameter) tungsten pellets using a CaCl₂ precipitation procedure as follows:

100 μl prepared tungsten particles in water
10 μl (1 μg) DNA in TrisEDTA buffer (1 μg total)
100 μl 2.5 M CaCl₂
10 μl 0.1 M spermidine

Each reagent is added sequentially to the tungsten particle suspension, while maintained on the multitube vortexer. The final mixture is sonicated briefly and allowed to incubate under constant vortexing for 10 minutes. After the precipitation period, the tubes are centrifuged briefly, liquid removed, washed with 500 ml 100% ethanol, and centrifuged for 30 seconds. Again the liquid is removed, and 105 µl 100% ethanol is added to the final tungsten particle pellet. For particle gun bombardment, the tungsten/DNA particles are briefly sonicated and 10 µl spotted onto the center of each macrocarrier and allowed to dry about 2 minutes before bombardment.

Particle Gun Treatment

The sample plates are bombarded at level #4 in particle gun #HE34-1 or #HE34-2. All samples receive a single shot at 650 PSI, with a total of ten aliquots taken from each tube of prepared particles/DNA.

Subsequent Treatment

Following bombardment, the embryos are kept on 560Y medium for 2 days, then transferred to 560R selection medium containing 3 mg/liter Bialaphos, and subcultured every 2 weeks. After approximately 10 weeks of selection, selection-resistant callus clones are transferred to 288J medium to initiate plant regeneration. Following somatic embryo maturation (2-4 weeks), well-developed

somatic embryos are transferred to medium for germination and transferred to the lighted culture room. Approximately 7-10 days later, developing plantlets are transferred to 272V hormone-free medium in tubes for 7-10 days until plantlets are well established. Plants are then transferred to inserts in flats (equivalent to 2.5"

pot) containing potting soil and grown for 1 week in a growth chamber, subsequently grown an additional 1-2 weeks in the greenhouse, then transferred to classic 600 pots (1.6 gallon) and grown to maturity. Plants are monitored and scored for expression of the RPA gene of interest.

APPENDIX

272 V

Ingredient	Amount	Unit
D-I H ₂ O	950.000	MI
MS Salts (GIBCO 11117-074)	4.300	G
Myo-Inositol	0.100	G
MS Vitamins Stock Solution ##	5.000	Ml
Sucrose	40.000	G
Bacto-Agar @	6.000	G

Directions:

- 5 @ = Add after bringing up to volume
 - Dissolve ingredients in polished D-I H₂O in sequence
 - Adjust to pH 5.6
 - Bring up to volume with polished D-I H₂O after adjusting pH
 - Sterilize and cool to 60°C.
- ## = Dissolve 0.100 g of Nicotinic Acid; 0.020 g of Thiamine.HCL; 0.100 g of Pyridoxine.HCL; and 0.400 g of Glycine in 875.00 ml of polished D-I H₂O in sequence. Bring up to volume with polished D-I H₂O. Make in 400 ml portions. Thiamine.HCL & Pyridoxine.HCL are in Dark Desiccator. Store for one month, unless contamination or precipitation occurs, then make fresh stock.
- 15 Total Volume (L) = 1.00

288 J

Ingredient	Amount	Unit
D-I H ₂ O	950.000	Ml
MS Salts	4.300	G
Myo-Inositol	0.100	G
MS Vitamins Stock Solution ##	5.000	Ml
Zeatin .5mg/ml	1.000	Ml
Sucrose	60.000	G
Gelrite @	3.000	G
Indoleacetic Acid 0.5 mg/ml #	2.000	Ml
0.1mM Abscisic Acid	1.000	Ml
Bialaphos 1 mg/ml #	3.000	Ml

Directions:

- @ = Add after bringing up to volume
- 5 Dissolve ingredients in polished D-I H₂O in sequence

Adjust to pH 5.6

Bring up to volume with polished D-I H_2O after adjusting pH Sterilize and cool to 60°C.

Add 3.5g/L of Gelrite for cell biology.

- ## = Dissolve 0.100 g of Nicotinic Acid; 0.020 g of Thiamine.HCL; 0.100 g of Pyridoxine.HCL; and 0.400 g of Glycine in 875.00 ml of polished D-I H₂O in sequence. Bring up to volume with polished D-I H₂O. Make in 400 ml portions. Thiamine.HCL & Pyridoxine.HCL are in Dark Desiccator. Store for one month, unless contamination or precipitation occurs, then make fresh stock.
- 15 Total Volume (L) = 1.00

560 R

Ingredient	Amount	Unit
D-I Water, Filtered	950.000	Ml
CHU (N6) Basal Salts (SIGMA C-1416)	4.000	G
Eriksson's Vitamin Mix (1000X SIGMA-1511)	1.000	Ml
Thiamine.HCL 0.4mg/ml	1.250	Ml
Sucrose	30.000	G
2, 4-D 0.5mg/ml	4.000	Ml
Gelrite @	3.000	G
Silver Nitrate 2mg/ml #	0.425	Ml
Bialaphos 1mg/ml #	3.000	MI

Directions:

5 @ = Add after bringing up to volume

= Add after sterilizing and cooling to temp.

Dissolve ingredients in D-I H₂O in sequence

Adjust to pH 5.8 with KOH

Bring up to volume with D-I H₂O

10 Sterilize and cool to room temp.

Total Volume (L) = 1.00

560 Y

Ingredient	Amount	Unit
D-I Water, Filtered	950.000	Ml
CHU (N6) Basal Salts (SIGMA C-1416)	4.000	G
Eriksson's Vitamin Mix (1000X SIGMA-1511)	1.000	Ml
Thiamine.HCL 0.4mg/ml	1.250	Ml
Sucrose	120.000	G
2,4-D 0.5mg/ml	2.000	Ml
L-Proline	2.880	G
Gelrite @	2.000	G
Silver Nitrate 2mg/ml #	4.250	Ml

Directions:

@ = Add after bringing up to volume

5 # = Add after sterilizing and cooling to temp.

Dissolve ingredients in D-I H₂O in sequence

Adjust to pH 5.8 with KOH

Bring up to volume with D-I H₂O

Sterilize and cool to room temp.

10 ** Autoclave less time because of increased sucrose**

Total Volume (L) = 1.00

All publications and patent applications mentioned in the specification are indicative of the level of those skilled in the art to which this invention pertains. All publications and patent applications are herein incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference.

Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, it will be obvious that certain changes and modifications may be practiced within the scope of the appended claims.

Applicant's or agent's		International application No.
file reference	5718-59-1	PCT/US99/

INDICATIONS RELATING TO DEPOSITED MICROORGANISM OR OTHER BIOLOGICAL MATERIAL

(PCT Rule 13bis)

A.	The indications made below relate to the deposited microorganism of 8 and 13	or other biological material referred to in the description on page 5, lines 5,									
В.	IDENTIFICATION OF DEPOSIT	Further deposits are identified on an additional sheet									
Nam	ne of depository institution American Type Culture Collect	tion									
Add	dress of depositary institution (including postal code and country)										
	10801 University Blvd. Manassas, VA 20110-2209 USA										
Date	e of deposit	Accession Number									
	21 August 1998 (21.08.98)	98843									
C.	ADDITIONAL INDICATIONS (leave blank if not applicable)	This information is continued on an additional sheet									
Acc	cession No. 98754 - page 5, lines 5, 8 and 13 - Date of de	eposit : 26 May 1998 (26.05.98)									
D.	DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (i	if the indicators are not for all designated States)									
	E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)										
Nur	e indications listed below will be submitted to the International Bureau I mber of Deposit")	later (specify the general nature of the indications e.g., Accession									
	For receiving Office use only	For International Bureau use only									
	This sheet was received with the international application	This sheet was received with the International Bureau on:									
Aut	thorized officer	Authorized officer									
Ì											

THAT WHICH IS CLAIMED:

5

25

1. An isolated protein having the amino acid sequence selected from the group consisting of:

- a) an amino acid sequence of a maize replication protein A large subunit;
 - b) an amino acid an amino acid sequence of a plant replication protein A middle subunit;
- c) an amino acid sequence set forth in SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 12, SEQ ID NO: 14, SEQ ID NO: 16, SEQ ID NO: 18, SEQ ID NO: 20, and SEQ ID NO: 22;
 - d) an amino acid sequence having substantial identity to an amino acid sequence of a), b), or c);
 - e) an amino acid sequence comprising at least 20 contiguous residues of an amino acid sequence of a), b, or c);
- 15 f) a variant of an amino acid sequence of a), b, or c).
 - 2. An isolated nucleotide sequence selected from the group consisting of:
- a) a nucleotide sequence encoding a maize replication protein
 A (RPA) large subunit;
 - b) a nucleotide sequence encoding a plant replication protein A (RPA) middle subunit;
 - c) a nucleotide sequence set forth in SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 17, SEQ ID NO: 19, and SEQ ID NO: 21;
 - d) a nucleotide sequence comprising at least 20 contiguous nucleotides of a nucleotide sequence of a) b), or c);
 - e) an antisense nucleotide sequence corresponding to a nucleotide sequence of a), b), or c);
- 30 f) a nucleotide sequence that hybridizes to the nucleotide sequences of a), b), or c) under stringent conditions; and

g) a nucleotide sequence that encodes an amino acid sequence according to claim 1.

- A DNA construct comprising a nucleotide sequence according to
 claim 2 wherein said nucleotide sequence is operably linked to a promoter that drives expression in a plant cell.
 - 4. The DNA construct of claim 3, wherein said promoter is a tissue-preferred promoter.

10

- 5. The DNA construct of claim 4, wherein said promoter is a pathogen-inducible promoter.
- 6. The DNA construct of claim 5, wherein said nucleotide sequence is an antisense sequence.
 - 7. The DNA construct of claim 3, wherein said promoter is a constitutive promoter.
- 20 8. A method for enhancing homologous recombination in a plant cell, said method comprising transforming said plant cell with at least one nucleotide sequence operably linked to a heterologous promoter that drives expression in a plant cell, said nucleotide sequence selected from the group consisting of:
- a) a nucleotide sequence encoding a maize replication protein
 A (RPA) large subunit;
 - b) a nucleotide sequence encoding a plant replication protein A (RPA) middle subunit;
 - c) a nucleotide sequence set forth in SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 17, SEQ ID NO: 19, and SEQ ID NO: 21;
 - d) a nucleotide sequence comprising at least 20 contiguous nucleotides of a nucleotide sequence of a) b), or c);

e) a nucleotide sequence that hybridizes to the nucleotide sequences of a), b), or c) under stringent conditions; and

f) a nucleotide sequence that encodes an amino acid sequence according to claim 1.

5

- 9. The method of claim 8, wherein said promoter is a constitutive promoter.
- The method of claim 9, wherein said promoter is an ubiquitin promoter.
 - 11. A method for increasing pathogen resistance in a plant cell, method comprising transforming said plant cell with at least one nucleotide sequence operably linked to a pathogen-inducible promoter said nucleotide sequence selected from the group consisting of:
 - a) an antisense nucleotide sequence corresponding to a maize replication protein A large subunit, and
 - b) an antisense nucleotide sequence corresponding to a plant replication protein A middle subunit

20

- 12. A transformed plant cell having stably incorporated into its genome at least one nucleotide sequence, said nucleotide sequence operably linked to a heterologous promoter that drives expression in a plant cell, wherein said nucleotide sequence is selected from the group consisting of:
- a) a nucleotide sequence encoding a maize replication protein A (RPA) large subunit;
 - b) a nucleotide sequence encoding a plant replication protein A (RPA) middle subunit;
- c) a nucleotide sequence set forth in SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 17, SEQ ID NO: 19, and SEQ ID NO: 21;
 - d) a nucleotide sequence comprising at least 20 contiguous nucleotides of a nucleotide sequence of a) b), or c);

e) an antisense nucleotide sequence corresponding to a nucleotide sequence of a), b), or c);

- f) a nucleotide sequence that hybridizes to the nucleotide sequences of a), b), or c) under stringent conditions; and
- 5 g) a nucleotide sequence that encodes an amino acid sequence according to claim 1.
 - 13. A transformed plant having stably incorporated into its genome at least one nucleotide sequence, said nucleotide sequence operably linked to a heterologous promoter that drives expression in a plant cell, wherein said nucleotide sequence is selected from the group consisting of:

- a) a nucleotide sequence encoding a maize replication protein A (RPA) large subunit;
- b) a nucleotide sequence encoding a plant replication protein A (RPA) middle subunit;
 - c) a nucleotide sequence set forth in SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 17, SEQ ID NO: 19, and SEQ ID NO: 21;
- d) a nucleotide sequence comprising at least 20 contiguous nucleotides of a nucleotide sequence of a) b), or c);
 - e) an antisense nucleotide sequence corresponding to a nucleotide sequence of a), b), or c);
 - f) a nucleotide sequence that hybridizes to the nucleotide sequences of a), b), or c) under stringent conditions; and
- g) a nucleotide sequence that encodes an amino acid sequence according to claim 1.
 - 14. Seed of the plant of claim 13.
- The plant claim 13, wherein said plant is a monocot.
 - 16. The plant of claim 15, wherein said monocot is maize, wheat, rice, barley, sorghum, or rye.

- 17. The plant of claim 13, wherein said plant is a dicot.
- The plant of claim 17, wherein said dicot is selected from the group consisting of soybean, canola, sunflower, alfalfa, or safflower.
 - 19. Seed of the plant of claim 17.
- 20. A method for modulating DNA metabolism in a plant cell, said method comprising transforming said plant cell with at least one nucleotide sequence operably linked to a promoter wherein said nucleotide sequence is selected from the group consisting of:
 - a) a nucleotide sequence encoding a maize replication protein A (RPA) large subunit;
- b) a nucleotide sequence encoding a plant replication protein A (RPA) middle subunit;
 - c) a nucleotide sequence set forth in SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 17, SEQ ID NO: 19, and SEQ ID NO: 21;
- d) a nucleotide sequence comprising at least 20 contiguous nucleotides of a nucleotide sequence of a) b), or c);
 - e) an antisense nucleotide sequence corresponding to a nucleotide sequence of a), b), or c);
- f) a nucleotide sequence that hybridizes to the nucleotide 25 sequences of a), b), or c) under stringent conditions; and
 - g) a nucleotide sequence that encodes an amino acid sequence according to claim 1.
- 21. A method for influencing cell cycle in a plant cell, said method comprising transforming said plant cell with at least one nucleotide sequence operably linked to a promoter wherein said nucleotide sequence is selected from the group consisting of:

a) a nucleotide sequence encoding a maize replication protein A (RPA) large subunit;

- b) a nucleotide sequence encoding a plant replication protein A (RPA) middle subunit;
- 5 c) a nucleotide sequence set forth in SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 17, SEQ ID NO: 19, and SEQ ID NO: 21;
 - d) a nucleotide sequence comprising at least 20 contiguous nucleotides of a nucleotide sequence of a) b), or c);
- 10 e) an antisense nucleotide sequence corresponding to a nucleotide sequence of a), b), or c);
 - f) a nucleotide sequence that hybridizes to the nucleotide sequences of a), b), or c) under stringent conditions; and
- g) a nucleotide sequence that encodes an amino acid sequence according to claim 1.

ZMRPALSH1 ZMRPALSH2 024183 Rfal_Xenla Rfal_Human Rfal_Drome Rfal_Schpo Rfal_Yeast	~~MDAAKLVT MDSDAAPSVT ~~~MALPQLS ~~~MVGQLS ~~~MVLASLS ~~~MAERLS	PVAVSHIL PGAVAFVLEN EGAISA-MLG EGAIAAIMQK TGVIARIM.H VGALRIINTS	AHPSAGSDGA I ASPDAATGVP GDSSCKPT GDTNIKPI GEVVDAPV DASSFPPNPI	VTDLVVQVLD VPEIVLQVVD LQVINIRPIN LQVINIRPIT LQILAIKKIN LQVLTVKELN	50 LKSIGMGS.R LKSVGTGS.R LKPIGTR TGNSPPR TGNSPPR SAADSER SNPTSGAPKR KSDGANSNRK
ZMRPALSH1 ZMRPALSH2 024183 Rfal_Human Rfal_Human Rfal_Drome Rfal_Schpo Rfal_Yeast	51 FSFTASDGND FSFTATDGKD FTFLASDGKD YRLLMSDGLN YRLLMSDGLN YRILISDGKY YRVVLSDSIN NLIMISDGIY	KIKA.MLPTY KIKA.MLPTN KIKT.MLLTQ TLSSFMLATQ TLSSFMLATQ FNSYAMLASQ YAQS.MLSTQ HMKA.LLRNQ	FGSEVRSGNL LAPEVRSGNI LNSLVDNNLL LNPLVEEEQL LNVMQHNGEL LNHLVAENKL	KNFGLIRILD KNLGLIRIID QNLGVIRVLD ATNCICQVSR SSNCVCQIHR EEFTIVQLDK QKGAGVQLTQ QRGDIIRV	100 YTCNSVKG YTCNVVKG YTCNTIGE FIVNNL.KD. FIVNTL.KD. YVTSLVGKDG FTVNVMKE IIAEPAIVRE
ZMRPALSH1 ZMRPALSH2 024183 Rfal_Xenla Rfal_Human Rfal_Drome Rfal_Schpo Rfal_Yeast	101 NADKVLIVVK KDDKVLVVIK KQEKVLIITK .GRRVIIVME .GRRVVILME AGKRVLIISE .RKILIVLG RKKYVLLVDD	CETVCEAL CELVCQAL LEVVFKAL LDVLKSADLV LEVLKSAEAV LTVVNPGAEV LNVLTELG.V FELVQSRADM	DAE INGEAKK DAE INGEAKK DSE IKCEAEK MGK IGNPQPY GVK IGNPVPY KSK IGEPVTY MDK IGNPAGL VNQTSTFLDN	EDPPIVLK EEPPIVLK QEEKPAILLS NDGQPQPA NEGLGQPQVA ENAAKQDLAP ETVDALRQQQ YFSEHPNETL	150 PKDEGSVVAE PKDECVGV PKEESVVLSK APAPASAPA. PPAPAASPAA KPAVTSNSKP NEQNNASAPR KDEDITDSGN
ZMRPALSH1 ZMRPALSH2 024183 Rfal_Xenla Rfal_Human Rfal_Drome Rfal_Schpo Rfal_Yeast	151 ETNSPPL. TSPL. PTNAPPLP PAPSKLQ SSRPQPQNGS IAKKEPSHNN TGISTSTNSF VANQTN	VMKPKQEV VMKPKQEV PVVLKPKQEV NNSAPPPSMN SGMGSTVSKA NN YGNNAAATAP ASNAGVPDML	KSASQIVTEQ KSASQIVTEQ KSASQIVNEQ RGTSKLFG YGASKTFGKA APPPMMKKPA HSNSNLNANE	RGNAAPATRL RGNAAPATRL RGNAAPAARL .GGSLLNTPG AGPSLSHTSG NIVMNSS APNSL RKFANENPNS	200 SMTRRVHPLI SMTRRVHPLI SMTRRVHPLI AMTRRVHPLI GSQSKVVPIA GTQSKVVPIA INSGMTHPIS .STIIYPIE QKTRPIFAIE
ZMRPALSH1 ZMRPALSH2 024183 Rfal_Xenla Rfal_Human Rfal_Drome Rfal_Schpo Rfal_Yeast	201 TLNPYQGNWV TLNPYQGNWV SLNPYQGNWI SLNPYQSKWT SLTPYQSKWT SLSPYQNKWV GLSPYQNKWT	IKVRVTSKGN IKVRVTSKGN IKVRVTSKGN VRARVTNKGQ ICARVTNKSQ IKARVTSKSG IRARVTNKSE IKARVSYKGE	LRTYRNARGE LRTYRNARGE LRTYKNARGE IRTWSNSRGE IRTWSNSRGE IRTWSNARGE VKHWHNQRGE IKTWHNQRGD	GKLFSTEHVD GKLFSTELVD GKLFSMDLMD GKLFSVNLLD	EDGTQIQATM EDGTQIQATM VDGTQIQATM VDGTQIQATM ESG EIRATA ESG EIRATA ESG EIRATA ESG EIRATA

TO FIG. 1B.

Comparison of eukaryotic RPA LS amino acid sequences FIG. 1A.

2/4

FROM FIG. 1A.

ZMRPALSH1 ZMRPALSH2 024183 Rfal_Xenla Rfal_Human Rfal_Drome Rfal_Schpo Rfal_Yeast	FNDAAKKFYF FNEAAKKFYF FNEQADKFFS FNEQVDKFFP FKEQCDKFYD FNDQVDAFYD	FELGKVYYV MFELGKVYYI IEVNKVYYF LIEVNKVYYF LIQVDSVYYI ILQEGSVYYI	SKGSLRIANK SKGSLRIANK SKGSLRVANK SKGTLKIANK SKGTLKIANK SKCQLKPANK SRCRVNIAKK SKAKLQPAKP	QFKTVKNDYE QFKTVQNDYE QFKTVHNDYE QYTSVKNDYE QFTAVKNDYE QYSSLNNAYE QYTNVQNEYE QFTNLTHPYE	300 LSLNENAIVE MSLNENAIVE MTLNENAVVE MTFNSETSVI MTFNNETSVM MTFSGETVVQ LMFERDTEIR LNLDRDTVIE
ZMRPALSH1 ZMRPALSH2 024183 Rfal_Xenia Rfal_Human Rfal_Drome Rfal_Schpo Rfal_Yeast	LCEDTDDDPI KAEDQTAV ECFDESNV		DQLGPYVGGR DQLGSYVGGR DQLGPYVGGR GELES.KNKD DDLEN.KSKD SDVSG.MENK QEVGD.VAKD DAIQN.QEVN	ELVDIVGVVQ ELVDIVGVVQ ELVDVIGVVQ TVLDIIGVCK SLVDIIGICK AAVDTIGICK AVIDVIGVLQ SNVDVLGIIQ	350 SVSPTLSVRR SVSPTLSVRR SVSPTLSVRR NVEEVTKVTI SYEDATKITV EVGELQSFVA NVGPVQQITS TINPHFELTS
ZMRPALSH1 ZMRPALSH2 024183 Rfal_Xenla Rfal_Human Rfal_Drome Rfal_Schpo Rfal_Yeast	351 KIDNETIPKR KIDNETIPKR KIDNETIPKR KSNNREVSKR RSNNREVAKR RTTNKEFKKR RATSRGFDKR RA GKKFDRR	DIVVADDSGK DIVVADDSSK DIVVADDSSK SIHLMDSSGK NIYLMDTSGK DITLVDMSNS DITIVDDSGF	TVTISLWNDL TVSISLVNDL TVTISLWNDL VVSTTLWGED VVTATLWGED AISLTLWGDD EMRVTLWGKT SISVGLWNQQ	ATTTGQELLD ATTTGQELLD ATTTGQELLD ADKFD ADKFD AVNFD AIEFS ALDFN	400 MVDSSPVVAI MADSSPVVAI MVDSAPIIAI GSRUPVVAI GSRQPVLAI GHVQPVILV VSEESILAF LPEGSVAAI
ZMRPALSH1 ZMRPALSH2 024183 Rfal_Xenla Rfal_Human Rfal_Drome Rfal_Schpo Rfal_Yeast	401 KSLKVSDFQ KSLKVSDFQ KSLKVSDFQ KGARLSDF GGARVSDF GGARVSDF GGARVSDF KGTRINEFNG KGVKVNDFQ KGVKVTDF G	GVSLSTIGRS GVSLSTVGKS GLSLSTVGRS GRSLSVLSSS GRSLSVLESSS GKSLSLGGGS GRSLSMLTSS GKSLSMGFSS	TLEINPDLPE TLAINPDLHE TIVVNPDLPE TVMINPDIPE TIIANPDIPE IMKINPDIPE TMSVDPDIQE TLIPNPEIPE	SHLLDGWYDG	450 EGKDTSLAPI EGKDTSLAPI EGKGTSMASI EGQVVEGTSI EGQALDGVSI GGGDSVANMV QGRGQEFAKH KGRNANFITL
ZMRPALSH1 ZMRPALSH2 024183 Rfal_Xenla Rfal_Human Rfal_Drome Rfal_Schpo Rfal_Yeast	451 SAEAGATRAG GAEMGAARAG GSDMGASRVG SESRGG. GTG SDLKSG. GVG SARTGG G SVISSTLSTT KQEPGMGGQS	GFKSTYSD GARSMYSD GGNTN GSNTN SFSTE GRSAE	RVFLSHITSD RVFLSHITSD WKSLLEVKNE WKTLYEVKSE WMTLKDARAR RKNIAEVQAE	PAMGQEKPVF PNLGQDKPVF NLGHGEKADY NLGQGDKPDY NLGSGDKPDY HLGMSETPDY	500 FSLYAIISHI FSLYAIISHI FSLNAYISLI FTSVATIVYL FSSVATVVYL FQCKAVVHIV FSLKGTIVYI FSVKAAISFL

TO FIG. 1C.


Comparison of eukaryotic RPA LS amino acid sequences FIG. 1B.

3/4

FROM FIG. 1B.

```
550
                       501
                                                                                     EGÖQKNDSEC
EGCQKNDSEC
EGCQKNDAEC
EKCNKEFPNF
                      KPDQNMWYRA
KPDQNMWYRA
                                                                 TEAFGSGYWC
TETFGSGYWC
TEAMGSGYWC
                                                                                                          SLRYIMVIKU
SLRYIMVIKV
                                                      CNKKY
   ZMRPALSH1
                                                     CNKKY
CNKKY
   ZMRPALSH2
         024183
                                            CKT
                                                                                                          SLRYIMVIKV
                       KPDQTMWYRA
                                            CIPSODCWKKY
CIPTODCWKKY
CIPOSDCWKKY
CIPAADCWKKY
                       RKE. NCLYQA
                                                                 IDQQNGLFRC
                                                                                                          KYRLILSANI
 Rfal_Xenla
                                                                IDOONGLYRO EKODTEFPNF
VDEGNDOFRO EKONALFPNF
FDOG GSWRO EKONKEYDAP
LEQPDCTWRO EKONKEYDAP
                      REK NCMYQA
 Rfal Human
                                                                                                           KYRMILSVNI
 Rfal_Drome
Rfal_Schpo
Rfal_Yeast
                      KQE:NAFYRA
                                                                                                          KYRLLINMSI
                      RKK NVSYPA
KVD NFAYPA
                                                                                                          QYRYIITIAV
                                            CSNENCNKKV
                                                                                                          NWRYILTISI
                                                                                                                        600
                      SDPTGEAWYS
SDPTGEAWFS
SDPTGEAWLS
ADFGENQWIT
                                                                                     RKEEGDDSYV
RKEEGDDSYV
RKEEGDDSYL
.KEKNEGAYD
                                          VFNEHAEKII GCSADELDRI
VFNEHAEKII GCSADELDRI
LFNDQAERIV GCSADELDRI
                                                                                                         LKLKEATWYP
LKLKEATWYP
LKLKEATWYP
   ZMRPALSH1
   ZMRPALSH2
                                           LFNDQAERIV
CFQESAISIL
CFQESAEAIL
        024183
                                                                                                          EVFQNANFRS
EVFQNANFRS
QIFSALNFTS
                                                                GQNATYLGEL
 Rfal_Xenia
                                                                                     KDKNEQAFE
LENDPAKAE
                                                                GONAAYLGEL
GHTSQEVGEA
 Rfal Human ADFQENQWYT
                                           SFNEVGEQLL
Rfal_Drome
                      GDWTSNRWVS
                                           VFDDVGKLIM
                                                                                      .QENDENAFM
Rfal_Schpo GDHTGQLWLN
                                                                HKTADELNDL
                                                                                                          NCMAEACYMP
Rfal Yeast IDETNOLVLT LFDDQAKQLL GVDANTLMSL
                                                                                                          KITQSIQMNE
                                                                                      KEEDPNEFT
                                                                                                                       650
                      601
                                                               TVRGEAPVDF
TVRSEAPVEH
TVRSEAPVDH
TAVDVKPVDH
TVMDVKPVDY
TVQSVAPINH
TVMSINQMDW
                                                                                    AAESKYLLEE
AAESKYLLEQ
AAEAKYMLEE
KEYSRRLIMN
REYGRRLVMS
KEYNKHLLKE
KEESKRLINF
RAEADYLADE
ZMRPALSHI HLFRVSVTQH EYMNEKRQRI
ZMRPALSH2 HLFRVSVTQH EYNNEKRQRI
O24183 HLFRVSVTQN EYMNEKRQRI
Rfal_Xenla YTFRARVKLE TYNDESRIKA
Rfal_Human FIFRVRVKVE TYNDESRIKA
Rfal_Drome HIFKLRCKNE VYGDMTRNKL
                                                                                                          TAKL TAC*~~
                                                                                                          IAKLTA***~
                                                                                                          IAKLTGC~~~
                                                                                                          IRKMATQGV~
                                                                                                          IRRSALM~~~
                                                                                                          LQELTGIGSS
                                          NEKGENRYRY
                                                                                                          IESAQ~~~~
Rfal_Schpo YIFQCRAKQD
Rfal_Yeast YDFRIRARED TYNDQSRIRY TVANLHSLNY
                                                                                                         LSKALLA~~~
                      651
  ZMRPALSH1
ZMRPALSH2
        024183
Rfal_Xenla
Rfal Human
Rfal_Drome N
Rfal_Schpo ~
Rfal_Yeast ~
```

Comparison of eukaryotic RPA LS amino acid sequences FIG. 1C.



SEQUENCE LISTING

	<110	> Maha	ajan,	Pra	amod	В.									
	<120	> Mai:	ze Re	plic	catio	n Pr	otei	n A	and	Use					
	<130	> 5718	3-59												
	<160	> 22													
	<170	> Fast	ESEQ	for	Wind	iows	Vers	sion	3.0						
	<212	> 249° > DNA	2497												
	<222	> CDS > (15° > Codi		eque		for	the	Maiz	e RI	PA La	ırge	Subu	ınit		
	<222	> miso > (0). > Mai:	(())		subu	ınit	Homo	ologi	ıe-1					
acgct	<400: atcata tcgccc tcgcca	ttata	ccca	ag co	ccca	ccga	a tco	cacga	igaa atg	acct	gct	gcc gcc	tccç aag	cggga tcg	60 120 174
	acg cc Thr Pr														222
	gat gg Asp Gl 2	y Ala													270
	atc gg Ile Gl 40						-		_	-		-			318
	aaa at Lys Il														366
	ggc aa Gly As		_						-			-			414
tgc	aac tc	c gtc	aaa	ggc	aac	gct	gac	aaa	gtc	ctg	att	gtc	gtċ	aaa	462

Cys A	Asn	Ser	Val 90	Lys	Gly	Asn	Ala	Asp 95	Lys	Val	Leu	Ile	Val 100	Val	Lys	
tgc (gag Glu	act Thr 105	gtg Val	tgc Cys	gaa Glu	gcg Ala	ctc Leu 110	gac Asp	gcc Ala	gag Glu	atc Ile	aac Asn 115	ggc Gly	gag Glu	gcc Ala	510
aag a Lys 1	aaa Lys 120	gag Glu	gat Asp	cct Pro	cca Pro	att Ile 125	gtg Val	ctg Leu	aag Lys	cct Pro	aaa Lys 130	gac Asp	gaa Glu	ggc Gly	tca Ser	558
gtc (Val V 135	gtg Val	gct Ala	gag Glu	gaa Glu	aca Thr 140	aat Asn	tct Ser	ccc Pro	cca Pro	ctc Leu 145	gtg Val	atg Met	aag Lys	cct Pro	aag Lys 150	606
caa (Gln (gag Glu	gtg Val	aag Lys	tcc Ser 155	gcg Ala	tcc Ser	cag Gln	atc Ile	gtg Val 160	act Thr	gag Glu	cag Gln	cgt Arg	gga Gly 165	aat Asn	654
gct (Ala i	gct Ala	cct Pro	gcc Ala 170	acg Thr	cgc Arg	ctt Leu	tcc Ser	atg Met 175	aca Thr	agg Arg	agg Arg	gtc Val	cat His 180	ccc Pro	ttg Leu	702
atc a																750
acg a	agc Ser 200	aaa Lys	ggc Gly	aat Asn	ctg Leu	aga Arg 205	acc Thr	tac Tyr	agg Arg	aat Asn	gct Ala 210	cgt Arg	gga Gly	gaa Glu	ggc Gly	798
tgc (Cys) 215																846
gcc . Ala '																894
ctg Leu																942
aag Lys	-		-		-			-			_					990
Asn					gaa Glu											1038
					aag Lys 300		-	-					-			1086
					att Ile											1134

,	315	320	325
ctc agt gtt agg Leu Ser Val Arg 330	Arg Lys Ile Asp	aac gag aca ata ccg aag Asn Glu Thr Ile Pro Lys 335 340	cgt gac 1182 Arg Asp
att gtt gta gca Ile Val Val Ala 345	gac gac tct ggc Asp Asp Ser Gly 350	aaa act gtt act att tct Lys Thr Val Thr Ile Ser 355	ctc tgg 1230 Leu Trp
aat gat ett get Asn Asp Leu Ala 360	act acg act ggc Thr Thr Thr Gly 365	caa gag ctt ttg gac atg Gln Glu Leu Leu Asp Met 370	gtt gac 1278 Val Asp
agt tcg cct gtt Ser Ser Pro Val 375	gtt gcg ata aag Val Ala Ile Lys 380	agc cta aaa gta tct gac Ser Leu Lys Val Ser Asp 385	ttc caa 1326 Phe Gln 390
ggc gtg tct ctt Gly Val Ser Leu	tca act att ggc . Ser Thr Ile Gly . 395	aga agt act ctc gag att Arg Ser Thr Leu Glu Ile 400	aat cct 1374 Asn Pro 405
gac ctg cct gag Asp Leu Pro Glu 410	Ala Lys Asn Leu	aag too tgg tat gac tot Lys Ser Trp Tyr Asp Ser 415 420	gaa ggc 1422 Glu Gly
aaa gat act tca Lys Asp Thr Ser 425	ctg gca cca atc Leu Ala Pro Ile : 430	agt gca gaa gcg ggt gcc Ser Ala Glu Ala Gly Ala 435	aca cgc 1470 Thr Arg
gct ggt ggt tto Ala Gly Gly Phe 440	aag too atg tat Lys Ser Met Tyr : 445	tot gat aga gtt ttt otg Ser Asp Arg Val Phe Leu 450	tct cac 1518 Ser His
atc acc agt gat Ile Thr Ser Asp 455	cct gct atg ggc (Pro Ala Met Gly (460	cag gaa aag cot gtt ttc Gln Glu Lys Pro Val Phe 465	ttc agt 1566 Phe Ser 470
ctg tac gcc atc Leu Tyr Ala Ile	ata agc cac atc lie Ser His Ile :	aag oot gat cag aat atg Lys Pro Asp Gln Asn Met 480	tgg tac 1614 Trp Tyr 485
cgt gct tgc acg Arg Ala Cys Thr 490	Thr Cys Asn Lys	aag gtg act gaa gct ttt Lys Val Thr Glu Ala Phe 495 500	ggg tct 1662 Gly Ser
gga tac tgg tgc Gly Tyr Trp Cys 505	gag ggg tgc caa Glu Gly Cys Gln : 510	aag aat gac tot gag tgo Lys Asn Asp Ser Glu Cys 515	tcg ctg 1710 Ser Leu
agg tac atc atg Arg Tyr Ile Met 520	gtg atc aag ctc Val Ile Lys Leu 525	tcc gat ccc act ggt gag Ser Asp Pro Thr Gly Glu 530	gct tgg 1758 Ala Trp
gtg too gtg tto Val Ser Val Phe 535	aac gag cat gcg Asn Glu His Ala 540	gag aag atc att ggc tgc Glu Lys Ile Ile Gly Cys 545	agc gcc 1806 Ser Ala 550

gac gag ctt gat cgg atc agg aaa gag gag ggg gac gac agc tac gtt Asp Glu Leu Asp Arg Ile Arg Lys Glu Glu Gly Asp Asp Ser Tyr Val 555 560 565	1854
ctc aag ctc aag gaa gcc acc tgg gtt cct cac ctg ttc cgc gtc agc Leu Lys Leu Lys Glu Ala Thr Trp Val Pro His Leu Phe Arg Val Ser 570 575 580	1902
gtc aca cag cat gaa tac atg aac gag aag agg cag aga atc acc gtg Val Thr Gln His Glu Tyr Met Asn Glu Lys Arg Gln Arg Ile Thr Val 585 590 595	1950
agg ggt gaa gca ccg gtc gac ttc gca gct gag tcc aag tac ttg ctt Arg Gly Glu Ala Pro Val Asp Phe Ala Ala Glu Ser Lys Tyr Leu Leu 600 605 610	1998
gaa gag atc gcg aag ctc acc gct tgc tagaagacgc agtctttctg Glu Glu Ile Ala Lys Leu Thr Ala Cys 615 620	2045
gtggttcttg aaggactggc ccccgatatg tctccctctc agtttttctt ttgagctcc gtaacttgat tactgttctg tgtgttgctc tcactgggtt ttagcacttc tgtaaggta atgtagatgc tagtttacct tggtgtcaag gaacagatgc tattataagc cttgcaaaa tgcagttcca attccgtgta tctgcaacct tgagcaaata gggaaagatt atgagtact attgatgatg ttaggtcgct gcagctaaca agtgtttggt ttttagtgac tactgttta tccctatatt ttattctatt ttagtattta aggttgcgtt tggttgcgtc gactagaca gttgtgcgtg tccgatgagt ctattattga agcacaaaat tgggaataaa aaaaaaaaa aaaaaaaaa aaaaaaaa aaaaaaa	2165 t 2225 a 2285 g 2345 t 2405 a 2465
<210> 2 <211> 623 <212> PRT <213> Zea Mays	2497
<211> 623 <212> PRT <213> Zea Mays	
<211> 623 <212> PRT <213> Zea Mays <400> 2 Met Asp Ala Ala Lys Ser Val Thr Pro Gly Ala Val Ser Tyr Ile Leu	
<pre></pre>	2431
<pre></pre>	
<pre></pre>	
<pre></pre>	
<pre></pre>	
<pre></pre>	2431

165 170 Arg Arg Val His Pro Leu Ile Thr Leu Asn Pro Tyr Gln Gly Asn Trp 180 185 Val Ile Lys Val Arg Val Thr Ser Lys Gly Asn Leu Arg Thr Tyr Arg 200 205 Asn Ala Arg Gly Glu Gly Cys Val Phe Asn Val Glu Leu Thr Asp Glu 215 Asp Gly Thr Gln Ile Gln Ala Thr Met Phe Asn Glu Ala Ala Lys Lys 230 235 Phe Tyr Pro Ile Phe Glu Leu Gly Lys Val Tyr Tyr Val Ser Lys Gly 245 250 Ser Leu Arg Ile Ala Asn Lys Gln Phe Lys Thr Val Lys Asn Asp Tyr 260 265 Glu Leu Ser Leu Asn Glu Asn Ala Ile Val Glu Glu Ala Glu Gly Glu 275 280 Thr Phe Leu Pro Pro Val Gln Tyr Asn Leu Val Lys Ile Asp Gln Leu 295 300 Gly Pro Tyr Val Gly Gly Arg Glu Leu Val Asp Ile Val Gly Val Val 310 315 Gln Ser Val Ser Pro Thr Leu Ser Val Arg Arg Lys Ile Asp Asn Glu 325 330 Thr Ile Pro Lys Arg Asp Ile Val Val Ala Asp Asp Ser Gly Lys Thr 345 Val Thr Ile Ser Leu Trp Asn Asp Leu Ala Thr Thr Thr Gly Gln Glu 355 360 Leu Leu Asp Met Val Asp Ser Ser Pro Val Val Ala Ile Lys Ser Leu 375 Lys Val Ser Asp Phe Gln Gly Val Ser Leu Ser Thr Ile Gly Arg Ser 390 395 Thr Leu Glu Ile Asn Pro Asp Leu Pro Glu Ala Lys Asn Leu Lys Ser 410 415 Trp Tyr Asp Ser Glu Gly Lys Asp Thr Ser Leu Ala Pro Ile Ser Ala 425 Glu Ala Gly Ala Thr Arg Ala Gly Gly Phe Lys Ser Met Tyr Ser Asp 440 445 Arg Val Phe Leu Ser His Ile Thr Ser Asp Pro Ala Met Gly Gln Glu 455 460 Lys Pro Val Phe Phe Ser Leu Tyr Ala Ile Ile Ser His Ile Lys Pro 470 475 Asp Gln Asn Met Trp Tyr Arg Ala Cys Thr Thr Cys Asn Lys Lys Val 485 490 Thr Glu Ala Phe Gly Ser Gly Tyr Trp Cys Glu Gly Cys Gln Lys Asn 505 Asp Ser Glu Cys Ser Leu Arg Tyr Ile Met Val Ile Lys Leu Ser Asp 515 520 Pro Thr Gly Glu Ala Trp Val Ser Val Phe Asn Glu His Ala Glu Lys 535 Ile Ile Gly Cys Ser Ala Asp Glu Leu Asp Arg Ile Arg Lys Glu Glu 550 555 Gly Asp Asp Ser Tyr Val Leu Lys Leu Lys Glu Ala Thr Trp Val Pro 565 570 His Leu Phe Arg Val Ser Val Thr Gln His Glu Tyr Met Asn Glu Lys 580 585 Arg Gln Arg Ile Thr Val Arg Gly Glu Ala Pro Val Asp Phe Ala Ala 600 Glu Ser Lys Tyr Leu Leu Glu Glu Ile Ala Lys Leu Thr Ala Cys

	<2 <2	12>	2202													
	<2 <2		(91)	ng F	Regio		r Ma	ize	RPA	Larg	e Su	buni	.t			
	<2	22>	misc (0). Maiz	(0))		Subu	nit	Homo	logu	e-2					
	tccc		acgo					atq Me	gac	gct	gco	: aag	ttg s Le	gtg	egatte g acg al Thr	60 114
ccg Pro	gtc Val 10	gct Ala	gtg Val	tct Ser	cac His	att Ile 15	ctg Leu	gcg Ala	cac His	ccg Pro	tcg Ser 20	gcg Ala	ggc Gly	tcc Ser	gac Asp	162
									gtc Val							210
									gca Ala 50							258
									ggg Gly							306
									atc Ile							354
									ttg Leu							402
									atc Ile							450
									aag Lys 130							498
									cag Gln							546

					cag Gln											594
					gtc Val											642
					aag Lys 190											690
					cgc Arg											738
					acc Thr											786
-		-			ccg Pro							-			-	834
					aga Arg		-		-	-		-		-		882
					tca Ser 270											930
					att Ile											978
				Ser	tat Tyr											1026
					gta Val											1074
		Glu			ccg Pro											1122
	Lys				atc Ile 350	Ser					Leu					1170
ggg Gly	caa Gln	gag Glu	ctt Leu	ttg Leu 365	gac Asp	atg Met	gct Ala	gac Asp	agt Ser 370	Ser	Pro	gtt Val	gtt Val	gcg Ala 375	Ile	1218

					tct Ser											1266
					gcg Ala											1314
					gac Asp											1362
					ggt Gly 430											1410
		-	_	-	ttt Phe	_					-	-		-	_	1458
					gtt Val											1506
					aac Asn											1554
					act Thr											1602
	_		_	-	gaa Glu 510	_		-	-			-	_		-	1650
					ggc Gly										His	1698
				Ile	ggc Gly									Ile		1746
			Gly					Val							acc Thr	1794
		Pro					Val					His			aat Asn	1842
aac Asn 585	Glu	aaa Lys	agg Arg	cag Gln	aga Arg 590	Ile	act	gtg Val	r agg . Arg	agt Ser 595	Glu	gcg Ala	ccg Pro	gto Val	gag Glu 600	1890
cac	gca	gct	gaa	tcc	: aag	tac	ctg	ctt	gaa	cag	, ata	gcg	aag	ctt	act	1938

His Ala Ala Glu Ser Lys Tyr Leu Leu Glu Gln Ile Ala Lys Leu Thr 610 gct tgatagtaga agatgcaacc ttactgcaaa tagcgaggat tattaggact 1991 aattgatggt gtcaggtcat tgcggcccta agctttagct ctctatcagc agtcagatgt attaaccatt cootgeteta atagteatet ateageagte agatgtattt aaccaaaaaa 2111 aaaaaaaaaa aaaaaaaaa aaaaaaaaaa aaaaagggcgg ccgctctaga 2171 ggatccaagc ttacgtacgc gtgcatgcga c 2202 <210> 4 <211> 617 <212> PRT <213> Zea Mays <400> 4 Met Asp Ala Ala Lys Leu Val Thr Pro Val Ala Val Ser His Ile Leu 10 Ala His Pro Ser Ala Gly Ser Asp Gly Ala Val Thr Asp Leu Val Val 20 25 Gln Val Leu Asp Leu Lys Ser Val Gly Thr Gly Ser Arg Phe Ser Phe 40 Thr Ala Thr Asp Gly Lys Asp Lys Ile Lys Ala Met Leu Pro Thr Asn 5.5 Phe Gly Ser Glu Val Arg Ser Gly Asn Leu Lys Asn Leu Gly Leu Ile 70 75 Arg Ile Ile Asp Tyr Thr Cys Asn Val Val Lys Gly Lys Asp Asp Lys 8.5 90 Val Leu Val Val Ile Lys Cys Glu Leu Val Cys Gln Ala Leu Asp Ala 100 105 Glu Ile Asn Gly Glu Ala Lys Lys Glu Glu Pro Pro Ile Val Leu Lys 120 Pro Lys Asp Glu Cys Val Gly Val Thr Ser Pro Leu Ala Met Lys Pro 135 Lys Gln Glu Val Lys Ser Ala Ser Gln Ile Val Asn Glu Gln Arg Gly 150 155 Asn Thr Ala Pro Val Lys Pro Leu Ser Met Thr Lys Arg Val His Pro 165 170 Leu Ile Thr Leu Asn Pro Tyr Gln Gly Asn Trp Val Ile Lys Val Arg 180 185 Val Thr Ser Lys Gly Asn Leu Arg Thr Tyr Arg Asn Ala Arg Gly Glu 200 Gly Cys Val Phe Asn Val Glu Leu Thr Asp Glu Asp Gly Thr Gln Ile 210 215 Gln Ala Thr Met Phe Asn Asp Ala Ala Lys Lys Phe Tyr Pro Ile Phe 230 235 Glu Leu Gly Lys Val Tyr Tyr Val Ser Lys Gly Ser Leu Arg Ile Ala 245 250 Asn Lys Gln Phe Lys Thr Val Gln Asn Asp Tyr Glu Met Ser Leu Asn 265 Glu Asn Ala Ile Val Glu Glu Ala Glu Gly Glu Thr Cys Ile Pro Gln 280 Val Gln Tyr Asn Leu Val Lys Ile Asp Gln Leu Gly Ser Tyr Val Gly 295

Gly Arg Glu Leu Val Asp Ile Val Gly Val Val Gln Ser Val Ser Pro

```
305
                310
                                315
Thr Leu Ser Val Arg Arg Lys Ile Asp Asn Glu Thr Ile Pro Lys Arg
       325 330
Asp Ile Val Val Ala Asp Asp Ser Gly Lys Thr Val Ser Ile Ser Leu
         340 345
Trp Asn Asp Leu Ala Thr Thr Thr Gly Gln Glu Leu Leu Asp Met Ala
 355
                              365
                        360
Asp Ser Ser Pro Val Val Ala Ile Lys Ser Leu Lys Val Ser Asp Phe
                    375
                                  380
Gln Gly Val Ser Leu Ser Thr Val Gly Lys Ser Thr Leu Ala Ile Asn
                 390
                                395
Pro Asp Leu His Glu Ala Gln Asn Leu Lys Ser Trp Tyr Asp Ser Glu
             405
                              410 415
Gly Lys Asp Thr Ser Leu Ala Pro Ile Gly Ala Glu Met Gly Ala Ala
         420
                          425 430
Arg Ala Gly Gly Phe Lys Ser Thr Tyr Ser Asp Arg Val Phe Leu Ser
                       440
                                       445
His Ile Thr Ser Asp Pro Ala Met Gly Gln Glu Lys Pro Val Phe Phe
                    455
                                   460
Ser Leu Tyr Ala Thr Ile Ser His Ile Lys Pro Asp Gln Asn Met Trp
                 470
                               475
Tyr Arg Ala Cys Lys Thr Cys Asn Lys Lys Val Thr Glu Thr Phe Gly
             485
                              490
Ser Gly Tyr Trp Cys Glu Gly Cys Gln Lys Asn Asp Ser Glu Cys Ser
         500
                          505
Leu Arg Tyr Ile Met Val Ile Lys Val Ser Asp Pro Thr Gly Glu Ala
                       520
                                        525
Trp Phe Ser Val Phe Asn Glu His Ala Glu Lys Ile Ile Gly Cys Ser
                    535
Ala Asp Glu Leu Asp Arg Ile Arg Lys Glu Glu Gly Asp Asp Ser Tyr
                550
                                 555
Val Leu Lys Leu Lys Glu Ala Thr Trp Val Pro His Leu Phe Arg Val
          565
                              570 575
Ser Val Thr Gln His Glu Tyr Asn Asn Glu Lys Arg Gln Arg Ile Thr
       580 585
Val Arg Ser Glu Ala Pro Val Glu His Ala Ala Glu Ser Lys Tyr Leu
    595 600
Leu Glu Gln Ile Ala Lys Leu Thr Ala
     <210> 5
     <211> 630
     <212> PRT
     <213> Oryza sativa
     <400> 5
Met Asp Ser Asp Ala Ala Pro Ser Val Thr Pro Gly Ala Val Ala Phe
                               10
Val Leu Glu Asn Ala Ser Pro Asp Ala Ala Thr Gly Val Pro Val Pro
    20
                           25
Glu Ile Val Leu Gln Val Val Asp Leu Lys Pro Ile Gly Thr Arg Phe
                        40
                                        4.5
Thr Phe Leu Ala Ser Asp Gly Lys Asp Lys Ile Lys Thr Met Leu Leu
                    55
                                    60
Thr Gln Leu Ala Pro Glu Val Arg Ser Gly Asn Ile Gln Asn Leu Gly
                 70
                                 75
Val Ile Arg Val Leu Asp Tyr Thr Cys Asn Thr Ile Gly Glu Lys Gln
```

_

				85					90					95	
	Lys		100					105					110	Ala	
	Ser	115					120					125			
	Leu 130					135					140				
145	Ala				150					155					160
	Ser			165					170					175	
	Ala		130					185					190		
	Pro	195					200					205			
	Asn 210					215					220				
225	Val				230					235					240
	Asn			245					250					255	
	Tyr		260					265					270		
	Thr	275					280					285			
	Glu 290 Val					295					300				
305	Asp				310					315					320
	Arg			325					330					335	
	Asp		340					345					350		
	Thr	355					360					365			
	370 Ile					375					380				
385	Ser				390					395					400
	Ala			405					410				_	415	
	Met		420					425					430		
	Arg	435					440					445			
	450 Pro					455					460				
465	Ile				470					475					480
	Thr			485					490					495	
	Glu		500					505					510		
	Val	515					520					525			
	530		<u>-</u>			5.35			~ - 1	u	540				

```
Phe Asn Asp Gln Ala Glu Arg Ile Val Gly Cys Ser Ala Asp Glu Leu
    550 555 560
Asp Arg Ile Arg Lys Glu Glu Gly Asp Asp Ser Tyr Leu Leu Lys Leu
           565 570
Lys Glu Ala Thr Trp Val Pro His Leu Phe Arg Val Ser Val Thr Gln
      580 585 590
Asn Glu Tyr Met Asn Glu Lys Arg Gln Arg Ile Thr Val Arg Ser Glu
 595 600 605
Ala Pro Val Asp His Ala Ala Glu Ala Lys Tyr Met Leu Glu Glu Ile
Ala Lys Leu Thr Gly Cys
    <210> 6
    <211> 609
    <212> PRT
    <213> Xenopus laevis
    <400> 6
Met Ala Leu Pro Gln Leu Ser Glu Gly Ala Ile Ser Ala Met Leu Gly
                           10
Gly Asp Ser Ser Cys Lys Pro Thr Leu Gln Val Ile Asn Ile Arg Pro
Ile Asn Thr Gly Asn Gly Pro Pro Arg Tyr Arg Leu Leu Met Ser Asp
                     40
Gly Leu Asn Thr Leu Ser Ser Phe Met Leu Ala Thr Gln Leu Asn Ser
  50 55
                                60
Leu Val Asp Asn Asn Leu Leu Ala Thr Asn Cys Ile Cys Gin Val Ser
65 70
                               75
Arg Phe Ile Val Asn Asn Leu Lys Asp Gly Arg Arg Val Ile Ile Val
                            90
           85
Met Glu Leu Asp Val Leu Lys Ser Ala Asp Leu Val Met Gly Lys Ile
        100
                                        110
                        105
Gly Asn Pro Gln Pro Tyr Asn Asp Gly Gln Pro Gln Pro Ala Ala Pro
                     120
                                     125
Ala Pro Ala Ser Ala Pro Ala Pro Ala Pro Ser Lys Leu Gin Asn Asn
  130 135
                                  140
Ser Ala Pro Pro Pro Ser Met Asn Arg Gly Thr Ser Lys Leu Phe Gly
145 150
                               155
Gly Gly Ser Leu Leu Asn Thr Pro Gly Gly Ser Gln Ser Lys Val Val
           165 170
Pro Ile Ala Ser Leu Asn Pro Tyr Gln Ser Lys Trp Thr Val Arg Ala
         180
                        185
Arg Val Thr Asn Lys Gly Gln Ile Arg Thr Trp Ser Asn Ser Arg Gly
   195 200 205
Glu Gly Lys Leu Phe Ser Ile Glu Met Val Asp Glu Ser Gly Glu Ile
  210 215 220
Arg Ala Thr Ala Phe Asn Glu Gln Ala Asp Lys Phe Phe Ser Ile Ile
225 230 235 240
Glu Val Asn Lys Val Tyr Tyr Phe Ser Lys Gly Thr Leu Lys Ile Ala
            245 250
Asn Lys Gln Tyr Thr Ser Val Lys Asn Asp Tyr Glu Met Thr Phe Asn
                         265
Ser Glu Thr Ser Val Ile Pro Cys Asp Asp Ser Ala Asp Val Pro Met
                     280
                                     295
Val Gln Phe Glu Phe Val Ser Ile Gly Glu Leu Glu Ser Lys Asn Lys
```

300

295

```
Asp Thr Val Leu Asp Ile Ile Gly Val Cys Lys Asn Val Glu Glu Val
              310
                               315
Thr Lys Val Thr Ile Lys Ser Asn Asn Arg Glu Val Ser Lys Arg Ser
                           330
Ile His Leu Met Asp Ser Ser Gly Lys Val Val Ser Thr Thr Leu Trp
                        345
Gly Glu Asp Ala Asp Lys Phe Asp Gly Ser Arg Gln Pro Val Val Ala
     355 360
Ile Lys Gly Ala Arg Leu Ser Asp Phe Gly Gly Arg Ser Leu Ser Val
        375
Leu Ser Ser Ser Thr Val Met Ile Asn Pro Asp Ile Pro Glu Ala Phe
             390
                      395 400
Lys Leu Arg Ala Trp Phe Asp Ser Glu Gly Gln Val Val Glu Gly Thr
          405
                           410
Ser Ile Ser Glu Ser Arg Gly Gly Gly Thr Gly Gly Gly Asn Thr Asn
        420
                       425
Trp Lys Ser Leu Leu Glu Val Lys Asn Glu Asn Leu Gly His Gly Glu
     435 440
Lys Ala Asp Tyr Phe Thr Ser Val Ala Thr Ile Val Tyr Leu Arg Lys
       455 460
Glu Asn Cys Leu Tyr Gln Ala Cys Pro Ser Gln Asp Cys Asn Lys Lys
     470 475 480
Val Ile Asp Gin Gln Asn Gly Leu Phe Arg Cys Glu Lys Cys Asn Lys
        485 490 495
Glu Phe Pro Asn Phe Lys Tyr Arg Leu Ile Leu Ser Ala Asn Ile Ala
      500 505
Asp Phe Gly Glu Asn Gln Trp Ile Thr Cys Phe Gln Glu Ser Ala Glu
  515 520
Ser Ile Leu Gly Gln Asn Ala Thr Tyr Leu Gly Glu Leu Lys Glu Lys
 530 535
Asn Glu Gln Ala Tyr Asp Glu Val Phe Gln Asn Ala Asn Phe Arg Ser
545 550
                              555 560
Tyr Thr Phe Arg Ala Arg Val Lys Leu Glu Thr Tyr Asn Asp Glu Ser
                           570
Arg Ile Lys Ala Thr Ala Val Asp Val Lys Pro Val Asp His Lys Glu
      580 585
Tyr Ser Arg Arg Leu Ile Met Asn Ile Arg Lys Met Ala Thr Gln Gly
Val
```

<210> 7 <211> 616 <212> PRT <213> Homo sapiens

<400> 7

 Met
 Val
 Gly
 Gln
 Leu
 Ser
 Glu
 Gly
 Ala
 Ile
 Ala
 Ala
 Ala
 Ala
 Ile
 Met
 Gln
 Lys

 Gly
 Asp
 Thr
 Asn
 Ile
 Lys
 Pro
 Ile
 Leu
 Gln
 Val
 Ile
 Asn
 Ile
 Arg
 Pro

 Jo
 Thr
 Thr
 Gly
 Asn
 Ser
 Pro
 Pro
 Arg
 Tyr
 Arg
 Leu
 Leu
 Met
 Ser
 Asn

 Gly
 Leu
 Asn
 Thr
 Leu
 Ser
 Ser
 Phe
 Met
 Leu
 Ala
 Thr
 Gln
 Leu
 Asn
 Pro

 50
 55
 60
 60
 60
 11e
 His
 His
 65
 70
 75
 80

Arg Phe Ile Val Asn Thr Leu Lys Asp Gly Arg Arg Val Val Ile Leu 85 90 Met Glu Leu Glu Val Leu Lys Ser Ala Glu Ala Val Gly Val Lys Ile 100 105 Gly Asn Pro Val Pro Tyr Asn Glu Gly Leu Gly Gln Pro Gln Val Ala 120 Pro Pro Ala Pro Ala Ala Ser Pro Ala Ala Ser Ser Arg Pro Gln Pro 135 140 Gln Asn Gly Ser Ser Gly Met Gly Ser Thr Val Ser Lys Ala Tyr Gly 150 155 Ala Ser Lys Thr Phe Gly Lys Ala Ala Gly Pro Ser Leu Ser His Thr 165 170 Ser Gly Gly Thr Gln Ser Lys Val Val Pro Ile Ala Ser Leu Thr Pro 180 185 190 Tyr Gln Ser Lys Trp Thr Ile Cys Ala Arg Val Thr Asn Lys Ser Gln 200 205 Ile Arg Thr Trp Ser Asn Ser Arg Gly Glu Gly Lys Leu Phe Ser Leu 215 Glu Leu Val Asp Glu Ser Gly Glu Ile Arg Ala Thr Ala Phe Asn Glu 230 235 Gln Val Asp Lys Phe Phe Pro Leu Ile Glu Val Asn Lys Val Tyr Tyr 245 · 250 255 Phe Ser Lys Gly Thr Leu Lys Ile Ala Asn Lys Gln Phe Thr Ala Val 260 265 Lys Asn Asp Tyr Glu Met Thr Phe Asn Asn Glu Thr Ser Val Met Pro 280 Cys Glu Asp Asp His His Leu Pro Thr Val Gln Phe Asp Phe Thr Gly 295 300 Ile Asp Asp Leu Glu Asn Lys Ser Lys Asp Ser Leu Val Asp Ile Ile 310 315 Gly Ile Cys Lys Ser Tyr Glu Asp Ala Thr Lys Ile Thr Val Arg Ser 325 330 Asn Asn Arg Glu Val Ala Lys Arg Asn Ile Tyr Leu Met Asp Thr Ser 340 345 Gly Lys Val Val Thr Ala Thr Leu Trp Gly Glu Asp Ala Asp Lys Phe 360 Asp Gly Ser Arg Gln Pro Val Leu Ala Ile Lys Gly Ala Arg Val Ser 375 380 Asp Phe Gly Gly Arg Ser Leu Ser Val Leu Ser Ser Ser Thr Ile Ile 390 395 Ala Asn Pro Asp Ile Pro Glu Ala Tyr Lys Leu Arg Gly Trp Phe Asp 405 410 Ala Glu Gly Gln Ala Leu Asp Gly Val Ser Ile Ser Asp Leu Lys Ser 420 425 Gly Gly Val Gly Gly Ser Asn Thr Asn Trp Lys Thr Leu Tyr Glu Val 435 440 Lys Ser Glu Asn Leu Gly Gln Gly Asp Lys Pro Asp Tyr Phe Ser Ser 455 Val Ala Thr Val Val Tyr Leu Arg Lys Glu Asn Cys Met Tyr Gln Ala 470 475 Cys Pro Thr Gln Asp Cys Asn Lys Lys Val Ile Asp Gln Gln Asn Gly 485 490 Leu Tyr Arg Cys Glu Lys Cys Asp Thr Glu Phe Pro Asn Phe Lys Tyr 500 505 Arg Met Ile Leu Ser Val Asn Ile Ala Asp Phe Gln Glu Asn Gln Trp 520 Val Thr Cys Phe Gln Glu Ser Ala Glu Ala Ile Leu Gly Gln Asn Ala

```
535
Ala Tyr Leu Gly Glu Leu Lys Asp Lys Asn Glu Gln Ala Phe Glu Glu
            550
                    555 560
Val Phe Gln Asn Ala Asn Phe Arg Ser Phe Ile Phe Arg Val Arg Val
            565 570 575
Lys Val Glu Thr Tyr Asn Asp Glu Ser Arg Ile Lys Ala Thr Val Met
         580 585 590
Asp Val Lys Pro Val Asp Tyr Arg Glu Tyr Gly Arg Arg Leu Val Met
   595 600
Ser Ile Arg Arg Ser Ala Leu Met
    <210> 8
    <211> 603
    <212> PRT
    <213> Drosophila melanogaster
    <400> 8
Met Val Leu Ala Ser Leu Ser Thr Gly Val Ile Ala Arg Ile Met His
            5
                          10
Gly Glu Val Val Asp Ala Pro Val Leu Gln Ile Leu Ala Ile Lys Lys
                         25
Ile Asn Ser Ala Ala Asp Ser Glu Arg Tyr Arg Iie Leu Ile Ser Asp
                    40
Gly Lys Tyr Phe Asn Ser Tyr Ala Met Leu Ala Ser Gln Leu Asn Val
 50 55
Met Gln His Asn Gly Glu Leu Glu Glu Phe Thr Ile Val Gln Leu Asp
                   75
               70
Lys Tyr Val Thr Ser Leu Val Gly Lys Asp Gly Ala Gly Lys Arg Val
            85
                90
Leu Ile Ile Ser Glu Leu Thr Val Val Asn Pro Gly Ala Glu Val Lys
         100 105
Ser Lys Ile Gly Glu Pro Val Thr Tyr Glu Asn Ala Ala Lys Gln Asp
      115
                      120
Leu Ala Pro Lys Pro Ala Val Thr Ser Asn Ser Lys Pro Ile Ala Lys
                  135 140
Lys Glu Pro Ser His Asn Asn Asn Asn Ile Val Met Asn Ser Ser
               150 155 160
Ile Asn Ser Gly Met Thr His Pro Ile Ser Ser Leu Ser Pro Tyr Gln
            165 170 175
Asn Lys Trp Val Ile Lys Ala Arg Val Thr Ser Lys Ser Gly Ile Arg
   180 185 190
Thr Trp Ser Asn Ala Arg Gly Glu Gly Lys Leu Phe Ser Met Asp Leu
                      200
Met Asp Glu Ser Gly Glu Ile Arg Ala Thr Ala Phe Lys Glu Gln Cys
 210 215
Asp Lys Phe Tyr Asp Leu Ile Gln Val Asp Ser Val Tyr Tyr Ile Ser
225 230
                               235
Lys Cys Gln Leu Lys Pro Ala Asn Lys Gln Tyr Ser Ser Leu Asn Asn
            245
                            250
Ala Tyr Glu Met Thr Phe Ser Gly Glu Thr Val Val Gln Leu Cys Glu
                        265
Asp Thr Asp Asp Pro Ile Pro Glu Ile Lys Tyr Asn Leu Val Pro
                     280
Ile Ser Asp Val Ser Gly Met Glu Asn Lys Ala Ala Val Asp Thr Ile
                   295
                                  300
Gly Ile Cys Lys Glu Val Gly Glu Leu Gln Ser Phe Val Ala Arg Thr
```

305 310 315 Thr Asn Lys Glu Phe Lys Lys Arg Asp Ile Thr Leu Val Asp Met Ser 330 325 Asn Ser Ala Ile Ser Leu Thr Leu Trp Gly Asp Asp Ala Val Asn Phe 340 345 Asp Gly His Val Gln Pro Val Ile Leu Val Lys Gly Thr Arg Ile Asn 360 Glu Phe Asn Gly Gly Lys Ser Leu Ser Leu Gly Gly Gly Ser Ile Met 375 Lys Ile Asn Pro Asp Ile Pro Glu Ala His Lys Leu Arg Gly Trp Phe 390 395 Asp Asn Gly Gly Gly Asp Ser Val Ala Asn Met Val Ser Ala Arg Thr 405 410 415 Gly Gly Gly Ser Phe Ser Thr Glu Trp Met Thr Leu Lys Asp Ala Arg 420 425 Ala Arg Asn Leu Gly Ser Gly Asp Lys Pro Asp Tyr Phe Gln Cys Lys 440 Ala Val Val His Ile Val Lys Gln Glu Asn Ala Phe Tyr Arg Ala Cys 455 460 Pro Gln Ser Asp Cys Asn Lys Lys Val Val Asp Glu Gly Asn Asp Gln 475 470 Phe Arg Cys Glu Lys Cys Asn Ala Leu Phe Pro Asn Phe Lys Tyr Arg 485 490 Leu Leu Ile Asn Met Ser Ile Gly Asp Trp Thr Ser Asn Arg Trp Val 505 Ser Ser Phe Asn Glu Val Gly Glu Gln Leu Leu Gly His Thr Ser Gln 520 Glu Val Gly Glu Ala Leu Glu Asn Asp Pro Ala Lys Ala Glu Gin Ile 535 Phe Ser Ala Leu Asn Phe Thr Ser His Ile Phe Lys Leu Arg Cys Lys 550 555 Asn Glu Val Tyr Gly Asp Met Thr Arg Asn Lys Leu Thr Val Gln Ser 565 570 Val Ala Pro Ile Asn His Lys Glu Tyr Asn Lys His Leu Leu Lys Glu 580 585 Leu Gln Glu Leu Thr Gly Ile Gly Ser Ser Asn 600 595 <210> 9 <211> 609 <212> PRT <213> Schizosaccharomyces pombe <400> 9 Met Ala Glu Arg Leu Ser Val Gly Ala Leu Arg Ile Ile Asn Thr Ser 10 Asp Ala Ser Ser Phe Pro Pro Asn Pro Ile Leu Gln Val Leu Thr Val 20 25 Lys Glu Leu Asn Ser Asn Pro Thr Ser Gly Ala Pro Lys Arg Tyr Arg 40 Val Val Leu Ser Asp Ser Ile Asn Tyr Ala Gln Ser Met Leu Ser Thr 55 Gln Leu Asn His Leu Val Ala Glu Asn Lys Leu Gln Lys Gly Ala Phe 70 75 Val Gln Leu Thr Gln Phe Thr Val Asn Val Met Lys Glu Arg Lys Ile 90 Leu Ile Val Leu Gly Leu Asn Val Leu Thr Glu Leu Gly Val Met Asp

			100					105					110		
		115					120	Glu				Ala 125	Leu		
	130					135					140	Thr			
145					150					155		Ala			160
				165					1.70			Asn		175	
			180					185				Gln	190		
		195					200					Lys 205			
	210					215					220	Leu			
225					230					235		Val			240
				245					250			Ser		255	
			260					265				Asn	270		
		275					280					Glu 285			
	290					295					300	Gln			
305					310					315		Val			320
				325					330			Ser		335	
			340					345				Tyr	350		
		355					360					Val 365			
	370					375					380	Phe			
385					390					395		Asp			400
				405					410			Gln		415	
			420					425				Leu Gln	430		
		435					440					445			
	450					455					460	Lys			
465					470					475		Cys			480
				485					490			Trp		495	
			500					505				Tyr	510		
		515					520					Asn 525			
	530					535					540	Glu Met			
545	9111	GIU	Maii	vsh	550	V211	VIG	r.ie	met	555	cys	Met	Ala	GIU	560

Cys Tyr Met Pro Tyr Ile Phe Gln Cys Arg Ala Lys Gln Asp Asn Phe 570 Lys Gly Glu Met Arg Val Arg Tyr Thr Val Met Ser Ile Asn Gln Met 580 585 Asp Trp Lys Glu Glu Ser Lys Arg Leu Ile Asn Phe Ile Glu Ser Ala 600 Gln <210> 10 <211> 621 <212> PRT <213> Saccharomyces cerevisiae <400> 10 Met Ser Ser Val Gln Leu Ser Arg Gly Asp Phe His Ser Ile Phe Thr 10 Asn Lys Gln Arg Tyr Asp Asn Pro Thr Gly Gly Val Tyr Gln Val Tyr 25 Asn Thr Arg Lys Ser Asp Gly Ala Asn Ser Asn Arg Lys Asn Leu Ile 40 Met Ile Ser Asp Gly Ile Tyr His Met Lys Ala Leu Leu Arg Asn Gln 55 Ala Ala Ser Lys Phe Gln Ser Met Glu Leu Gln Arg Gly Asp Ile Ile 70 75 Arg Val Ile Ile Ala Glu Pro Ala Ile Val Arg Glu Arg Lys Lys Tyr 85 90 Val Leu Leu Val Asp Asp Phe Glu Leu Val Gln Ser Arg Ala Asp Met 100 105 Val Asn Gln Thr Ser Thr Phe Leu Asp Asn Tyr Phe Ser Glu His Pro 115 120 Asn Glu Thr Leu Lys Asp Glu Asp Ile Thr Asp Ser Gly Asn Val Ala 135 140 Asn Gln Thr Asn Ala Ser Asn Ala Gly Val Pro Asp Met Leu His Ser 145 150 155 160 Asn Ser Asn Leu Asn Ala Asn Glu Arg Lys Phe Ala Asn Glu Asn Pro 165 170 Asn Ser Gln Lys Thr Arg Pro Ile Phe Ala Ile Glu Gln Leu Ser Pro 180 185 Tyr Gln Asn Val Trp Thr Ile Lys Ala Arg Val Ser Tyr Lys Gly Glu 200 205 Ile Lys Thr Trp His Asn Gln Arg Gly Asp Gly Lys Leu Phe Asn Val 215 220 Asn Phe Leu Asp Thr Ser Gly Glu Ile Arg Ala Thr Ala Phe Asn Asp 230 235 240 Phe Ala Thr Lys Phe Asn Glu Ile Leu Gln Glu Gly Lys Val Tyr Tyr 245 Val Ser Lys Ala Lys Leu Gln Pro Ala Lys Pro Gln Phe Thr Asn Leu 260 265 Thr His Pro Tyr Glu Leu Asn Leu Asp Arg Asp Thr Val Ile Glu Glu 280 Cys Phe Asp Glu Ser Asn Val Pro Lys Thr His Phe Asn Phe Ile Lys 295 Leu Asp Ala Ile Gln Asn Gln Glu Val Asn Ser Asn Val Asp Val Leu 310 315 Gly Ile Ile Gln Thr Ile Asn Pro His Phe Glu Leu Thr Ser Arg Ala

330

```
Gly Lys Lys Phe Asp Arg Arg Asp Ile Thr Ile Val Asp Asp Ser Gly
           340 345
Phe Ser Ile Ser Val Gly Leu Trp Asn Gln Gln Ala Leu Asp Phe Asn
                          360
Leu Pro Glu Gly Ser Val Ala Ala Ile Lys Gly Val Arg Val Thr Asp
                      375
                                          380
Phe Gly Gly Lys Ser Leu Ser Met Gly Phe Ser Ser Thr Leu Ile Pro
                  390
                                     395
Asn Pro Glu Ile Pro Glu Ala Tyr Ala Leu Lys Gly Trp Tyr Asp Ser
              405
                                  410
Lys Gly Arg Asn Ala Asn Phe Ile Thr Leu Lys Gln Glu Pro Gly Met
           420
                               425
Gly Gly Gln Ser Ala Ala Ser Leu Thr Lys Phe Ile Ala Gln Arg Ile
                          440
Thr Ile Ala Arg Ala Gln Ala Glu Asn Leu Gly Arg Ser Glu Lys Gly
                      455
                                         460
Asp Phe Phe Ser Val Lys Ala Ala Ile Ser Phe Leu Lys Val Asp Asn
                  470
                                      475
Phe Ala Tyr Pro Ala Cys Ser Asn Glu Asn Cys Asn Lys Lys Val Leu
              485
                                  490
Glu Gln Pro Asp Gly Thr Trp Arg Cys Glu Lys Cys Asp Thr Asn Asn
                             505
                                                 510
Ala Arg Pro Asn Trp Arg Tyr Ile Leu Thr Ile Ser Ile Ile Asp Glu
                          520
                                              525
Thr Asn Gln Leu Trp Leu Thr Leu Phe Asp Asp Gln Ala Lys Gln Leu
                      535
                                         540
Leu Gly Val Asp Ala Asn Thr Leu Met Ser Leu Lys Glu Glu Asp Pro
                  550
                                     555
Asn Glu Phe Thr Lys Ile Thr Gln Ser Ile Gln Met Asn Glu Tyr Asp
               565
                                  570
                                                   575
Phe Arg Ile Arg Ala Arg Glu Asp Thr Tyr Asn Asp Gln Ser Arg Ile
                              585
Arg Tyr Thr Val Ala Asn Leu His Ser Leu Asn Tyr Arg Ala Glu Ala
                          600
Asp Tyr Leu Ala Asp Glu Leu Ser Lys Ala Leu Leu Ala
                       615
     <210> 11
      <211> 1124
      <212> DNA
      <213> Zea mays
     <220>
     <221> misc feature
      <222> (0)...(0)
      <223> Maize RPA Middle Subunit Homologue-1
      <221> CDS
      <222> (76)...(894)
      <400> 11
tegacecacg egteegatee teseatetge geacecgeaa gestattege egeaceteet
                                                                   60
caggingaccy graad atg atg ccg tig age caa acc gae tie teg ccg teg
                                                                   111
                Met Met Pro Leu Ser Gln Thr Asp Phe Ser Pro Ser
                                                                   159
cag tto acc too too cag aat goo goo goo too acc acg cot too
```

Gln	Phe	Thr 15	Ser	Ser	Gln	Asn	Ala 20	Ala	Ala	Asp	Ser	Thr 25	Thr	Pro	Ser		
aag Lys	atg Met 30	cgc Arg	ggc Gly	gcg Ala	tcc Ser	agc Ser 35	acc Thr	atg Met	ccg Pro	ctc Leu	acc Thr 40	gtg Val	aag Lys	cag Gln	gtc Val	20	7
gtc Val 45	gac Asp	gcg Ala	cag Gln	cag Gln	tct Ser 50	ggc	acg Thr	ggc Gly	gag Slu	aag Lys 55	ggc Gly	gct Ala	ccg Pro	ttc Phe	atc Ile 60	25	5
gtc Val	aat Asn	ggc Gly	gtc Val	gag Glu 65	atg Met	gct Ala	aac Asn	att Ile	cga Arg 70	ctt Leu	gtg Val	G] À Bàà	atg Met	gtc Val 75	aat Asn	30	3
gcc Ala	aag Lys	gtg Val	gag Glu 80	cgg Arg	acg Thr	acc Thr	gat Asp	gtg Val 85	acc Thr	ttc Phe	acg Thr	ctc Leu	gac Asp 90	gat Asp	ggc Gly	35	1
acc Thr	ggc Gly	cgc Arg 95	ctc Leu	gat Asp	ttc Phe	atc Ile	aga Arg 100	tgg Trp	gtg Val	aat Asn	gat Asp	gct Ala 105	tca Ser	gat Asp	tct Ser	39	9
ttt Phe	gaa Glu 110	act Thr	gct Ala	gct Ala	att Ile	cag Gln 115	aat Asn	ggt Gly	atg Met	tac Tyr	att Ile 120	gcg Ala	gtc Val	att Ile	gga Gly	44	7
agc Ser 125	ctc Leu	aag Lys	gga Gly	ctg Leu	caa Gln 130	gag Glu	agg Arg	aag Lys	cgt Arg	gct Ala 135	act Thr	gct Ala	ttc Phe	tca Ser	atc Ile 140	49	5
agg Arg	cct Pro	ata Ile	acc Thr	gat Asp 145	ttc Phe	aat Asn	gag Glu	gtt Val	acg Thr 150	ctg Leu	cat His	ttc Phe	att Ile	cag Gln 155	tgt Cys	54	3
gtt Val	cąg Arg	atg Met	cat His 160	ata Ile	gag Glu	aac Asn	att Ile	gaa Glu 165	tta Leu	aag Lys	gct Ala	ggc Gly	agt Ser 170	cct Pro	gca Ala	59	1
cga Arg	atc Ile	agt Ser 175	tct Ser	tct Ser	atg Met	gga Gly	gtg Val 180	tca Ser	ttc Phe	tca Ser	aat Asn	gga Gly 185	ttc Phe	agt Ser	gaa Glu	63	9
tca Ser	agc Ser 190	aca Thr	ccg Pro	aca Thr	tct Ser	ttg Leu 195	aaa Lys	tcc Ser	agt Ser	ccc Pro	gca Ala 200	ccg Pro	gtg Val	acc Thr	agc Ser	68	7
ggg Gly 205	tca Ser	tcc Ser	gat Asp	act Thr	gat Asp 210	ctg Leu	cac His	acg Thr	cag Gln	gtc Val 215	ctg Leu	aat Asn	ttt Phe	ttt Phe	aat Asn 220	73	5
gaa Glu	cca Pro	gcg Ala	aac Asn	ctc Leu 225	gag Glu	agt Ser	gag Glu	cat His	ggg Gly 230	gtg Val	cac His	gtt Val	gat Asp	gaa Glu 235	gta Val	78	3
ctc Leu	aag Lys	cgg Arg	ttc Phe	aaa Lys	ctt Leu	ttg Leu	ccg Pro	aag Lys	aag Lys	cag Gln	atc Ile	acg Thr	gat Asp	gct Ala	att Ile	83	1

240 245 gat tac aat atg gac tog ggg cgt ctt tac toa aca att gat gaa ttc 879 Asp Tyr Asn Met Asp Ser Gly Arg Leu Tyr Ser Thr Ile Asp Glu Phe 260 cac tac aag gca act taaccgattt gaaggccagc ctgctggaaa tggcagagga 934 His Tyr Lys Ala Thr 270 ctaagtatca cttgtactaa accaaagtct ggaaatgtca tgttgtgtca tgaaatgcat 994 ggttggttta tggaaacatt tatatcttgt atcaactagt tgatttgtat ctcgtgtcaa 1054 cttaatgact gagccaagaa aaggaagatg tagaggccga cagaaaaaaa aaaaaaaaa 1114 aaaaaaaaa 1124 <210> 12 <211> 273 <212> PRT <213> Zea mays <400> 12 Met Met Pro Leu Ser Gln Thr Asp Phe Ser Pro Ser Gln Phe Thr Ser 5 10 Ser Gln Asn Ala Ala Ala Asp Ser Thr Thr Pro Ser Lys Met Arg Gly 20 25 Ala Ser Ser Thr Met Pro Leu Thr Val Lys Gln Val Val Asp Ala Gln 40 Gln Ser Gly Thr Gly Glu Lys Gly Ala Pro Phe Ile Val Asn Gly Val 55 Glu Met Ala Asn Ile Arg Leu Val Gly Met Val Asn Ala Lys Val Glu 70 75 Arg Thr Thr Asp Val Thr Phe Thr Leu Asp Asp Gly Thr Gly Arg Leu 85 90 Asp Phe Ile Arg Trp Val Asn Asp Ala Ser Asp Ser Phe Glu Thr Ala 100 105 Ala Ile Gln Asn Gly Met Tyr Ile Ala Val Ile Gly Ser Leu Lys Gly 120 125 Leu Gln Glu Arg Lys Arg Ala Thr Ala Phe Ser Ile Arg Pro Ile Thr 135 140 Asp Phe Asn Glu Val Thr Leu His Phe Ile Gln Cys Val Arg Met His 150 155 Ile Glu Asn Ile Glu Leu Lys Ala Gly Ser Pro Ala Arg Ile Ser Ser 165 170 Ser Met Gly Val Ser Phe Ser Asn Gly Phe Ser Glu Ser Ser Thr Pro 185 180 190 Thr Ser Leu Lys Ser Ser Pro Ala Pro Val Thr Ser Gly Ser Ser Asp 200 205 Thr Asp Leu His Thr Gln Val Leu Asn Phe Phe Asn Glu Pro Ala Asn 215 220 Leu Glu Ser Glu His Gly Val His Val Asp Glu Val Leu Lys Arg Phe 230 235 Lys Leu Leu Pro Lys Lys Gln Ile Thr Asp Ala Ile Asp Tyr Asn Met 245 250 255 Asp Ser Gly Arg Leu Tyr Ser Thr Ile Asp Glu Phe His Tyr Lys Ala 265 Thr

```
<210> 13
      <211> 979
      <212> DNA
      <213> Zea mays
      <220>
      <221> misc_feature
      <222> (0)...(0)
      <223> Maize RPA Middle Subunit Homologue-2 and 3
      <221> CDS
      <222> (37)...(855)
      <400> 13
ttcggcacga gcgcacctcc tcaggtgacc gggaag atg atg ccg ttg agc caa
                                                                      54
                                        Met Met Pro Leu Ser Gln
acc gac tto tog cog tog cag tto acc too too cag aat goo goo goo
                                                                     102
Thr Asp Phe Ser Pro Ser Gln Phe Thr Ser Ser Gln Asn Ala Ala Ala
             10
                                 15
gac too acc acg cot too aag atg ogc gog too ago acc atg cog
Asp Ser Thr Thr Pro Ser Lys Met Arg Gly Ala Ser Ser Thr Met Pro
         25
ctc acc gtg aag cag gtc gtc gac gcg cag cag tct ggc acg ggc gac
                                                                      198
Leu Thr Val Lys Gln Val Val Asp Ala Gln Gln Ser Gly Thr Gly Asp
     40
aag ggc gct ccg ttc atc gtc aat ggc gtc gag atg gct aac att cga
                                                                      246
Lys Gly Ala Pro Phe Ile Val Asn Gly Val Glu Met Ala Asn Ile Arg
                     60
ctt gtg ggg atg gtc aat gcc aag gtg gag cgg acg acc gat gtg acc
                                                                      294
Leu Val Gly Met Val Asn Ala Lys Val Glu Arg Thr Thr Asp Val Thr
ttc acg ctc gac gat ggc acc ggc cgc ctc gat ttc atc aga tgg gtg
                                                                      342
Phe Thr Leu Asp Asp Gly Thr Gly Arg Leu Asp Phe Ile Arg Trp Val
aat gat gct tca gat tct ttt gaa act gct gct att cag aat ggt atg
                                                                      390
Asn Asp Ala Ser Asp Ser Phe Glu Thr Ala Ala Ile Gln Asn Gly Met
        105
                            110
tac att gcg gtc att gga agc ctc aag gga ctg caa gag agg aag cgt
                                                                      438
Tyr Ile Ala Val Ile Gly Ser Leu Lys Gly Leu Gln Glu Arg Lys Arg
                        125
    120
gct act gct ttc tca atc agg cct ata acc gat ttc aat gag gtt acg
                                                                      486
Ala Thr Ala Phe Ser Ile Arg Pro Ile Thr Asp Phe Asn Glu Val Thr
                     140
ctg cat ttc att cag tgt gtt cgg atg cat ata gag aac att gaa tta
Leu His Phe Ile Gln Cys Val Arg Met His Ile Glu Asn Ile Glu Leu
```

				155					160					165		
_	-		_		gca Ala						-					582
					gaa Glu							-				630
	•	•			agc Ser				-		-	-		_	-	678
-	-				aat Asn 220	-						-				726
		•	-	-	gta Val		-					-	-	_	-	774
					att Ile											822
					ttc Phe						taad	cgat	tt (gaag	gccagc	875
-	tgtg: <2	ca 210>	tgaaa 14		ga ci at go								ict (ggaa	atgtca	935 979
	<:	212>	273 PRT Zea	may	s											
		400> Pro		Ser 5	Gln	Thr	Asp	Phe	Ser 10	Pro	Ser	Gln	Phe	Thr 15	Ser	
l Ser	Gln	Asn	Ala 20	_	Ala	Asp	Ser	Thr 25		Pro	Ser	Lys	Met 30		Gly	
Ala	Ser	Ser 35		Met	Pro	Leu	Thr 40	Val	Lys	Gln	Val	Val 45	Asp	Ala	Gln	
	50	_			Asp	55					60					
Glu 65	Met	Ala	Asn	Ile	Arg 70	Leu	Val	Gly	Met	Val 75	Asn	Ala	Lys	Val	Glu 80	
Arg	Thr	Thr	Asp	Val 85	Thr	Phe	Thr	Leu	Asp 90	Asp	Gly	Thr	Gly	Arg 95	Leu	
Asp	Phe	Ile	Arg		Val	Asn	Asp	Ala 105		Asp	Ser	Phe	Glu 110		Ala	
Ala	Ile	Gln 115	Asn		Met	Туг	11e	Ala		Ile	Gly	Ser 125	Leu		Gly	
Leu	Gln 130	Glu		Lys	Arg	Ala 135	Thr		Phe	Ser	: Ile	: Arg		Il€	e Thr	

```
Asp Phe Asn Glu Val Thr Leu His Phe Ile Gln Cys Val Arg Met His
145
       150 155 160
Ile Glu Asn Ile Glu Leu Lys Ala Gly Ser Pro Ala Arg Ile Ser Ser
              165
                                 170
Ser Met Gly Val Ser Phe Ser Asn Gly Phe Ser Glu Ser Ser Thr Pro
           180
                             185
Thr Ser Leu Lys Ser Ser Pro Ala Pro Val Thr Ser Gly Ser Ser Asp
                           200
                                          205
Thr Asp Leu His Thr Gln Val Leu Asn Phe Phe Asn Glu Pro Ala Asn
                       215
                                        220
Leu Glu Ser Glu His Gly Val His Val Asp Glu Val Leu Lys Arg Phe
225
                   230
                                      235
Lys Leu Pro Lys Lys Gln Ile Thr Asp Ala Ile Asp Tyr Asn Met
               245
                                  250
Asp Ser Gly Arg Leu Tyr Ser Thr Ile Asp Glu Phe His Tyr Lys Ala
           260
                              265
Thr
      <210> 15
      <211> 1051
      <212> DNA
      <213> Zea mays
     <220>
      <221> misc feature
      <222> (0)...(0)
      <223> Maize RPA Middle Subunit Homologue-4
      <221> CDS
      <222> (76)...(894)
      <400> 15
tegacecacg egteegatee teccatetge geacecgeaa geetattege egeaceteet
                                                                   60
caggigaccg ggaag atg atg ccg ttg agc caa acc gac ttc tcg ccg tcg
                                                                  111
                Met Met Pro Leu Ser Gln Thr Asp Phe Ser Pro Ser
cag ttc acc tcc tcc cag aat gcc gcc gcc gac tcc acc acg cct tcc
                                                                  159
Gln Phe Thr Ser Ser Gln Asn Ala Ala Ala Asp Ser Thr Thr Pro Ser
        15
                            20
aag atg cgc ggc gcg tcc agc acc atg ccg ctc acc gtg aag cag gtc
                                                                  207
Lys Met Arg Gly Ala Ser Ser Thr Met Pro Leu Thr Val Lys Gln Val
                        35
gtc gac gcg cag cag tct ggc acg ggc gag aag ggc gct ccg ttc atc
                                                                  255
Val Asp Ala Gln Gln Ser Gly Thr Gly Glu Lys Gly Ala Pro Phe Ile
gtc aat qqc qtc gag atg gct aac att cga ctt gtg ggg atg gtc aat
                                                                  303
Val Asn Gly Val Glu Met Ala Asn Ile Arg Leu Val Gly Met Val Asn
                 65
gcc aag gtg gag egg acg acc gat gtg acc ttc acg ctc gac gat ggc
                                                                  351
Ala Lys Val Glu Arg Thr Thr Asp Val Thr Phe Thr Leu Asp Asp Gly
```

acc Thr	ggc Gly	Arg 95	ctc Leu	gat Asp	Phe	Ile	aga Arg 100	tgg Trp	gtg Val	aat Asn	gat Asp	gct Ala 105	tca Ser	gat Asp	tct Ser	399
			gct Ala													447
			gga Gly													495
			acc Thr													543
			cat His 160													591
			tct Ser													639
			ccg Pro													687
			gat Asp													735
			aac Asn													783
	_		ttc Phe 240			_	-	_	_	-		_	-	-		831
			atg Met					Leu								879
		Lys	gca Ala		taa	ccga	ttt	gaag	gtca	gc c	tgct	ggaa	a tg	gcag	agga	934
	_		cttg tgga							-	_			-	atgcat aaa	994 1051
		210>	16 273													

<211> 273 <212> PRT <213> Zea mays

```
<400> 16
Met Met Pro Leu Ser Gln Thr Asp Phe Ser Pro Ser Gln Phe Thr Ser
Ser Gln Asn Ala Ala Ala Asp Ser Thr Thr Pro Ser Lys Met Arg Gly
         20
                              25
Ala Ser Ser Thr Met Pro Leu Thr Val Lys Gln Val Val Asp Ala Gln
       35
                          40
Gln Ser Gly Thr Gly Glu Lys Gly Ala Pro Phe Ile Val Asn Gly Val
                      55
Glu Met Ala Asn Ile Arg Leu Val Gly Met Val Asn Ala Lys Val Glu
                  70
                                      75
Arg Thr Thr Asp Val Thr Phe Thr Leu Asp Asp Gly Thr Gly Arg Leu
                                 90
Asp Phe Ile Arg Trp Val Asn Asp Ala Ser Asp Ser Phe Glu Thr Ala
           100
                             105
Ala Ile Gln Asn Gly Met Tyr Ile Ala Val Ile Gly Ser Leu Lys Gly
      115
                         120
Leu Gln Glu Arg Lys Arg Ala Thr Ala Phe Ser Ile Arg Pro Ile Thr
                     135
                                         140
Asp Phe Asn Glu Val Thr Leu His Phe Ile Gln Cys Val Arg Met His
       150
                                     155
Ile Glu Asn Thr Glu Leu Lys Ala Gly Ser Pro Ala Arg Ile Asn Ser
              165
                                 170
Ser Met Gly Val Ser Phe Ser Asn Gly Phe Ser Glu Ser Ser Thr Pro
                             185
                                              190
Thr Ser Leu Lys Ser Ser Pro Ala Pro Val Thr Ser Gly Ser Ser Asp
                          200
                                             205
Thr Asp Leu His Thr Gln Val Leu Asn Phe Phe Asn Glu Pro Ala Asn
                       215
                                          220
Leu Glu Ser Glu His Gly Val His Val Asp Glu Val Leu Lys Arg Phe
                   230
                                      235
Lys Leu Leu Pro Lys Lys Gln Ile Thr Asp Ala Ile Asp Tyr Asn Met
               245
                                  250
Asp Ser Gly Arg Leu Tyr Ser Thr Ile Asp Glu Phe His Tyr Lys Ala
           260
                              265
                                                 270
Thr
      <210> 17
      <211> 1087
      <212> DNA
      <213> Zea mays
      <220>
      <221> misc_feature
      <222> (0)...(0)
      <223> Maize RPA Middle Subunit Homologue-5
      <221> CDS
      <222> (91)...(1044)
      <400> 17
aattoogggg ocgaccoacg ogtoogcate gatootocca totgogcaco ogcaagoota
ttcgccgcac ctcctcaggt gaccgggaag atg atg ccg ttg agc caa acc gac
                                Met Met Pro Leu Ser Gln Thr Asp
                                  1
```

						acc Thr 15										162
						cgc Arg										210
						gcg Ala										258
						ggc Gly										306
						gtg Val										354
						cgc Arg 95										402
						act Thr										450
-	-			-		aag Lys		-				-	-	-		498
						ata Ile										546
		-	-			atg Met										594
						aat Asn 175										642
	Phe					Thr					Lys				gca Ala 200	690
					Ser					Leu					ctg Leu	738
				Glu					Glu					Val	cac His	786
gtt	: gat	gaa	gta	ctc	aaç	cgg	tto	aac	: ttt	tgc	cga	aga	ago	aga	tca	834

Val.	Asp	Glu 235	Val	Leu	Lys	Arg	Phe 240	Asn	Phe	Cys	Arg	Arg 245	Ser	Arg	Ser	
cgg Arg	atg Met 250	cta Leu	ttg Leu	att Ile	aca Thr	ata Ile 255	tgg Trp	act Thr	cgg	ggc Gly	gtc Val 260	ttt Phe	act Thr	caa Gln	caa Gln	882
_	_	aat Asn								_		-		-		930
gct Ala		aat Asn														978
gga Gly	aat Asn	gtc Val	atg Met 300	ttg Leu	tgt Cys	cat His	gaa Glu	atg Met 305	cat His	ggt Gly	tgg Trp	ttt Phe	atg Met 310	gaa Glu	aca Thr	1026
		tct Ser 315	-			tagt	itgat	itt g	tato	tctt	g to	gtcaa	aaaa	ì		1074
aaaa	aaaa	aaa a	aaa													1087
	<2 <2	210> 211> 212> 213>	318 PRT	mays	5											
		220>	VAR:	TANT												
	<: <:	220> 221> 222> 222>	(1)	(3		mino	Acid	d d								
Met	<: <: <:	221> 222> 223> 400>	(1) Xaa 18	(: = Ai	ny Ai				Ser	Pro	Ser	Gln	Phe	Thr	Ser	
1	<: <: <: Met	221> 222> 223> 400> Pro	(1) Xaa 18 Leu	(: = A: Ser 5	ny Ar Gln	Thr	Asp	Phe	10					15		
l Ser	<2	221> 222> 223> 400> Pro	(1) Xaa 18 Leu Ala 20	= Ai Ser 5 Ala	Gln Ala	Thr Asp	Asp Ser	Phe Thr 25	10 Thr	Pro	Ser	Lys	Met 30	15 Arg	Gly	
l Ser Ala	<pre></pre> <pre></pre> <pre></pre> <pre> <pre>Met</pre> <pre> Gln</pre> <pre>Ser</pre></pre>	221> 222> 223> 400> Pro Asn Ser 35	(1) Xaa 18 Leu Ala 20 Thr	Ser 5 Ala	Gln Ala Pro	Thr Asp Leu	Asp Ser Thr 40	Phe Thr 25 Val	10 Thr Lys	Pro Xaa	Ser Val	Lys Val 45	Met 30 Asp	15 Arg Ala	Gly Gln	
l Ser Ala Gln	<pre> </pre> <pre> </pre> <pre> </pre> <pre> Met Gln Ser Ser 50</pre>	221> 222> 223> 400> Pro Asn Ser 35 Gly	(1) Xaa 18 Leu Ala 20 Thr	Ser 5 Ala Met	Gln Ala Pro Glu	Thr Asp Leu Lys 55	Asp Ser Thr 40 Gly	Phe Thr 25 Val	10 Thr Lys Pro	Pro Xaa Phe	Ser Val Ile 60	Lys Val 45 Val	Met 30 Asp Asn	15 Arg Ala Gly	Gly Gln Val	
l Ser Ala Gln	<pre> </pre> <pre> </pre> <pre> </pre> <pre> Met Gln Ser Ser 50</pre>	221> 222> 223> 400> Pro Asn Ser 35	(1) Xaa 18 Leu Ala 20 Thr	Ser 5 Ala Met	Gln Ala Pro Glu	Thr Asp Leu Lys 55	Asp Ser Thr 40 Gly	Phe Thr 25 Val	10 Thr Lys Pro	Pro Xaa Phe	Ser Val Ile 60	Lys Val 45 Val	Met 30 Asp Asn	15 Arg Ala Gly	Gly Gln Val	
l Ser Ala Gln Glu 65	<pre> </pre> <pre> </pre> <pre> Met Gln Ser Ser Met Met </pre>	221> 222> 223> 400> Pro Asn Ser 35 Gly	(1) Xaa 18 Leu Ala 20 Thr Thr	Ser 5 Ala Met Gly Ile Val	Gln Ala Pro Glu Arg 70	Thr Asp Leu Lys 55 Leu	Asp Ser Thr 40 Gly Val	Phe Thr 25 Val Ala Gly	10 Thr Lys Pro Met Asp	Pro Xaa Phe Val 75	Ser Val Ile 60 Asn	Lys Val 45 Val Ala	Met 30 Asp Asn Lys	15 Arg Ala Gly Val	Gly Gln Val Glu 80	
l Ser Ala Gln Glu 65 Arg	<pre> </pre> <pre> </pre> <pre> </pre> <pre> </pre> <pre> </pre> <pre> <pre> </pre> <pre> <pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre>	221> 222> 223> 400> Pro Asn Ser 35 Gly	(1) Xaa 18 Leu Ala 20 Thr Thr Asn Asp	Ser 5 Ala Met Gly Ile Val 85 Trp	Gln Ala Pro Glu Arg 70 Thr	Thr Asp Leu Lys 55 Leu Phe	Asp Ser Thr 40 Gly Val	Phe Thr 25 Val Ala Gly Leu Ala	10 Thr Lys Pro Met Asp 90	Pro Xaa Phe Val 75 Asp	Ser Val Ile 60 Asn Gly	Lys Val 45 Val Ala Thr	Met 30 Asp Asn Lys Gly	Ala Gly Val Arg 95 Thr	Gly Gln Val Glu 80 Leu	
l Ser Ala Gln Glu 65 Arg	<pre><? <pre><? <pre></pre> <pre></pre> <pre></pre> <pre>Ser</pre> <pre>50</pre> <pre>Met</pre> <pre>Thr</pre> <pre>Phe</pre>	221> 222> 223> 400> Pro Asn Ser 35 Gly Ala Thr Ile	(1) Xaa 18 Leu Ala 20 Thr Thr Asn Asp	Ser 5 Ala Met Gly Ile Val 85 Trp	Gln Ala Pro Glu Arg 70 Thr	Thr Asp Leu Lys 55 Leu Phe Asn	Asp Ser Thr 40 Gly Val Thr Asp	Phe Thr 25 Val Ala Gly Leu Ala 105 Ala	10 Thr Lys Pro Met Asp 90 Ser	Pro Xaa Phe Val 75 Asp	Ser Val Ile 60 Asn Gly Ser	Lys Val 45 Val Ala Thr Phe Ser	Met 30 Asp Asn Lys Gly Glu 110 Leu	Ala Gly Val Arg 95 Thr	Gly Gln Val Glu 80 Leu	
l Ser Ala Glu 65 Arg Asp	<pre> <pre> <pre> <pre> <pre> <pre> </pre> </pre> <pre> <pre< td=""><td>221> 222> 223> 400> Pro Asn Ser 35 Gly Ala Thr Ile Gln 115 Glu</td><td>(1) Xaa 18 Leu Ala 20 Thr Thr Asn Asp</td><td>Ser 5 Ala Met Gly Ile Val 85 Trp Gly</td><td>Gln Ala Pro Glu Arg 70 Thr Val</td><td>Thr Asp Leu Lys 55 Leu Phe Asn Tyr</td><td>Asp Ser Thr 40 Gly Val Thr Asp Ile 120 Thr</td><td>Phe Thr 25 Val Ala Gly Leu Ala 105 Ala</td><td>10 Thr Lys Pro Met Asp 90 Ser Val</td><td>Pro Xaa Phe Val 75 Asp Asp</td><td>Ser Val Ile 60 Asn Gly Ser Gly Ile</td><td>Lys Val 45 Val Ala Thr Phe Ser 125 Arg</td><td>Met 30 Asp Asn Lys Gly Glu 110 Leu</td><td>Ala Gly Val Arg 95 Thr Lys</td><td>Gly Gln Val Glu 80 Leu Ala Gly</td><td></td></pre<></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre>	221> 222> 223> 400> Pro Asn Ser 35 Gly Ala Thr Ile Gln 115 Glu	(1) Xaa 18 Leu Ala 20 Thr Thr Asn Asp	Ser 5 Ala Met Gly Ile Val 85 Trp Gly	Gln Ala Pro Glu Arg 70 Thr Val	Thr Asp Leu Lys 55 Leu Phe Asn Tyr	Asp Ser Thr 40 Gly Val Thr Asp Ile 120 Thr	Phe Thr 25 Val Ala Gly Leu Ala 105 Ala	10 Thr Lys Pro Met Asp 90 Ser Val	Pro Xaa Phe Val 75 Asp Asp	Ser Val Ile 60 Asn Gly Ser Gly Ile	Lys Val 45 Val Ala Thr Phe Ser 125 Arg	Met 30 Asp Asn Lys Gly Glu 110 Leu	Ala Gly Val Arg 95 Thr Lys	Gly Gln Val Glu 80 Leu Ala Gly	
l Ser Ala Gln Glu 65 Arg Asp Ala Leu	<pre> <pre> <pre> <pre> <pre> <pre> </pre> </pre> <pre> <pre< td=""><td>221> 222> 223> 400> Pro Asn Ser 35 Gly Ala Thr Ile Gln 115 Glu</td><td>(1) Xaa 18 Leu Ala 20 Thr Thr Asn Asp 100 Asn</td><td>Ser 5 Ala Met Gly Ile Val 85 Trp Gly Lys</td><td>Gln Ala Pro Glu Arg 70 Thr Val Met</td><td>Thr Asp Leu Lys 55 Leu Phe Asn Tyr Ala 135 Leu</td><td>Asp Ser Thr 40 Gly Val Thr Asp Ile 120 Thr</td><td>Phe Thr 25 Val Ala Gly Leu Ala 105 Ala Ala</td><td>10 Thr Lys Pro Met Asp 90 Ser Val</td><td>Pro Xaa Phe Val 75 Asp Asp Ile Ser</td><td>Ser Val Ile 60 Asn Gly Ser Gly Ile 140 Cys</td><td>Lys Val 45 Val Ala Thr Phe Ser 125 Arg</td><td>Met 30 Asp Asn Lys Gly Glu 110 Leu</td><td>Ala Gly Val Arg 95 Thr Lys</td><td>Gly Gln Val Glu 80 Leu Ala Gly Thr</td><td></td></pre<></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre></pre>	221> 222> 223> 400> Pro Asn Ser 35 Gly Ala Thr Ile Gln 115 Glu	(1) Xaa 18 Leu Ala 20 Thr Thr Asn Asp 100 Asn	Ser 5 Ala Met Gly Ile Val 85 Trp Gly Lys	Gln Ala Pro Glu Arg 70 Thr Val Met	Thr Asp Leu Lys 55 Leu Phe Asn Tyr Ala 135 Leu	Asp Ser Thr 40 Gly Val Thr Asp Ile 120 Thr	Phe Thr 25 Val Ala Gly Leu Ala 105 Ala Ala	10 Thr Lys Pro Met Asp 90 Ser Val	Pro Xaa Phe Val 75 Asp Asp Ile Ser	Ser Val Ile 60 Asn Gly Ser Gly Ile 140 Cys	Lys Val 45 Val Ala Thr Phe Ser 125 Arg	Met 30 Asp Asn Lys Gly Glu 110 Leu	Ala Gly Val Arg 95 Thr Lys	Gly Gln Val Glu 80 Leu Ala Gly Thr	

```
165
                               170
                                                  175
Ser Met Gly Val Ser Phe Ser Asn Gly Phe Ser Glu Ser Ser Thr Pro
         180 185
                                    190
Thr Ser Leu Lys Ser Ser Pro Ala Pro Val Thr Ser Gly Ser Ser Asp
                        200 205
Thr Asp Leu His Thr Gln Val Leu Asn Phe Phe Asn Glu Pro Ala Asn
                     215
                                       220
Leu Glu Ser Glu His Gly Val His Val Asp Glu Val Leu Lys Arg Phe
                  230
                                   235
Asn Phe Cys Arg Arg Ser Arg Ser Arg Met Leu Leu Ile Thr Ile Trp
              245
                               250 255
Thr Arg Gly Val Phe Thr Gln Gln Leu Met Asn Ser Thr Thr Arg Gln
          260
                            265
Leu Asn Arg Phe Glu Gly Gln Pro Ala Gly Asn Gly Arg Gly Leu Ser
                         280 285
Ile Thr Cys Thr Lys Pro Lys Ser Gly Asn Val Met Leu Cys His Glu
   290 295
                         300
Met His Gly Trp Phe Met Glu Thr Phe Ile Ser Cys Ile Asn
                  310
     <210> 19
     <211> 1074
     <212> DNA
     <213> Zea mays
     <220>
     <221> misc feature
     <222> (0)...(0)
     <223> Maize RPA Middle Subunit Homologue-6
     <221> CDS
     <222> (55)...(873)
     <400> 19
gacccacgcg tccgcgcaag cctattcgcc gcacctcctc aggtgaccgg gaag atg
                                                               57
atg ccg ttg age caa acc gac ttc tcg ccg tcg cag ttc acc tcc tcc
                                                               105
Met Pro Leu Ser Gln Thr Asp Phe Ser Pro Ser Gln Phe Thr Ser Ser
                              10
caq aat gcc gcc gac tcc acc acg cct tcc aag atg cgc ggc gcg
                                                               153
Gln Asn Ala Ala Ala Asp Ser Thr Thr Pro Ser Lys Met Arg Gly Ala
        20
                                                               201
tcc agc acc atg ccg ctc acc gtg aag cag gtc gtc gac gcg cag cag
Ser Ser Thr Met Pro Leu Thr Val Lys Gln Val Val Asp Ala Gln Gln
                                                               249
tot ggc acg ggc gag aag ggc gct ccg ttc atc gtc aat ggc gtc gag
Ser Gly Thr Gly Glu Lys Gly Ala Pro Phe Ile Val Asn Gly Val Glu
                                                               297
atg gct aac att cga ctt gtg ggg atg gtc aat gcc aag gtg gag Ggg
Met Ala Asn Ile Arg Leu Val Gly Met Val Asn Ala Lys Val Glu Arg
                                  75
                70
```

PCT/US99/21277 WO 00/15816

					ttc Phe											345
ttc Phe	atc Ile	aga Arg 100	tgg Trp	gtg Val	aat Asn	gat Asp	gct Ala 105	tca Ser	gat Asp	tct Ser	ttt Phe	gaa Glu 110	act Thr	gct Ala	gct Ala	393
att Ile	cag Gln 115	aat Asn	ggt Gly	atg Met	tac Tyr	att Ile 120	gcg Ala	gtc Val	att Ile	gga Gly	agc Ser 125	ctc Leu	aag Lys	gga Gly	ctg Leu	441
					gct Ala 135											489
					ctg Leu											537
			_		aag Lys			-		-	-					585
					tca Ser											633
					ccc Pro											681
-	_		_	_	gtc Val 215	-					-					729
	_	-			gtg Val			-	-	_		-				777
	_	-	-	Lys	cag Gln		_	-	Ala		-			-	-	825
-		-	Leu		tca Ser			Asp	-				_	_		873
acc tat	aaag atct	tct tgt	ggaa atca	atgt acta	ca t	gttg gatt	tgtc	a tġ	aaat	gcat	ggt	tggt	tta	tgga	tactaa aacatt gccaac	933 993 1053 1074

<210> 20 <211> 273 <212> PRT

<213> Zea mays <400> 20 Met Met Pro Leu Ser Gln Thr Asp Phe Ser Pro Ser Gln Phe Thr Ser 10 Ser Gln Asn Ala Ala Ala Asp Ser Thr Thr Pro Ser Lys Met Arg Gly 20 25 Ala Ser Ser Thr Met Pro Leu Thr Val Lys Gln Val Val Asp Ala Gln 40 Gln Ser Gly Thr Gly Glu Lys Gly Ala Pro Phe Ile Val Asn Gly Val 5.5 Glu Met Ala Asn Ile Arg Leu Val Gly Met Val Asn Ala Lys Val Glu 70 Arg Thr Thr Asp Val Thr Phe Thr Leu Asp Asp Gly Thr Gly Arg Leu 85 90 Asp Phe Ile Arg Trp Val Asn Asp Ala Ser Asp Ser Phe Glu Thr Ala 100 105 Ala Ile Gln Asn Gly Met Tyr Ile Ala Val Ile Gly Ser Leu Lys Gly 120 Leu Gln Glu Arg Lys Arg Ala Thr Ala Phe Ser Ile Arg Pro Ile Thr 135 Asp Phe Asn Glu Val Thr Leu His Phe Ile Gln Cys Val Arg Met His 150 155 Ile Glu Asn Thr Glu Leu Lys Ala Gly Ser Pro Ala Arg Ile Asn Ser 165 170 Ser Met Gly Val Ser Phe Ser Asn Gly Phe Ser Glu Ser Ser Thr Pro 180 185 Thr Ser Leu Lys Ser Ser Pro Ala Pro Val Thr Ser Gly Ser Ser Asp 195 200 Thr Asp Leu His Thr Gln Val Leu Asn Phe Phe Asn Glu Pro Ala Asn 210 215 Leu Glu Ser Glu His Gly Val His Val Asp Glu Val Leu Lys Arg Phe 230 235 Lys Leu Leu Pro Lys Lys Gln Ile Thr Asp Ala Ile Asp Tyr Asn Met 245 250 255 Asp Ser Gly Arg Leu Tyr Ser Thr Ile Asp Glu Phe His Tyr Lys Ala 260 265 Thr <210> 21 <211> 1231 <212> DNA <213> Zea mays <220> <221> misc feature <222> (0)...(0) <223> Maize RPA Middle Subunit Homologue-7 <221> CDS <222> (85)...(903)

Met Met Pro Leu Ser Gla Thr Asp Phe

60

111

tocogggtog accoacgegt cogegatest cocatetgeg caccegeaag cetatteges

gcacctcctc aggtgaccgg gaag atg atg ccg ttg agc caa acc gac ttc

<400> 21

1 5

tcg Ser 10	ccg Pro	tcg Ser	cag Gln	ttc Phe	acc Thr 15	tcc Ser	tcc Ser	cag Gln	aat Asn	gcc Ala 20	gcc Ala	gcc Ala	gac Asp	tcc Ser	acc Thr 25	159
acg Thr	cct Pro	tcc Ser	aag Lys	atg Met 30	cgc Arg	ggc Gly	gcg Ala	tcc Ser	agc Ser 35	acc Thr	atg Met	ccg Pro	ctc Leu	acc Thr 40	gtg Val	207
aag Lys	cag Gln	gtc Val	gtc Val 45	gac Asp	gcg Ala	cag Gln	cag Gln	tct Ser 50	gly ggc	acg Thr	ggc Gly	gag Glu	aag Lys 55	ggc Gly	gct Ala	255
ccg Pro	ttc Phe	atc Ile 60	gtc Val	aat Asn	ggc Gly	gtc Val	gag Glu 65	atg Met	gct Ala	aac Asn	att Ile	cga Arg 70	ctt Leu	gtg Val	Gly ggg	303
atg Met	gtc Val 75	aat Asn	gcc Ala	aag Lys	gtg Val	gag Glu 80	cgg Arg	acg Thr	acc Thr	gat Asp	gtg Val 85	acc Thr	ttc Phe	acg Thr	ctc Leu	351
gac Asp 90	gat Asp	ggc Gly	acc Thr	ggc	cgc Arg 95	ctc Leu	gat Asp	ttc Phe	atc Ile	aga Arg 100	tgg Trp	gtg Val	aat Asn	gat Asp	gct Ala 105	399
tca Ser	gat Asp	tct Ser	ttt Phe	gaa Glu 110	act Thr	gct Ala	gct Ala	att Ile	cag Gln 115	aat Asn	ggt Gly	atg Met	tac Tyr	att Ile 120	gcg Ala	447
											aag Lys					495
											gtt Val					543
	_	-	-								gaa Glu 165		_	-		591
-		Ala	_	Ile	Asn	Ser	Ser	Met		Val	tca Ser					639
											tcc Ser					687
									Leu		acg Thr					735
								Glu			cat His					783

gat Asp	gaa Glu 235	gta Val	ctc Leu	aag Lys	cgg Arg	ttc Phe 240	aaa Lys	ctt Leu	ttg Leu	ccg Pro	aag Lys 245	aag Lys	cag Gln	atc Ile	acg Thr	831
gat Asp 250	gct Ala	att Ile	gat Asp	tac Tyr	aat Asn 255	atg Met	gac Asp	tcg Ser	ggg Gly	cgt Arg 260	ctt Leu	tac Tyr	tca Ser	aca Thr	att Ile 265	879
					aag Lys			taad	ccgat	itt q	gaago	jtcaç	ge et	igato	ggaaa	933
tgaa ctct tgta	atgo tgto agati	cat q gtc a egg q	ggtto aactt ctgat	ggtt: caatq cagc:	ta to ga ct tg at	ggaaa :gago :tcgo	catt caad ggtag	t tat c aaa g ctq	tatct aagga	tgt aga aat	atca tgta tgca	iacta igago iatci	gt (gca (gatt gacaq ggcc	gtgtca stgtat gacatt saataa aaaa	993 1053 1113 1173 1231
	<2 <2 <2	210> 211> 212> 212> 213>	273 PRT Zea	may	5											
				Ser	Gln	Thr	Asp	Phe	Ser	Pro	Ser	Gln	Phe		Ser	
1 Ser	Gln	Asn		Ala	Ala	Asp	Ser		10 Thr	Pro	Ser	Lys		15 Arg	Gly	
Ala	Ser		20 Thr	Met	Pro	Leu		25 Val	Lys	Gln	Val		30 Asp	Ala	Gln	
Gln		35 Gly	Thr	Gly	Glu		40 Gly	Ala	Pro	Phe		45 Val	Asn	Gly	Val	
Glu 65	50 Met	Ala	Asn	Ile	Arg 70	55 Leu	Val	Gly	Met		60 Asn	Ala	Lys	Val		
	Thr	Thr	Asp	Val 85		Phe	Thr	Leu	Asp 90	75 Asp	Gly	Thr	Gly		80 Leu	
Asp	Phe	Ile	Arg 100		Val	Asn	Asp		Ser	Asp	Ser	Phe		95 Thr	Ala	
Ala	Ile	Gln 115		Gly	Met	Tyr	Ile 120	105 Ala	Val	Ile	Gly	Ser 125	110 Leu	Lys	Gly	
Leu	Gln 130		Arg	Lys	Arg	Ala 135		Ala	Phe	Ser	Ile 140		Pro	Ile	Thr	
Asp 145		Asn	Glu	Val	Thr 150		His	Phe	Ile	Gln 155		Val	Arg	Met	His 160	
	Glu	Asn	Thr	Glu 165		Lys	Ala	Gly	Ser 170		Ala	Arg	Ile	Asn 175		
Ser	Met	Gly	Val 180		Phe	Ser	Asn	Gly 185	Phe	Ser	Glu	Ser	Ser 190		Pro	
Thr	Ser	Leu 195		Ser	Ser	Pro	Ala 200		Val	Thr	Ser	Gly 205		Ser	Asp	
Thr	Asp 210		His	Thr	Gln	Val 215		Asn	Phe	Phe	Asn 220		Pro	Ala	Asn	
Leu 225		Ser	Glu	His	Gly 230		His	Val	Asp	Glu 235		Leu	Lys	Arg	Phe 240	
	Leu	Leu	Pro	Lys 245		Gln	Ile	Thr	Asp 250		Ile	Asp	Tyr	Asn 255		

Asp Ser Gly Arg Leu Tyr Ser Thr Ile Asp Glu Phe His Tyr Lys Ala
260 265 270

Inte ional Application No PCT/US 99/21277

		PCT/US 9	9/21277
CLASSIF	CATION OF SUBJECT MATTER C12N15/82 C12N15/11 A01H5/	00	
According to	International Patent Classification (IPC) or to both national class	effication and IPC	
A FIELDS S			
	sumerization searched (classification system followed by classifi C12N A01H	cation symbolis)	
Documentation	on searched other than minimum documentation to the extent the	at such documents are included in the field	s searched
Bectronic da	ta base consulted during the international securch (name of data	a base and, where practical, search terms u	
2 2004400	INTS CONSIDERED TO BE RELEVANT		
Category •	Citation of document, with indication, where appropriate, of the	e relevant passages	Relevant to daim No.
	Consecut of Consecution of Alife & Description of Management of Alife		
X	VAN DER KNAAP, E., ET AL: "Exam ortholog of replication pro (RPA1) is induced by gibberell deepwater rice"	tein Al in in	1-3
	PROCEEDINGS OF THE NATIONAL AC SCIENCES OF USA, vol. 94, September 1997 (1997- 9979-9983, XP002131706		
	WASHINGTON US the whole document -& VAN DER KNAAP, E., ET AL.:	"Oryza	
	sativa replication protein AlmRNA, complete cds" EMBL ACCESSION NO:AF009179, 18 July 1997 (1997-07-18), XP0		
		-/	
*			
X Furt	her documents are lated in the continuation of box C.	Patent family members are 8	sted in annex.
"A" docum	stagories of cited documents: ent defining the general state of the art which is not sered to be of particular relevance	"T" later document published after the or priority date and not in conflict cited to understand the principle invention	with the application but or theory underlying the
filing of "L" docume which citatio	ent which may throw doubts on priority claim(s) or is cited to establish the publication date of another in or other special reason (as specified)	"X" document of particular relevance; cannot be considered novel or or involve an inventive step when it "Y" document of particular relevance; cannot be considered to involve	unnot be considered to ne document is taken alone the cisimed invention an inventive step when the
other	ent referring to an oral disclosure, use, exhibition or means ent published prior to the international filling date but	document is combined with one ments, such combination being on in the art.	
later t	han the priority date claimed	"&" document member of the same p	
	actual completion of the international search 28 February 2000	Date of mailing of the internation	ш өөшин торин
L	▼	7	
	mailing address of the ISA European Patent Office, P.B. 5818 Patentiaan 2	Authorized officer	

Inte. Jonel Application No PCT/US 99/21277

		PCT/US 99/21277			
Category *	ntion) DOCUMENTS CONSIDERED TO BE RELEVANT Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.			
X	DBEST ID:52849,18 July 1994 (1994-07-18), XP002131708	1,2			
	the whole document & EMBL ACCESSION NO:T23395, 21 July 1994 (1994-07-21),				
X	CHURIN, Y., ET AL.: "Hordeum vulgare cv. Haisa mRNA for cp31BHv protein" EMBL ACCESSION NO:AJ224324, 4 September 1998 (1998-09-04), XP002131709 the whole document	1			
X	SHEN, B., ET A.: "5C04G01-T7 membrane-free polysomes from endosperm Zea mays cDNA clone 5C04G01 5' end similar to 60s ribosomal protein L19." EMBL ACCESSION NO:T18701, 14 May 1994 (1994-05-14), XP002131710 the whole document	2			
X	ISHIAI, M., ET AL.: "Purification, gene cloning, and reconstitution of the heterotrimeric single-stranded DNA-binding protein from Schizosaccharomyces pombe." JOURNAL OF BIOLOGICAL CHEMISTRY., vol. 271, 23 August 1996 (1996-08-23), pages 20868-20878, XP002131711 AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD., US ISSN: 0021-9258 figure 2B -& ISHIAI M., ET AL.: "REPLICATION FACTOR-A PROTEIN 2 (SINGLE-STRANDED DNA-BINDING PROTEIN P30 SUBUNIT)." SWISSPROT ACCESSION NO: 092373.	1,2			
X	1 November 1997 (1997-11-01), XP002131712 NAKAMURA, Y., ET AL.: "Arabidopsis thaliana genomic DNA, chromosome 5, P1 clone: MNL12." EMBL ACCESSION NO:AB017070, 3 September 1998 (1998-09-03), XP002131713 nts 6376-6501	2			
X	WILSON, R., ET AL.: "Caenorhabditis elegans cosmid K12C11." EMBL ACCESSION NO:AF043701, 23 January 1998 (1998-01-23), XP002131714 see reverse complement of nts 22422-22441	2			
P,X	WALBOT, V., ET AL.: DBEST ID:2980430, 22 July 1999 (1999-07-22), XP002131715 the whole document & EMBL ACCESSION NO:AI881882, 23 July 1999 (1999-07-23),	1,2			
	-/				

Intex. coned Application No PCT/US 99/21277

		PCT/US 99/21277			
(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT about 'Classon of document, with indication where appropriate, of the relevant passages [Referent to claim No					
and ory	Cuttation of document, with indication, where appropriate, of the relevant passages	Relevant to claim: No.			
·,χ	WALBOT, V: DBEST ID:2943612, 15 July 1999 (1999-07-15), XP002131716 the whole document & EMBL ACCESSION NO:AI855065, 22 July 1999 (1999-07-22),	1,2			
, χ	WALBOT, V., ET AL.: DBEST ID:2970064, 21 July 1999 (1999-07-21), XP002131717 & EMBL ACCESSION NO:AI881517, 22 July 1999 (1999-07-22),	1,2			
·,χ	WALBOT, V.: DBEST ID:2922893, 14 July 1999 (1999-07-14), XP002131718 & EMBL ACCESSION NO:AI834577, 16 July 1999 (1999-07-16),	1,2			
, χ	WALBOT, V., ET AL.: "606058D02.x2 606 - Ear tissue cDNA library from Schmidt lab Zea mays cDNA, mRNA sequence." EMBL ACCESSION NO:AI770788, 30 June 1999 (1999-06-30), XP002131719 the whole document	2			
, X	WALBOT, V.: "618009B07.x1 618 - Inbred Tassel cDNA Library Zea mays cDNA, mRNA sequence." EMBL ACCESSION NO:AI901688, 28 July 1999 (1999-07-28), XP002131720 the whole document	2			
, X	WALBOT, V.: "605089A07.x1 605 - Endosperm cDNA library from Schmidt lab Zea mays cDNA, mRNA sequence." EMBL ACCESSION NO:AI833411, 14 July 1999 (1999-07-14), XP002131721 the whole document	2			
, Х	WALBOT, V., ET AL.: "487012G02.x1 487 - apical meristem cDNA library from Hake lab Zea mays cDNA, mRNA sequence." EMBL ACCESSION NO:AI396192, 5 February 1999 (1999-02-05), XP002131722 the whole document	2			
,χ	LIN, X., ET AL.: "Arabidopsis thaliana chromosome II section 137 of 255 of the complete sequence." EMBL ACCESSION NO:AC006403, 18 January 1999 (1999-01-18), XP002131723 the whole document	1,2			
1	WO 97 08331 A (MAX PLANCK GESELLSCHAFT; KLEMM MANFRED (DE); REISS BERND (DE); SCH) 6 March 1997 (1997-03-06) the whole document	8			

Inter onel Application No

		nation on patent family mem		PCT/US 99/21277			
Patent documer cited in search rep	nt Sort	Publication date	Patent family member(s)		Publication date		
WO 9708331	A	06-03-1997	EP	0847445 A	17-06-1998		
					•		
			•				